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ABSTRACT 
 
 Besides age, inheritance of the apoE-ε4 allele is the main risk factor for 
late-onset AD. To determine the role of apoE in amyloid deposition, we studied 
mice expressing both mutant human amyloid ß-protein precursor (APP) and 
presenilin 1 (PS1) that were either normal or knocked-out for apoE.  By 7 
months, amorphous Aß deposition developed equally in both lines, indicating that 
Aß alone is sufficient for deposition to occur.  In contrast, filamentous amyloid 
deposition was catalyzed at least 3000 fold by apoE.  Electron micrographs 
further illustrate the filamentous nature of these plaques.  These results and 
other, behavioral, data indicate that the primary function of apoE in AD is to 
promote the polymerization of Aß into mature, neurotoxic, amyloid. 
 ApoE is also synthesized in the liver and is crucial in cholesterol 
metabolism, for mice lacking apoE exhibit hypercholesterolemia.  We 
investigated neuropathology in mice using an uncommon technique, parabiosis, 
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to determine whether apoE in the peripheral circulation influences brain amyloid 
formation. This surgical procedure allows exchange of proteins via peripheral 
circulation.  We show that plasma apoE is found in parabiosed PS/APP/apoE-KO 
mice, rescuing their hypercholesterolemia.  Unexpectedly, amyloid deposition is 
reduced in parabiosed PS/APP/apoE-KO mice compared to PS/APP controls. 
ApoE in the periphery seems to slightly reduce amyloid burden, by likely 
promoting efflux of Aß from the brain. These findings reinforce that the 
mechanisms whereby apoE affects Aß metabolism are complex, and the 
modulation of peripheral apoE metabolism is not likely to impact AD 
neuropathology.   
 Since cognitive stimulation is associated with lower risk of AD, we sought 
to investigate the preventative potential of environmental enrichment (EE) using 
our mouse model.  At weaning, mice were placed into either enriched or standard 
housing (SH).  Behavioral testing at 4½-6 months showed that EE-PS1/APP 
mice outperformed mice in SH, and were behaviorally indistinguishable from 
nontransgenic mice.  PS1/APP mice given both EE and behavioral testing had 
50% less brain ß-amyloid (Aß), but did not exhibit changes in dendritic 
morphology.  Microarray analysis of hippocmapal RNA revealed large EE-
induced changes in the expression of genes/proteins related to memory, 
neuroprotection, and Aß sequestration.  Inhibition of one such protein, PDE4, a 
cAMP-phosphodiesterase, by Rolipram, mimicked the cognitive benefits of EE. 
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INTRODUCTION 
 
ALZHEIMER’S DISEASE 
 Alzheimer’s disease (AD) is the most prevalent form of dementia in people 
over the age of 65, and it is estimated that for every five years a person lives 
over the age of 65, the chance of developing AD doubles.  In fact, approximately 
58% of those living at the age of 95 develop AD (Ebly et al., 1994).  Using data 
from the year 2000 United States census, it was estimated that there were 
roughly 4.5 million Americans living with the disease, and that, due to the rapidly 
aging population, this figure should triple by the year 2050 (Hebert et al., 2003).  
At a current estimated cost of $100 billion per year to the US economy, AD is a 
burden to more than patients, families, and health care providers.       
 The main overt symptoms of AD, initially described by Alois Alzheimer in 
1907, are progressive memory loss and dementia. From a pathological 
perspective, AD results in two distinct brain lesions, neuritic plaques and 
neurofibrillary tangles, with concomitant neuronal loss, occurring primarily in the 
hippocampus and cerebral cortex, two brain regions intimately associated with 
memory and higher cognitive functions. 
 Neurofibrillary tangles are highly insoluble cytosolic aggregates made of 
paired helical filaments (PHF) of an abnormally phosphorylated 
(hyperphosphorylated) microtubule associated protein, tau.  Tau normally 
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stabilizes and promotes the assembly of microtubules, but when phosphorylated 
at either serine 262 or 214, it detaches from the microtubule and is made 
available for polymerization (Mandelkow and Mandelkow, 1998).  Tau is 
necessary for the outgrowth of neurites, so it is likely that alterations in 
microtubule binding could contribute to a breakdown in intracellular transport and 
the resultant dying back of neurons indicative of AD.  It has also been shown that 
cyclin dependant kinase 5 (cdk5) can be constitutively active in patients with AD.  
Cdk5 can hyperphosphorylate tau, therefore inducing NFT formation, and has 
been shown to accumulate in tangle-bearing neurons, adding yet another 
potential mechanism for the development of AD pathology (Patrick et al., 1999).   
Since the mouse models employed in our research do not develop neurofibrillary 
tangles, our efforts focus specifically on the other main pathological hallmark of 
AD, neuritic plaques.   
Neuritic, or amyloid, plaques are extracellular protein aggregates typically 
surrounded by both dystrophic neurites and reactive astrocytes.  The primary 
constituent of these lesions is a short peptide called amyloid-beta (Aß).  It was 
the 1984 isolation and characterization of the Aß peptide by Glenner and Wong 
that ushered in the modern era of AD research (Glenner and Wong, 1984).  
Later, it was discovered that Aß is really the proteolytic cleavage product of a 
larger, membrane bound, protein termed the amyloid precursor protein (APP) 
(Goldgaber et al., 1987; Kang et al., 1987; Robakis et al., 1987; Tanzi et al., 
1987).  APP, a protein whose function is still not known, is ubiquitously 
expressed, and its cleavage, resulting in Aß production, seems to be a normal 
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cellular event. Discerning the mechanism whereby cellular homeostasis is altered 
to confer a disease state has been challenging for the field.  One known change 
that does occur in many AD patients, especially those with FAD, is an altered 
ratio between the two major species of Aß, the shorter form ending in amino acid 
(AA) 40, and the longer 42 AA form.  Though still far less abundant than Aß1-40, a 
higher percentage of Aß1-42 is found in diseased brains.  This is of particular 
interest since Aß1-42 seems to have a greater propensity for aggregation (Jarrett 
et al., 1993).  Furthermore, it has been suggested that pre-amyloid, or diffuse, 
plaques which are immunoreactive, but not classified as amyloid due to a lack of 
birefringengence, are made predominantly of Aß1-42, and serve as the foundation 
for later Aß1-40 accumulation and eventual amyloid formation (Lemere et al., 
1996).   
 Greater than 97% of all AD cases are sporadic, or of unknown etiology.  
The remaining cases are attributable to genetic defects.  Most of what is known 
about the cellular events of sporadic AD comes from research on the relatively 
rare inherited forms of the disease.  The majority of familial AD cases are early 
onset and due to autosomal dominant mutations in the APP, presenilin 1 (PS1), 
or presenilin 2 (PS2) genes.  Another inherited variety of AD takes the form of 
trisomy 21, or Down’s syndrome (DS).  Phenotypically, autosomal dominantly 
inherited AD is indistinguishable from sporadic AD with the exception of an 
earlier onset age.   
Mutations in the APP gene, which is on chromosome 21, are thought to 
alter its proteolytic processing.  The most common mutations are found as point 
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mutations adjacent to the two proteolytic cleavage sites utilized to excise the Aß 
fragment from the APP holoprotein.  Both N-terminal ß-site (AA 670/671) and C-
terminal γ-site (AA717) mutations increase the amounts of extracellular Aß1-42, 
thereby promoting the initial deposition of this amyloidogenic species.  Similarly, 
mutated presenilin proteins, which are aslo inherited in an autosomal dominant 
manner, shift the ratio of Aß1-40/Aß1-42 towards Aß1-42.   
Presenilin is an intramembrane protease which is thought to be the γ-
secretase, or at least an inseparable cofactor in the APP cleavage pathway 
(Iwatsubo, 2004).  Since a genetic ablation of this gene is lethal by birth (Qian et 
al., 1998), inherited mutations most likely invoke pathogenesis through a toxic 
gain of function, which is further supported by the fact that, with two exceptions, 
all of these mutations cause amino acid substituitions (i.e. no frameshifts, stops, 
etc…).  Just increasing the bulk amount of APP also confers a disease state.  By 
having one extra copy of chromosome 21, such as in DS, these individuals 
develop large amounts of Aß deposits at an early age, and eventually the 
memory deficits associated with AD.   
 Insight into the role of APP and Aß in AD may be provided by genetic and 
biochemical studies that have explored the roles of other proteins thought to be 
involved in the disease process. For example, Aß amyloid deposits also contain 
α1-antichymotrypsin (ACT) and apolipoprotein E (ApoE), which are over-
expressed in affected regions of the AD brain as part of an inflammatory process 
(Abraham et al., 1988; Xu et al., 1999).  ACT levels are also increased in AD 
serum and CSF (see Licastro et al., 1995 for data and discussion).  It was 
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proposed at the time of their discoveries that ApoE and ACT might function as 
amyloid promoters or “Pathological Chaperones”, and both in vitro and in vivo 
studies support this model.  
 As with APP, the importance of inflammation and specifically ApoE and 
ACT in AD is supported by genetic studies.  Inheritance of an ApoE ε4 allele is 
the strongest risk factor for AD besides age, and an ACT/A signal peptide variant 
that increases mature glycosylated ACT available for secretion also increases 
AD susceptibility and pathology (Kamboh, 1995; Kamboh et al., 1995).  Similarly, 
polymorphisms in the IL-1 promoter greatly increase the risk of AD.  These 
genetic variations increase IL-1 expression during inflammation and therefore 
promote amyloid formation by increasing the production of both APP and ACT. 
Genetic and biochemical studies have identified key proteins in the AD 
pathogenic pathway and much research has sought to ascertain the role that Aß, 
ApoE, and ACT play in the formation of amyloid and the resultant cognitive 
dysfunction of AD.  To begin to answer these questions, we performed cognitive 
studies with AD mouse models in which the inflammatory proteins and the Aß 
deposition they influence could be regulated without changing the level of 
monomeric Aß peptide. To this end, we generated and analyzed a number of 
ACT and/or apoE-expressing/non-expressing mouse models of AD and found 
that: 1) ApoE and ACT independently and synergistically promote Aß 
immunoreactive and mature amyloid deposition without initially affecting Aß 
levels and 2) cognitive impairment in aged AD mice depends on the amyloid 
promoting effect of ApoE and/or ACT (Nilsson et al., 2004, APPENDIX B). 
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The compilation of manuscripts presented in this volume seeks, using 
transgenic mouse models of AD, to more clearly define the role of apoE in 
amyloidogenesis, and to ascertain whether the systemic circulating pool of apoE 
is able to exert an affect on pathogenic Aß lesions localized in the brain.  
Furthermore, we explore the beneficial pathological and genetic effects of 
cognitive stimulation on the Alzheimer brain.  Both avenues of study, apoE and 
environmental enrichment, are discussed in detal below.    
 
APOLIPOPROTEIN E 
 Besides age, the apolipoprotein E gene is the greatest known genetic 
susceptibility factor for AD.  Three apoE alleles exist, ε2, ε3, and ε4, each 
conferring a different relative risk of developing the disease (ε4 > ε3 > ε2).  There 
exists an allelic dose response for the apoE ε4 allele in particular which is 
exemplified by the 20 year acceleration of the mean age of onset for those 
people with two copies of apoE ε4 (average onset age = 70) vs. those with a 
ε2/ε3 combination (average onset age = 90) (Strittmatter and Roses, 1996).  
Another particularly interesting example of the affect of apoE ε4 comes from 
studies of the Japanese population as a whole, where the allelic frequency of 
individuals homozygous for apoE ε4 is lower than that of the United states, which 
results in an overall prevalence of the disease that is therefore lower, and an 
observed population age of onset of sporadic AD that is shown to be higher, 
furthing implicating apoE ε4 as a risk factor in AD (Ueki et al., 1993).  Though not 
8 
known with any great deal of certainty, there are a number of putative roles that 
apoE plays in relation to AD: ApoE, 1) forms stable complexes with the Aß 
peptide; 2) In an isoform-specific manner, alters the aggregation properties of 
Aß; 3) inhibits Aß-induced neurotoxicity; and, 4) promotes the clearance of Aß in 
a receptor mediated fashion. 
 ApoE is a 34 kDa (299 amino acids in length) lipoprotein produced 
predominately in the liver whose primary function is to transport lipids via either 
low density lipoproteins (LDL), very low density lipoproteins (VLDL), or high 
density lipoproteins (HDL).  The brain has the second highest amount of ApoE in 
the body (after the liver) where it is predominantly produced by astrocytes 
(Driscoll and Getz, 1984).  In the course of AD, both the levels of apoE mRNA 
and protein are increased in astrocytes, and though neurons do not produce 
apoE, for no apoE mRNA is detectable, apoE protein is present in neurons of 
patients with AD.   
Besides genetic linkage studies implicating apoE’s role in AD, there are a 
number of reasons that apoE is thought to be directly involved in the process of 
amyloidogenesis.  Several apoE promoter mutations exist whereby the gross 
levels of apoE are increased which is correlated with an increased risk of AD 
(Strittmatter and Roses, 1996).  Furthermore, apoE has been shown to bind to 
Aß, and lastly, apoE accumulates in extracellular amyloid plaques.  In vitro, both 
apoE ε3 and ε4 bind, in an irreversible manner, to the Aß peptide (Strittmatter et 
al., 1993).  Both isoforms catalyze the formation of fibrils, but the ε4 isoform 
promotes Aß polymerization roughly 25-times faster than apeE ε2 or ε3 (Ma et 
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al., 1994; Wisniewski et al., 1994).  Furthermore, the character of the fibrils 
formed in the presence of apoE adopt a simple 10nm fiber shape, as compared 
to a non-apoE catalyzed aggregate which can best be described as a twisted 
ribbon-like conformation.  Interestingly, it has been shown that apoE confers a 
greater degree of protease resistance to Aß upon binding, which could be 
responsible for the irreversible nature of this interaction (Zhou et al., 1996), and 
may help explain the propensity for apoE-mediated fibril accumulation.   
 The vast majority of existing literature would suggest that ApoE does not 
affect APP production.  Transcription or translation of APP does not change in 
the presence of apoE, and this has been demonstrated with both mouse and the 
ε3 and ε4 human isoforms (Bales et al., 1999; Koistinaho et al., 2004).  Even 
though there is a reported gene dose effect of mouse apoE on Aß 
immunoreactivity and Thioflavine S staining (apoE+/+ > apoE+/- > apoE -/-), at 
two months of age there is no difference in Aß levels, as shown by enzyme 
linked immunosorbent assay (ELISA) (Bales et al., 1997; Nilsson et al., 2004, 
APPENDIX B).  The immunohistochemical staining patterns of transgenic AD 
mouse models suggests that Aß1-42 deposition precedes ApoE deposition, while 
Ab1-40 follows (Terai et al., 2001), further indicating that it is likely that apoE plays 
an important role in the maturation of plaques, but not necessarily initial APP 
processing.  Other authors have conversely reported that hippocampal levels of 
Aß are suppressed in APP mice expressing human apoE ε3 or ε4 (Fagan et al., 
2002).  These results, combined with the findings that apoE can complex with 
both soluble and fibrillar Aß (Permanne et al., 1997; Russo et al., 1998), has led 
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to an isoform-dependant dual-role hypothesis for apoE.  First, as previously 
mentioned, the ε4 isoform of apoE promotes the fibrillarization of deposited pre-
amyloid Aß1-42 aggregates into mature amyloid.  Secondly, since one manuscript 
has reported that more soluble Aß is found in mice with human apoE4 than those 
expressing apoE3 (Bales et al., 1997), it has been proposed that apoE ε3 inhibits 
Aß oligomer deposition (short oligomers of Aß are thought to be neurotoxic and 
the precursors to longer fibrils) and that pre-fibrillar Aß/apoE3 interactions could 
foster apoE-mediated clearance of Aß.  This precedent has been set by other 
Aß-associated molecules such as transthyretin, which have been shown to 
sequester Aß (Goldgaber et al., 1993). 
 The classical amyloid cascade hypothesis describes a process whereby 
APP is processed into Aß, which in turn leads to plaque deposition and ultimately 
neuronal cell dysfunction and death.  Unfortunately, the temporal and spatial 
distribution of brain amyloid deposition does not correlate well with the clinical 
progression of the disease (Ma et al., 1996; Naslund et al., 2000).  There is a 
large body of research implicating the soluble Aß oligomer, rather than mature, 
deposited, amyloid as the causative agent in AD.  It has been shown in vitro that 
neuronal viability is adversely affected by oligomeric Aß 10-fold more than the 
fibrillar form, and roughly 40-fold more than the monomeric peptide (Dahlgren et 
al., 2002).  Furthermore, Aß oligomers cause an increase in inflammatory 
markers such as interleukin-1 (IL-1) or inducible nitric oxide synthase (iNOS), 
while fibrillar Aß does not (Manelli et al., 2004).  It therefore seems that 
oligomeric Aß is far more neurotoxic than unaggregated or fibrillar Aß.  
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Interestingly, ApoE3 has been shown to prevent Aß-induced neurotoxicity, while 
ApoE4 has not (Jordan et al., 1998).  Specifically, apoE3 attenuates oligomer 
toxicity (Manelli et al., 2004).  This is not a general anti-inflammatory mechanism 
of apoE, for other inflammatory agents such as LPS are not attenuated in the 
same manner as Aß (Hu et al., 1998).  Furthermore, Since APP/ApoE-KO mice 
perform poorly in behavioral tasks designed to measure memory deficits, even 
with a lack of ApoE-catalyzed plaque formation, a detrimental effect on memory 
independent of fibrillarzation events exists (Dodart et al., 2000).  This supports 
the beneficial role of apoE ε3 in the inhibition of oligomer-induced neurotoxicity 
and inflammation while not discounting apoE ε4’s catalytic role in promoting Aß 
fibrillarization. 
 ApoE’s role in the brain inflammatory response and neuritic pathology is 
well characterized, but not widely agreed upon.  It is known that apoE levels rise 
due to brain injury (Poirier et al., 1993), and that that there is a marked reduction 
in gliosis (as measured by GFAP immunostaining) in apoE knockout mice (Bales 
et al., 1999).  Since Aß is known to increase apoE production, it has been 
hypothesized that apoE negatively feeds back to limit further inflammation 
caused by this molecule.  It has been noted by more than one author that apoE-
KO mice do not develop dendritic or long term potentiation deficits (Dodart et al., 
2000; Holtzman et al., 2000)  The neuritic pathology of APP mice (i.e. – swollen 
and distorted neurites) is absent when apoE is selectively ablated, and 
dystrophic neurites re-appear when either mApoE, hApoE3, or hApoE4 is 
expressed, indicating that apoE-induced fibrillar plaque formation is most likely 
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responsible for neuritic pathology (Holtzman et al., 2000).  Opposing research 
has reported that apoE-KO mice present a 15 to 40% loss in synaptophysin 
staining and a decrease in tubulin immunoreactivity.  This lends credence to the 
idea that apoE might play an important role in maintaining dendritic and synaptic 
stability and plasticity, and any alterations could be responsible for typical AD-
related synaptic and cytoskeletal deficits (Masliah et al., 1995).  Since apoE3, but 
not apoE4, delays age-dependant decline of synaptophysin levels in the 
presynaptic terminals of APP mice, the fact that the cognitive decline in AD 
correlates better with synaptophysin reactivity than plaque load (DeKosky and 
Scheff, 1990) could be relevant to apoE-conferred risk of AD and an apoE-driven 
early onset.   Furthermore, apoE might even bind to tau and prevent its 
phosphorylation (Strittmatter et al., 1994) in an isoform specific manner, for apoE 
ε3 forms an irreversible complex with tau, but ApoE ε4 does not.  The same holds 
true for another microtubule associated protein, MAP2c.  Therefore, apoE may 
play a role in Aß fibrillarization, inflammation, synaptic health, and neurofibrillary 
tangle formation.                 
 The apoE molecule contains two functionally important domains: an LDL 
receptor (LDLr) binding domain, and a lipoprotein binding domain.  Neurons 
express several apoE receptors, including the LDLr, the LDLr-related protein 
(LRP), and the VLDL receptor (Terai et al., 2001).  Neurons are thought to 
uptake apoE and their associated lipid particles in a receptor mediated fashion, 
for In vitro, apoE is taken up from the growth media by neurites and neuronal 
growth cones (Strittmatter and Roses, 1996).  After neuronal injury, cholesterol is 
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endocytosed via apoE and the LDLr in order to support the growth of neurons 
undergoing reinnervation (Poirier et al., 1993), indicating yet another role for 
apoE in brain maintenance – lipid transport due to CNS injury.  It is likely that 
apoE’s role in the brain is, like in the periphery, to regulate plasma lipid transport 
and clearance as the ligand for lipoprotein receptors.  ApoE isoform differences 
emerge yet again, for ApoE ε3 and ε4 bind, with high affinity, to the LDL receptor, 
while apoE ε2 does not (Weisgraber et al., 1982).  This readily explains the 
atherosclerotic deposition found in apoE ε2/ε2 and apoE-KO mice, due to 
respectively decreased or abolished receptor mediated apoE endocytosis.  A 
reason that apoE ε4 may be detrimental in AD, aside from its fibrillogenic 
properties, is that it is thought to be a less efficient cholesterol and lipid mobilizer 
and transporter during CNS injury (Mahley et al., 1989).  Furthermore, apoE-
enriched VLDL particles have been shown to modulate neurite outgrowth in an 
LRP mediated and isoform specific manner, with apoE ε3 stimulating outgrowth 
to a larger extent than ε4 (Holtzman et al., 1995).  Aß has been found to be 
preferentially internalized by astrocytes, but ApoE-KO astrocytes do not degrade 
Aß, and blocking LRP also blocks the degradation.  It has therefore been 
concluded that apoE is essential for astrocytes to associate with, internalize, and 
degrade soluble, but not fibrillar Aß (Koistinaho et al., 2004), once again pointing 
to the dual role that apoE plays in AD.   
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Given the importance of apoE, we have decided to further examine the 
role of endogenous mouse apoE in a transgenic mouse model of AD.  To 
determine which part or product of the deposition process is controlled by apoE, 
we examined a mouse model in which the production of Aß is not rate limiting, 
thus allowing the unique effect of apoE to be determined.  We used animals 
expressing mutant forms of both the human APP and presenilin-1 transgenes 
which express high ratios of Aß1-42 /Aß1-40 and develop large amounts of both 
amorphous and filamentous Aß (amyloid) deposits.  Specifically, we crossed 
PS1M146L+/-, APPV717F+/- doubly transgenic animals with an apoE knockout mouse 
(Bales et al., 1999) in order to explore the effect(s) of apoE in a mouse model 
that produces large amounts of Aß1-42 and develops early and severe AD-like 
pathology. We predicted two likely alternative results: 1) If apoE affects Aß 
availability or clearance, it should have little positive or negative effect in our 
model due to the already large amounts of PS1-enhanced Aß production in these 
doubly transgenic mice, or 2) If apoE promotes Aß fibrillarization, then its 
expression should elevate the amount, and/or change the character of the brain 
Aß deposition.   
 Mouse brains were analyzed for AD pathology at seven months of age, 
and we observed that large amounts of amorphous, non-fibrillar, Aß had been 
generated in both sets of animals in statistically similar amounts, reflecting the 
presence of large levels of Aß1-42.  The physical appearance and distribution of 
the immunoreactive deposits was quite different. We found that mature plaque 
deposition was strikingly dependent on the presence of apoE.  In particular, apoE 
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expression induced a more than 3000-fold increase in the formation of mature, 
fibrillar, amyloid (to our knowledge the largest reported effect of any molecule on 
amyloid formation other than the mutant APP itself).  In the absence of apoE, the 
area occupied by the few thioflavine S-positive Aß deposits was not sufficiently 
large to be statistically significantly different from the background thioflavine S 
staining in a completely non-transgenic mouse.  Once apoE’s effect on Aß 
maturation was determined, we wished to determine the source of apoE most 
responsible for this occurrence. 
 It is a curious fact that most (if not all) of the proteins involved in Alzheimer 
amyloid formation are also present in the circulation.  It is therefore important to 
know whether the amyloid deposits of the brain are derived in part from the 
circulating proteins or only from local proteins produced in the brain. The 
evidence that brain expression of Aß, apoE, and ACT can lead to local amyloid 
deposition is strongly supported in the transgenic mouse models of amyloid 
formation.  However, in human, these proteins are made in equal or larger 
amounts in the rest of the body and, as mentioned above, are present in large 
amounts in the blood.  Certain facts point to the possibility that blood-derived 
proteins may contribute significantly to the brain deposits. For example, Aß 
levels, particularly Aß1-42 are elevated in the blood of FAD and many SAD 
patients (Scheuner et al., 1996).  Serum ACT and apoE levels are also generally 
increased in AD patients (Licastro et al., 1995; Lieberman et al., 1995; Blain et 
al., 1997) and apoE4 has been shown to shuttle Aß across the blood brain 
barrier (Martel et al., 1997).  It is therefore reasonable to hypothesize that apoE 
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from the circulation may contribute importantly to the amyloid deposits in the 
brain.  
 We attempted to ascertain whether circulating apoE could contribute to 
Alzheimer amyloid formation using a not often used surgical technique called 
parabiosis whereby mice are sutured together early in life as to allow the sharing 
of their blood circulation (Martinez et al., 1959).  In practice, any circulating 
protein produced in one mouse will be passed to the other and vice versa.  By 
parabiosing an endogenously apoE-expressing mouse to an apoE-KO mouse, 
we sought to determine whether the pathological chaperone, apoE, must be 
synthesized in the brain or can be derived from the blood.  The significance of 
this experiment for drug development is derived from the fact that circulating 
proteins are far easier to administer versus those given intra-cortically. 
       
ENVIRONMENTAL ENRICHMENT 
The development of drugs to effectively treat and/or prevent AD has 
proven a most difficult task for the research community.  Therefore, significant 
effort has been placed in studying non-pharmacological means of delaying or 
preventing AD.  One such avenue of study is that of preventative and therapeutic 
cognitive stimulation regimens.  The correlation between basic cognitive abilities 
in later life and early performance measures such as IQ and educational status 
have been studied by a number of research groups.  For example, Plassman et 
al. (1995) established that performance on the Army General Classification Test 
directly correlated with late-life (i.e. 50 years later) cognitive fitness.  Similarly, 
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low levels of education have also been associated with later cognitive deficits 
and an increased risk of AD (Letenneur et al., 1999). One such study even 
proposed that each year of education reduces the risk of generating AD by 17% 
(Evans et al., 1997).  Though these results are maybe optimistic, a similar study 
found that high occupational attainment is also protective against AD (Stern et 
al., 1994).  No doubt, these reports led to one of the most famous psychological 
inquiries in the AD community; the “nun study.”  Here, Snowdon et al. (1996) 
examined early life linguistic ability, in a population of nuns, as a marker for later 
cognitive decline.  The content of autobiographies for admission into their 
convent written by 93 nuns before the year of 1917 (Average age = 22) were 
studied.  It was found that the scores from cognitive testing (Mini Mental State 
Exam) administered roughly 50-60 years later were highly correlated with both 
idea density and grammatical complexity as well as years of education.  
Furthermore, of those nuns who died during the course of the study (n=14), 
100% of those diagnosed with AD had low idea density in their essays.  Idea 
density was also correlated with the severity of AD pathology (Snowdon et al., 
1996).  Besides education and job attainment, overall low activity levels (physical 
and especially mental) in mid life have also been shown to increase the risk of 
AD (Friedland et al., 2001).   
Recently, several cognitive stimulation/rehabilitation programs have been 
developed in an attempt to slow or reverse the cognitive decline in AD (Davis et 
al., 2001; Wenisch et al., 2005). These programs have generally involved a 
relatively short 4–12 week period of cognitive training classes and/or daily 
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caregiver-directed mental activities, resulting in modest degrees of improvement. 
One such study showed that specific cognitive rehabilitation techniques given to 
patients with mild AD over a 12-week period improved a variety of cognitive skills 
with benefits seen even 3 months following CS (Loewenstein et al., 2004). 
Nonetheless, the therapeutic potential of intensive, longterm CS has not yet been 
evaluated in AD patients.  Moreover, the biochemical and potential pathological 
changes due to CS cannot be easily studied in humans.  Furthermore, for the 
aforementioned risk factors, early-life education, activity, and cognition, the 
cause and affect relationship between AD and poor early-life performance 
markers has not been determined.  The fact that AD exerts its affects on the 
brain at a young age is exemplified by the finding that patients with Down’s 
syndrome can have Aß1-42 accumulation in the brain as early as 12 years old.  Do 
education and mental activity buffer against AD, or does AD predispose one, 
from an early age, to have a low propensity for participation in mentally 
stimulating activities?  Since retrospective studies like those above cannot 
sufficiently answer this question, and long-term prospective studies are not 
practical, the use of rodents, specifically mouse models of AD, must be employed 
for this direction of study.   
Rodents undergoing cognitive stimulation (CS) by being placed in an 
enriched environment (e.g. socially housed in large cages containing toys, 
tunnels, running wheels, etc.) are shown to exhibit improved cognitive 
performance in behavioral testing regimens (e.g. – Morris water maze, Radial 
arm water maze, etc…) (Kobayashi et al., 2002).  EE protects rats against kainic 
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acid-induced seizures (Young et al., 1999), and can even reverse the cognitive 
deficits in rats subjected to long-term lead exposure (Guilarte et al., 2003).  In 
addition, a number of structural and biochemical changes have been noted in 
rodents due to an enriched environment.  For example, the overall thickness of 
the cerebral cortex has been shown to be increased (Diamond et al., 1972).  
There are increases in hippocampal dentate gyrus neurogenesis (Kempermann 
et al., 1997; Brown et al., 2003), increases in the density of synapses 
(Greenough and Volkmar, 1973; Ramirez-Amaya et al., 1999), and the extent of 
dendritic branching (Globus et al., 1973).  EE is also protective, in that Young et 
al (1999) observed a 45% decrease in spontaneous brain cell death as 
measured by TUNEL assay. 
Besides physical and structural changes in brain architecture, a large 
number of genetic and neurochemical measures have been described as being 
altered as a result of exposure to a cognitively stimulating environment.  For 
example, mRNA and protein levels of glial-derived neurotrophic factor and brain-
derived neurotrophic factor, both of which have been associated with neuronal 
plasticity and survival, are increased in the rat hippocampus after exposure to an 
enriched environment (Fischer et al., 1992).  In addition, the levels of another 
growth-related molecule, nerve growth factor (NGF) are increased due to EE.  
When injected into the rat forebrain, NGF improves spatial learning and memory 
(Fischer et al., 1991).  NGF is thought to be important for cholinergic neuron 
maintenance, and has been shown to increase levels of choline 
acetyltransferase, an enzyme whose levels decrease in the AD brain (Gnahn et 
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al., 1983).  Various receptor and receptor-related proteins also undergo changes 
in expression due to EE.  For example, NMDA receptors, which are known to 
play a pivotal role in hippocampal synaptic plasticity (Singer, 1990; Gu, 1995), 
are essential for triggering long-term potentiation and increasing the expression 
of memory related molecules such as phospholipase A2 (PLA2) and the 
immediate early gene (IEG) nerve growth factor induced-A (NGFI-A) (Diamond et 
al., 1972).  PLA2 expression is further linked to synaptic plasticity via Ca2+-
dependant and AMPA receptor-dependant mechanisms (Fischer and Bjorklund, 
1991), for GluR1-4 subunits (i.e. AMPA receptor subunits) are increased due to 
EE.  Additionally, the IEG, NGFI-A is thought to be involved in the early stages of 
memory formation, for its expression is rapidly induced after neuronal activity in 
brain regions with the most pronounced EE-induced structural changes (Wallace 
et al., 1995).  ARC, or activity regulated cytoskeletal protein, is another IEG up-
regulated due to EE and known to be important for learning, for inhibiting it 
blocks both LTP and long-term memory.  These are just a few of the described 
neurochemical changes induced by cognitive stimulation. Our current study of 
environmental enrichment hopes to elucidate some of the genetic and 
biochemical changes most important for preserving memory and reducing 
pathology in a mouse model of AD.          
A previous study from our laboratory sought to elucidate the cognition-
enhancing potential of long-term environmental enrichment (EE) as a therapeutic 
intervention in aged transgenic mouse model of AD, which overexpresses the 
Swedish doubly mutant (K670N,M671L) amyloid precursor protein and bears 
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moderate cortical/hippocampal Aß deposition within mature AD-like neuritic 
plaques (Arendash et al., 2001a, APPENDIX B).  We found that environmental 
enrichment begun relatively late during aging in APPsw transgenic mice provided 
cognitive benefit across multiple cognitive domains (reference learning/memory, 
working memory, recognition, strategy switching – For detailed descriptions of 
behavioral tasks, see (King and Arendash, 2002)) through mechanisms that do 
not seem to involve a reduction in brain Aß deposition. Those results suggested 
that long-term, intensive cognitive stimulation could be therapeutic in stabilizing 
or improving cognitive function in Alzheimer’s disease. 
 One aim of this dissertation sought to answer the key question regarding 
whether pre-emptive EE, as a means of prophylaxis, can protect against the 
pathology of AD, or its associated mental decline, and to further characterize the 
resultant molecular changes.  At weaning, doubly transgenic mouse models of 
AD (hAPPV717F / hPS1M146L) were placed into either standard housing or an 
enriched environment.  These mice were then behaviorally tested between the 
ages of 4½-6 months.  We found that AD mice raised in EE outperformed those 
raised in SH across a variety of behavioral/memory tasks, in which they were 
statistically indistinguishable from non-transgenic (NT) mice.  We found that, 
brain Aß deposition in Tg+ mice was not affected by EE alone, but only when in 
combination with the behavioral testing paradigm which is in and of itself a form 
of cognitive stimulation.  When combined with behavioral testing, EE resulted in 
large reductions in brain Aß deposition.  Golgi staining revealed that the extent of 
dendritic branching and dendritic spine number in the brain were unchanged by 
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enrichment, indicating that one effect of EE is to overcome the dendritic deficits 
present in transgenic AD mice.  Microarray analysis of hippocampal tissue 
revealed that transgenic mice exposed to EE exhibited increased expression of 
multiple memory-related genes, a number of neuroprotective genes involved in 
anti-apoptotic BAD phosphorylation such as IGF2, IGFBP2, and PRLR, as well 
as increased expression of a known Aß sequestering molecule, transthyretin. 
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ABSTRACT 
 
 To determine the role of apolipoprotein E (apoE) in the deposition of 
different forms of Alzheimer amyloid deposit, we studied mice expressing both 
mutant human amyloid ß-protein precursor (AßPP) and presenilin 1 (PS1) that, in 
addition, were either normal or knocked-out for apoE.  By 7 months of age, 
extensive deposits of amorphous amyloid ß (Aß) had developed equally in both 
lines, indicating that, when present in high amounts, Aß alone is sufficient for 
such deposition to occur.  In contrast, filamentous, thioflavine S-positive amyloid 
deposition in AßPP/PS mice was catalyzed at least 3000 fold by apoE.  Electron 
micrographs further illustrated the filamentous nature of Aß deposits in mice 
expressing apoE.  These and other behavior data indicate that the primary 
function of apoE in Alzheimer’s disease is to promote the polymerization of Aß 
into mature, beta pleated sheet filaments, a process that is necessary for 
inducing cognitive decline.  Thus, preventing apoE from binding to Aß may prove 
to be an effective means of therapeutic intervention.  
 
Key Words:  Alzheimer’s Disease, Amyloid ß, Amyloid ß −Protein Precursor 
Apolipoprotein E, Transgenic Mouse Model 
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INTRODUCTION  
 Several lines of investigation indicate that the deposition of Aß peptide into 
amyloid underlies the neurodegeneration and cognitive decline that characterize 
Alzheimer's disease (AD) (Hardy and Selkoe, 2002). Using experimental animal 
models of AD, two proteins have been shown to be essential for both the 
formation of such deposits and for the cognitive decline in these animals (Games 
et al., 1995; Bales et al., 1999; Holtzman et al., 2000; DeMattos et al., 2004; 
Nilsson et al., 2004). The first is the Aß-peptide itself, particularly the Aß1-42 
isoform.  The second protein is apolipoprotein E (apoE) which, when produced 
from the ε4 allele, is the strongest known risk factor for developing sporadic AD 
besides age itself (Wisniewski and Frangione, 1992; Strittmatter and Roses, 
1995).  Increases in both Aß and apoE expression promote Aß deposition in a 
dose dependent manner (Games et al., 1995; Bales et al., 1999; Holtzman et al., 
2000; Fryer et al., 2003). 
 Because cognitive deficits in several models of memory/learning observed 
in mutant AßPP-expressing mouse models of AD are dependent upon 
pathological chaperones such as apoE (and the Aß deposition that they promote) 
(Nilsson et al., 2004), it is important to know which part or product of the 
deposition process is controlled by apoE.  We therefore examined a mouse 
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model of AD in which the production of Aß (and in particular, C-terminally 
extended and highly fibrillogenic Aß species such as Aß1-42) is not rate limiting, 
thus allowing the unique effect of apoE to be determined.  Specifically, we took 
advantage of the fact that animals expressing mutant forms of both human AßPP 
and presenilin-1 transgenes from families carrying inherited Alzheimer's disease 
have a high ratio of Aß1-42 /Aß1-40 and develop large amounts of both amorphous 
and filamentous Aß (amyloid) deposits, resembling that of end-stage human AD 
(Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997; Holcomb et al., 
1998).  We then crossed PS1M146L+/-, AßPPV717F+/+ doubly transgenic animals with 
an apoE knockout mouse(Bales et al., 1999) to explore the effect(s) of apoE in a 
mouse model that develops early and severe AD-like pathology due to the 
relatively high levels of brain Aß1-42.  Current hypotheses predict two alternative 
outcomes: 1) If apoE affects Aß availability or clearance, it should have little 
positive or negative effect in our model due to the already large amounts of PS1-
enhanced Aß production in PS1M146L+/-, APPV717F+/+ mice, or 2) If apoE promotes 
Aß polymerization, then its expression should increase the amount, and/or 
change the character of the Aß deposits in the brains of these mice.  
 At seven months of age, both the apoE+/- and apoE-/- animals were 
euthanized, and the brains analyzed for AD-related pathology. Very large 
amounts of amorphous, non-fibrillar, Aß were generated equally in both sets of 
animals, reflecting the presence of large amounts of Aß1-42 in the brain.  
However, the quality of the deposits was strikingly dependent on the presence of 
apoE.  Specifically, apoE expression induced a more than 3000-fold increase in 
27 
the formation of thioflavine S-positive filamentous amyloid—to our knowledge the 
largest reported effect of any molecule on amyloid formation other than the 
mutant AßPP transgene itself.  Indeed, in the absence of apoE, the area 
occupied by the few thioflavine S-positive Aß deposits was not sufficiently high to 
be statistically significantly different from the background thioflavine S staining in 
a completely non-transgenic mouse. 
 
 
MATERIAL AND METHODS 
Construction of transgenic mice. All animals were housed in shoe box cages with 
static microisolator tops under climate-controlled conditions on a 12 hour light/12 
hour dark cycle, fed Harlan Teklad Global Diet #2018 and provided with tap 
water ad libitum.  Heterozygous PDGF-hAßPP(V717F) mice [Swiss-Webster x 
C57BL/6 x DBA/2] were crossed with PDGF-hPS1(M146L) heterozygotes to 
generate mice with an AßPP+/-,PS1+/- genotype. These mice were subsequently 
crossed with ApoE-/- mice [Swiss-Webster x C57BL/6 xDBA/2] to generate mice 
with genotype AßPP+/-,PS1+/-ApoE+/-. These mice were bred to generate either 
AßPP+/-,PS1+/-,ApoE+/- , or AßPP+/-,PS1+/-,ApoE+/- mice.  All offspring were 
screened by PCR for identity the PDGF-hAPP gene(Games et al., 1995), the 
PDGF-hPS1 gene(Duff et al., 1996), as well as the mouse ApoE gene and neo 
gene (Bales et al., 1997).   
Immunohistochemical Procedures. Mice that have been fasted over night were 
anesthetized with Nembutal (0.1mg/g). The animals were then be intracardially 
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perfused with 0.9% NaCl (25ml) followed by 50ml 4% paraformaldehyde in 1x 
Sorenson’s phosphate buffer. The mounted sections were processed through 
antigen retrieval in prewarmed 25mM citrate buffer (pH 7.3) at +82°C for 5 min 
and further processed as previously described(Nilsson et al., 2001). The sections 
were incubated with primary antibodies against Aß (6E10, dil 1:5000) overnight 
at +4°C. Secondary antibody was anti-mouse IgG developed with NovaRED 
substrate kit (Vector). Thioflavine S staining was performed as previously 
described(Nilsson et al., 2001).   
 
Image Analysis. Data were collected from three equally spaced coronal tissue 
sections for both dorsal hippocampus and overlying parietal cortex (Bregma -
1.30 to -2.30 mm) for each mouse.  The sections were examined with a Nikon 
Eclipse E1000 microscope using either 4X or 10X Plan Fluor objective lenses.  A 
Retiga 1300 CCD (Qimaging) with a Qimaging RGB LCD-slider was used to 
capture images.  For thioflavin S, a Nikon BV-2B fluorescence filter cube was 
used.  Customized software written in Visual Basic 6.0 (Microsoft) utilizing Auto-
Pro function calls (Image Pro Plus, Media Cybernetics) was used to segment and 
quantify images.  Aß deposition was calculated as percent area of interest (=Area 
Stainedtot/Area Measuredtot).  Results were analyzed using a two-tailed, unpaired 
student’s t test with Welch’s correction. 
Electron Microscopy.  Tissue was fixed in 2.5% phosphate buffered 
glutaraldehyde (Electron Microscopy Sciences) overnight at 4 degrees C. The 
cells were post-fixed in 1% osmium tetroxide (Electron Microscopy Sciences) in 
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the above buffer for 1 hour at 4 degrees C. Following buffer rinsing, the cells 
were dehydrated in a graded series of acetone, then infiltrated and embedded in 
LX112 plastic (Ladd Research Industries, Inc). Blocks containing tissue were 
polymerized overnight at 70 degrees C. Cell blocks were sectioned on a Reichert 
Ultracut E ultramicrotome (Leica, Inc), and sections were stained with 6 % uranyl 
acetate and Reynold's lead citrate. Sections were observed and photographed 
with a Philips CM10 electron microscope (FEI, Inc) at 60kV.  
 
 
RESULTS 
 Total Aß deposition was measured in both hippocampus and parietal 
cortex as the percentage of 6E10 antibody immunoreactive staining.  Figures 1a-
b show that overall Aß deposition was not much affected by the presence or 
absence of apoE in these PS/AßPP mice.  No significant difference was found in 
either the hippocampus (apoE+, 5.5%±1.3 vs. apoE KO, 8.3%±3.2) or parietal 
cortex (apoE+, 3.0%±1.3 vs. apoE KO, 1.5%±0.3) (Figure 1c).   
Although total Aß deposition was statistically similar in the apoE+/- and 
apoE-/- mice, there was a clear difference in the regional distribution and 
morphology of the Aß deposits.  The presence of apoE promoted the formation of 
more compact-type plaque structures throughout the hippocampus and parietal 
cortex (Figure 1a), while mice without apoE contained few, if any, compact-like 
plaques anywhere in the brain, instead manifesting a rather diffuse pattern of 
deposition.  Furthermore, mice lacking apoE developed almost no Aß in the 
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granular and molecular layers of the dentate gyrus of the hippocampus (Figure 
1b). 
To confirm the distinction between amorphous Aß deposition and dense 
core plaques, sections were stained with thioflavine S, which detects ß-pleated 
sheet structures characteristic of mature amyloid plaques.  Thioflavine S staining 
was elevated in PS1M146L+/-, AßPPV717F+/- mice containing one copy of 
endogenous apoE by ≥ 3200 fold in both hippocampal and cortical regions as 
compared to mice with the apoE-/- genotype (Figure 2). The increase was 
statistically significant in both the hippocampus (apoE+/-, 0.64%±0.18 vs. apoE-/-, 
0.0002%±0.0001, p=0.0004) and the parietal cortex (apoE+/-, 0.35%±0.04 vs. 
apoE-/-, 0.0001%±0.00005, p=0.0001).  Because there was a difference in 
staining between apoE+/- and apoE-/- mice of three orders of magnitude, a 
logarithmic scale was necessary to resolve the low levels of thioflavine S staining 
in the apoE-/- animals (Figure 2c-d). Electron microscopy confirmed the presence 
of extensive filamentous amyloid deposits in the PS1/AßPP/apoE+/- animals and 
only amorphous deposits in the PS1/AßPP/apoE-/- animals (Figure 2). 
 
DISCUSSION 
 In sum, we report that doubly transgenic mice with both human PS1M146L 
and AßPPV717F mutations do not develop significant thioflavine S-positive amyloid 
plaque deposits by 7 months in the absence of apoE expression, despite the 
accumulation of large amounts of immunoreactive Aß deposition.  Only the 
presence of apoE allows mature filamentous amyloid deposits to form. These 
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data contrast with previous reports utilizing mice expressing only a human AßPP 
mutation (PDAPP mice) in which apoE has been shown to promote both total Aß 
deposition and amyloid formation.  Evidently, because the AßPP/PS1 double 
transgenic mice express very high levels of Aß1-42 in the brain, perhaps 
overriding any effect of apoE on Aß production or clearance, they provide a clear 
proof that apolipoprotein E directly catalyzes the polymerization of Aß into ß-
sheet fibrils and its consequent aggregation to form mature amyloid plaques.  
In vitro (Ma et al., 1994) and in vivo (Nilsson et al., 2001) studies show 
that both of the major pathogenic chaperones found in amyloid ß plaques, apoE 
and ACT, promote Aß filament formation, with apoE showing the higher catalytic 
activity.  Since ACT and apoE act synergistically with regard to Aß deposition, 
future studies with ACT expressing mice could show even more drastic amyloid ß 
deposition. Furthermore, since endogenous mouse-apoE is most related to the 
human ε4 allele of apoE, the human isotype-specific effects of the human apoE 
alleles, specifically the protective properties of the ε2 allele should also be further 
explored in this mouse model of AD.       
Inasmuch as the presence of amyloid plaques is pathonomic for 
Alzheimer's disease, preventing apoE from binding to Aß and stimulating its 
polymerization into ß-sheet filaments may prove to be a promising therapeutic 
approach for AD drug development. An indication that such an approach may be 
effective has been provided by in vitro experiments in which small fragments of 
the Aß peptide were shown to completely inhibit the apoE-catalyzed 
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polymerization of Aß1-42 into neurotoxic amyloid filaments (Ma et al., 1994; Ma et 
al., 1996). 
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Fig. 1.   Little or no effect of ApoE on total Aß deposition - Total Aß 
deposition, diffuse and compact, in 7-month-old PS1M146L+/-, APPV717F+/+, ApoE+/- 
mice (a) and 7-month-old PS1M146L+/-, APPV717F+/+, ApoE-/- mice (b), as measured 
by 6E10 immunostaining. (c) Quantitative image analysis of total Aß deposition 
from all investigated animals.  Hippocampal amyloid load (left) or cortical amyloid 
load (right).  Solid bar, PS1M146L+/-, APPV717F+/+, ApoE+/- (n=3); open bar, 
PS1M146L+/-, APPV717F+/+, ApoE-/- (n=3)
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 Fig. 2.   Strong catalytic effect of ApoE on mature amyloid deposition - 
Thioflavine S plaque staining is increased over 3200 fold in 7-month-old 
PS1M146L+/-, APPV717F+/+, ApoE+/- mice (a) compared to 7-month-old PS1M146L+/-, 
APPV717F+/+, ApoE-/- mice (b).  Quantitative image analysis of compact amyloid 
deposition from all investigated animals is represented on a linear y-axis (c) or 
logarithmic y-axis (d) measuring hippocampal amyloid load (left) or cortical 
amyloid load (right). Solid bar, PS1M146L+/-, APPV717F+/+, ApoE+/- (n=3); open bar, 
PS1M146L+/-, APPV717F+/+, ApoE-/- (n=3); ***, p<0.001. Transmission electron 
microscopy reveals the filamentous nature of plaques in the apoE+/- mice (E, 
6300X and G 44,000X) as compared to the more amorphous deposits found in 
the apoE-/- mice (F and H).       
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ABSTRACT  
Apolipoprotein E (apoE) is expressed in the brain and present in 
Alzheimer’s disease (AD) amyloid plaques. The apoE-ε4 allele, the main genetic 
risk factor for late-onset AD, increases amyloid-beta peptide fibrillization and 
amyloid plaques density.  ApoE is also synthesized in the liver and plays a 
crucial role in cholesterol metabolism, for transgenic mice devoid of apoE show 
hypercholesterolemia and cardiovascular lipid deposition.  Here we investigate 
the neuropathology of transgenic PS1+/-,APP+/- Alzheimer’s disease mouse 
models, either with or without the apoE gene, using parabiosis to determine if 
apoE in the peripheral circulation influences amyloid formation. This surgical 
procedure allows free exchange of proteins via peripheral circulation.  We show 
that apoE is found in the plasma of parabiosed PS1+/-,APP+/-,apoE-KO mice, 
resulting in a reversion of hypercholesterolemia.  Unexpectedly, amyloid 
deposition is reduced in parabiosed PS1+/-,APP+/-,apoE-KO mice as compared to 
unoperated controls. Our findings demonstrate that apoE in the peripheral 
circulation slightly reduces amyloid burden, most clearly in transgenic mice 
devoid of apoE, by likely promoting efflux of amyloid-beta peptides from the 
brain. These findings further reinforce that the mechanisms whereby apoE 
affects amyloid-beta metabolism are complex, and that the modulation of 
peripheral apoE metabolism is not likely to profoundly impact Alzheimer’s 
disease neuropathology.   
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INTRODUCTION  
Amyloid deposits, which are primarily composed of the amyloid beta peptide 
(Aß), are a key feature of Alzheimer’s disease (AD) neuropathology, and their 
formation is likely to contribute to the neuronal degeneration that underlies 
clinical dementia.  Certainly, genetic data point to Aß as the central component of 
the Alzheimer’s pathogenic pathway.  However, several other proteins are found 
in amyloid deposits, and some of these have been proven to alter the rate of 
amyloid filament formation. The best characterized of these amyloid promoters 
are apolipoprotein E (apoE) and α1-antichymotrypsin (ACT), which have been 
shown to facilitate Aß deposition in vitro and in APP transgenic mouse models 
(Ma et al., 1994; Bales et al., 1997; Holtzman et al., 1999; Holtzman et al., 2000; 
Nilsson et al., 2001).  Indeed, without apoE or ACT, even at 2 years of age, 
roughly 50% of homozygous PDAPP mice still do not develop filamentous 
amyloid (Nilsson et al., 2004). These findings agree nicely with the demonstration 
that postmortem AD brain of ApoE4 carriers have increased plaque density 
(Corder et al., 1993; Rebeck et al., 1993).  
A long-standing question in AD research is whether Aß and other proteins 
that are present in the peripheral circulation are involved in amyloid formation 
and the associated brain pathology.  Plasma Aß levels, particularly Aß1-42, are 
elevated in some familial and sporadic AD patients (Scheuner et al., 1996) and 
have been suggested as a potential AD biomarker.  In addition, serum ACT and 
apoE levels have been shown to be generally increased in AD patients (Licastro 
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et al., 1995; Lieberman et al., 1995; Blain et al., 1997), and apoE has been 
shown to shuttle Aß across the blood brain barrier (Martel et al., 1997).  It is 
therefore important to analyze whether Aß peptides, apoE, and ACT in the 
peripheral circulation may have a pathogenic role in AD with respect to amyloid 
deposition in the brain. 
Parabiosis is a technique that enables shared peripheral circulation between 
surgically joined animals and thus gives us the ability to address such questions 
(Martinez et al., 1959).  It allows the influence of circulating factors or hormones 
to be studied, since any circulating protein produced in one mouse will be passed 
to its parabiosed partner and vice versa (Finerty, 1952).  In the present study, we 
used parabiosis to investigate the effect of apoE present in the peripheral 
circulation on brain amyloid deposition in a transgenic model of Alzheimer’s 
disease.  Transgenic mice expressing both the human mutant presenillin-1 
(PS1M146L) and the human mutant amyloid precursor protein (APPV717F) genes 
were parabiosed.  However, one of the parabiosed mice was heterozygous for 
endogenous apoE, while its parabiosed partner lacked apoE expression 
altogether. 
PS1+/-,APP+/- transgenic mice rapidly develop robust Aß-immunoreactive 
deposition by 3 to 4 months of age.  The pathology mainly consists of mature 
cored plaques, which is totally prevented in the absence of apoE in this 
transgenic model (Costa et al., 2004).  We considered PS1+/-,APP+/- mice, with or 
without apoE, to be an excellent choice for parabiosis experiments due their 
rapid onset of amyloid pathology.  Furthermore, the strong impact of apoE on 
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amyloid deposition in this model is ideal, since it is likely that even minute 
amounts of apoE in the central nervous system will strongly affect the amyloid 
phenotype of a parabiosed PS1+/-,APP+/-,apoE-KO mouse.  Thus, parabiosis of 
such transgenic mice would allow us to determine whether the pathological 
chaperone, apoE, needs to be synthesized within the brain or whether its 
presence in the peripheral circulation is sufficient to promote amyloid formation. 
This knowledge will allow strategies for therapeutic interventions against 
Alzheimer disease to be more appropriately devised. 
 
MATERIAL AND METHODS 
 All described procedures were approved by the Institutional Animal Care 
and Use Committee and conducted in compliance with the “Guide for the Care 
and Use of Laboratory Animals”. All animals were housed in shoe box cages with 
static microisolator tops under climate-controlled conditions on a 12 hour light/12 
hour dark cycle, fed Harlan Teklad Global Diet #2018 and provided with tap 
water ad libitum. The animal facility maintains a specific pathogen free status 
based on a sentinel system including colony representatives and quarantine of 
animals received from non-approved vendors or other institutions, respectively.   
 
Parabiosis 
 Six week-old siblings of the same sex were selected for parabiosis.  Both 
animals were transgenic for APP (PDGF-hAPPV717F, human mutant amyloid 
precursor protein) and PS1 (PDGF-hPS1M146L, human mutant presenilin-1). 
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Subsequent crossings of these mice with an apoE-/- mouse generated the APP+/-
,PS1+/-,apoE+/- genotype.  This schedule allowed the generation of siblings with 
genotypes PS1+/-,APP+/-,apoE+/- and PS1+/-,APP+/-,apoE-/- as partners for the 
parabiosis.  Animals were anesthetized with 100 mg/kg, Xylazine 20 mg/kg, and 
Acepromazine 3 mg/kg.  For the parabiosis, the mice were placed in a parallel 
orientation, and a left lateral incision was made on one mouse while a right one 
was made on the partner mouse, extending from the base of the ear toward the 
middle of the femur of the extended pelvic extremity.  The incision included skin 
and muscle along thorax and abdomen. Starting at the last rib, the opening was 
extended into the abdominal cavities to accomplish convergence. The peritonea 
and muscle layers of the two animals were joined by simple interrupted suture 
with 4-0 PDS® (polydioxanone) whereas the skin was closed via stainless steel 
clips.  The animals were allowed to recover in a warm, clean environment before 
being transferred into the husbandry area. Due to the expected 
immunosuppression, prophylactic antibiotic treatment (Enrofloxacin, 5mg/kg), 
was started one day prior to surgery, and was continued for three days.  All 
animals received analgesic/anti-inflammatory treatment (Acetyl salicylic acid 
5mg/kg), for 14 days.  Six months after surgery, the parabiotic pairs were 
euthanized for brain analysis at seven months of age.   
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Immunohistochemical Procedures 
Parabiosed mice were fasted overnight and subsequently anesthetized with 
Nembutal (0.1mg/g body weight).  Blood was collected by cardiac puncture and 
immediately supplemented with 0.1% (w/v) EDTA followed by centrifugation 
(2000xG, 15min).  Plasma was aspirated and total cholesterol was measured 
with a colorimetric assay (Infinity Cholesterol Reagent procedure 401, Sigma).  
The animals were then intracardially perfused with 0.9% NaCl (25ml) followed by 
50ml 4% paraformaldehyde in 1x Sorenson’s phosphate buffer. Brains were 
cryoprotected  through sequential immersion in 10%, 20% and 30% sucrose and 
sectioned (25μm) using a sledge microtome. The mounted brain sections were 
processed through antigen retrieval in prewarmed 25mM citrate buffer (pH 7.3) at 
+82°C for 5 min and further processed as previously described(Nilsson et al., 
2004). The sections were incubated with primary antibodies against Aß (6E10, dil 
1:5000, Signet and rAß40, dil 1:3000, QCB) and apoE (AB947, dil 1:5000, 
Chemicon) overnight at +4°C.  Secondary antibodies were anti-rabbit IgG or anti-
mouse IgG (1:300, Vector).  The immunostaining was visualized with a NovaRED 
substrate kit (Vector). Thioflavine S-staining was performed as previously 
described (Nilsson et al., 2004).  For each mouse, data were collected from three 
equally spaced coronal tissue sections for both dorsal hippocampus and 
overlying parietal cortex (Bregma -1.30 to -2.30 mm).  The sections were 
examined with a Nikon Eclipse E1000 microscope using either 4X or 10X Plan 
Fluor objective lenses.  A Retiga 1300 CCD (Qimaging) with a Qimaging RGB 
LCD-slider was used to capture images.  For thioflavin S stained sections, a 
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Nikon BV-2B fluorescence filter cube was used.  Customized software, written in 
Visual Basic 6.0 (Microsoft) utilizing Auto-Pro function calls (Image Pro Plus, 
Media Cybernetics) was used to segment and quantify images.  Aß deposition 
was calculated as percent area of interest (=Area Stainedtot/Area Measuredtot) 
from no less than seven microscope fields.  Results were analyzed using a two-
tailed, unpaired student’s t test with Welch’s correction.         
 
RESULTS 
Apolipoprotein E is transferred to the parabiosed apoE-KO mice via blood 
circulation.  Endogenous apoE in the plasma of nontransgenic mice can be 
detected at up to 100-fold dilutions.  Plasma apoE expression was examined with 
western blot analysis to verify that apoE from the apoE-positive parabiont was 
able to gain access to the apoE-knockout mouse.  ApoE, in PS1+/-,APP+/+,apoE-
KO mice that had been parabiosed to PS1+/-,APP+/+,apoE+/- mice, was detected at 
a level corresponding to about 5% of that found in nontransgenic mice, as 
determined by densitometric analysis. In contrast no apoE was found in control 
non-parabiosed apoE-KO mice (Figure 1A).  This finding could be interpreted as 
restricted exchange of plasma proteins, such as apoE, between the partners. 
Alternatively the low plasma apoE levels in the parabiosed apoE-knockout 
partner could be due to the need to quickly sequester lipoprotein particles from 
the blood stream in these mice.  This would tend to increase turnover and lower 
steady state levels of apoE in the plasma.  We decided to determine whether the 
parabiosis allowed free exchange of blood cells between parabiosed partners by 
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analyzing serum DNA.  PCR analysis revealed that parabiosed apoE-KO mice 
contain almost equal amounts of apoE DNA in their blood as their apoE 
heterozygous parabiosis partners.  This DNA analysis demonstrates a successful 
and efficient white blood cell transfer between the two parabionts (Figure 1B).   
 
Apolipoprotein E transferred through parabiosis prevents 
hypercholesterolemia in the apoE-KO mice.  Mice with targeted disruption of 
the mouse-apoE gene are known to develop severe hypercholesterolemia and 
atherosclerosis (Plump et al., 1992; Zhang et al., 1992).  Accordingly, the PS1+/-
,APP+/+,apoE-KO mice used in these experiments show elevated levels of serum 
cholesterol as compared to nontransgenic, wild type, mice and PS1+/-,APP+/+ 
mice with the endogenous murine apoE gene (Table 1).  Nontransgenic mice 
had, on average, 105±6 mg/dl (n=19) of total cholesterol in their plasma, while 
PS1+/-,APP+/+ transgenic mice with only one copy of apoE (PS1+/-,APP+/+,apoE+/-) 
had levels averaging near 79±6 mg/dl (n=8).  In contrast, the levels of total 
cholesterol were roughly four times higher in PS1+/-,APP+/+,apoE-KO 
mice(392±121 mg/dl, n=3) and five times higher in apoE-KO mice lacking APP 
expression (501±39 mg/dl, n=13).  In PS1+/-,APP+/+,apoE-KO mice that had been 
parabiosed with a partner harboring one copy of the murine apoE gene, 
cholesterol levels in the apoE knock-out mice were rescued (125 mg/dl for a 5-
month PS1+/-,APP+/+,apoE-KO mouse and 87 mg/dl for a 7 month PS1+/-
,APP+/+,apoE-KO mouse, Table 1). The latter result was reproduced in all 
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parabiosed pairs whose Aß-immunoreactive and amyloid deposition was 
quantified. 
 
Apolipoprotein E in the peripheral circulation alone does not reach the 
brain parenchyma and is unable to promote brain amyloid deposition.  
Immunohistochemical analysis of Aß-immunoreactive deposition using the 6E10 
monoclonal anti-Aß antibody on coronal brain sections from parabiosed partners 
and their respective non-parabiosed controls at seven months of age revealed 
only minor differences (Figure 2).  In the cerebral cortex no statistically significant 
difference in Aß burden between the parabiosed (1.55%±0.5; n=6) and the 
nonparabiosed (1.50%±0.1; n=3) PS1+/-,APP+/+,apoE-KO mice was found.  This 
suggests that apoE present in the peripheral circulation is not sufficient to 
promote brain Aß-immunoreactive deposition. There also was no statistically 
significant difference in Aß burden in cerebral cortex between the parabiosed 
(2.2%±0.5; n=6) and the nonparabiosed (3.0%±0.7; n=3) PS1+/-,APP+/+,apoE+/- 
mice.  However, a slightly greater amount (p=0.043) of Aß deposition was found 
in the hippocampus, of the nonparabiosed PS1+/-,APP+/+,apoE+/- mice (5.5%±0.7; 
n=3) as compared to the parabiosed PS1+/-,APP+/+,apoE+/- mice (3.3%±0.7; n=6; 
Figure 2F). Again, there was no statistically significant difference in Aß burden 
between parabiosed and control PS1+/-,APP+/+,apoE-KO mice in the 
hippocampus (Figure 2F). ApoE-immunoreactivity was detected in virtually all 
amyloid plaques of parabiosed PS1+/-,APP+/+,apoE+/- in the brain (Figure 3a,b) 
and in astrocytes of nontransgenic mice (Figure 3c,d). In contrast, parabiosed 
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PS1+/-,APP+/+,apoE-KO with an Aß burden showed some apoE-immunoreactive 
staining in the choroid plexus, but none in the brain parenchyma (Figure 3e), 
suggesting that apoE in the peripheral circulation is essentially unable to cross 
the blood brain barrier to reach the brain parenchyma thereby limiting its impact 
on AD neuropathology. Control experiments verified that no apoE-
immunostaining was present in choroid plexus of unoperated PS1+/-
,APP+/+,apoE-KO mouse (Figure 3f). 
 
Amyloid deposition is reduced in parabiosed mice lacking ApoE. 
Previous studies have shown a striking difference in the structure of amyloid and 
Aß immunoreactive deposition in PS1+/-,APP+/+ mice expressing endogenous 
apoE as compared to PS1+/-,APP+/+,apoE-KO mice (Costa et al., 2004). This 
structural difference is not associated with similar quantitative differences in the 
Aß-immunoreactive burden. In fact, immunohistochemical detection of Aß 
immunoreactive deposition showed equal amounts in PS1+/-,APP+/+ mice with 
and without apoE, albeit with a different anatomic distribution. In the present 
study, Thioflavin S staining was performed to compare the levels of mature, 
compact, amyloid between the parabiosed mice pairs and their respective non-
parabiosed controls.  No statistically significant difference in the %-area of 
Thioflavin S-staining was found between parabiosed PS1+/-,APP+/+,apoE+/- mice 
and non-parabiosed controls of the same genotype (Figure 4a).  Because the 
deposition of compact amyloid is a specific effect of apoE, in general, only minute 
amounts of compact amyloid were found in apoE-/- mice.   The few, detectable, 
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plaques were counted at 400x magnification.  Remarkably, even though apoE 
knock-out mice develop only a very low amount of amyloid deposition, this 
number was further reduced in PS1+/-,APP+/+,apoE-KO mice that had been 
parabiosed.  Both, the hippocampal and cortical regions showed a significant 
difference between parabiosed PS1+/-,APP+/+,apoE-KO mice (hippocampus, 
17.2±5.4; n=6 and cortex, 13.0±3.0; n=6) and non-parabiosed PS1+/-
,APP+/+,apoE-/- mice (hippocampus, 28.3±3.0 n=3; and cortex, 20.7±5.2; n=3) in 
the number of plaques per brain section (Fig. 4b). Thus, the amyloid plaque 
loads were 53% and 112% higher for the hippocampus and the cerebral cortex 
respectively in non-parabiosed mice versus parabiosed apoE-KO mice.  
Similarly, the optical density of thioflavine S plaque deposition was also 
significantly higher in the apoE-KO control mice as compared to those that were 
not parabiosed (data not shown). 
  
DISCUSSION  
It has long been debated to what extent proteins derived from the blood 
stream contribute to Alzheimer´s disease pathology.  A hematogenous origin of 
amyloidogenic proteins in AD is supported by the fact that systemic amyloid 
disorders are driven by high concentrations of these proteins in the peripheral 
circulation.  Furthermore, the frequent presence of cerebral amyloid angiopathy 
(CAA) in AD postmortem brain might affect BBB permeability and further 
increase influx and efflux of amyloidogenic proteins such as apoE and Aß.  It is 
known that Aß in the blood stream can reach the brain and adhere to amyloid 
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deposits, as demonstrated through intra-arterial injection of labeled [125I]-Aß in 
squirrel monkeys (Ghilardi et al., 1996).  Serum amyloid P component, which is 
derived from the peripheral circulation and believed to render amyloid plaques in 
AD brain less prone to clearance, is an example of a peripheral protein that is 
suspected to impact AD neuropathology (Pepys et al., 2002). Developing an AD 
therapy against a peripheral target has clear pharmacological and clinical 
advantages.  
Here we show that parabiosis is a feasible approach to determine whether a 
given protein in the blood stream is involved in AD amyloidosis.  This procedure 
allows free flux of apoE between the parabiosed partners, as assessed by the 
level of blood cell DNA.  Despite this fact, we observed rather low steady state 
levels of apoE (5% of nontransgenic mice) in parabiosed apoE knockout mice.  
We speculate that the low steady state levels of plasma apoE are caused by the 
rapid turnover of apoE and the high demand for apoE to clear lipoprotein 
particles in the apoE knockout mice.  The very rapid clearance of plasma apoE 
(t1/2= 20 min), through uptake by the liver (Vogel et al., 1985; Mahley et al., 
1989), does support this hypothesis.  
The low amounts of apoE transferred through parabiosis are however 
sufficient to normalize the hypercholesterolemia of apoE-knockout mice. 
Previous studies have also shown that a rather small amount of apoE is sufficient 
to restore essentially normal cholesterol metabolism in mice.  Normalization of 
hypercholesterolemia of apoE knockout mice has been shown by 
supplementation with apoE through bone marrow transplantation (Linton et al., 
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1995) or from hypomorphic apoE alleles (Raffai and Weisgraber, 2002). In fact 
only ≈ 3% of wild-type apoE levels in plasma appear to be required to maintain 
normal plasma cholesterol levels, and even less plasma apoE is needed to 
reduce atherosclerosis and lipid deposition in the aorta (Thorngate et al., 2000). 
ApoE gene dosage also strongly determines the onset and extent of amyloid 
deposition in amyloid precursor protein transgenic mice. The absence of apoE 
anatomically redistributes Aß immunoreactivity in the brain and essentially blocks 
amyloid deposition (Bales et al., 1999; Holtzman et al., 2000; Nilsson et al., 
2004). Experiments in bigenic mice containing both presenilin-1 and APP 
demonstrated that the main effect exerted by apoE is on the formation of senile 
(Thioflavine S positive) plaques (Costa et al., 2004).  Thus, we considered the 
crossed PS1xAPP animal model to be an ideal animal model to evaluate the role 
of peripheral apoE on Aß and amyloid pathology.  It is reasonable to anticipate 
that even a very small amount of apoE entering the CNS compartment would 
profoundly facilitate amyloid pathology in such a transgenic model. To our 
surprise we did not see any enhanced amyloid deposition in parabiosed PS1+/-
,APP+/-,apoE-/- mice.  In fact, on the contrary, we found a reduced number of 
Thioflavine S-positive deposits in the parabiosed mice that were devoid of apoE.  
These results show that very little, if any, apoE synthesized in the periphery 
reaches the brain and that apoE derived from the periphery does not accelerate 
the amyloid pathology.  We were only able to detect apoE-immunoreactivity in 
the choroid plexus of parabiosed PS1+/-,APP+/-,apoE-/- mice, which is in 
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agreement with studies where 125I-labeled apoE has been infused via the carotid 
artery in guinea pigs (Martel et al., 1997).  
Amyloid deposition, at least in APP transgenic mice, is a rather dynamic 
process whereby the size of an individual plaque can grow or shrink dramatically 
within months (Christie et al., 2001).  Clearly different pools of Aß in the body 
exist in a dynamic equilibrium prior to onset of amyloid deposition. There is, for 
example, a strong correlation between Aß levels in the CSF, plasma, and brain of 
young PDAPP mice (DeMattos et al., 2002b), and this equilibrium can be quickly 
altered by injecting a high-affinity Aß antibody that is able to sequester soluble 
Aß in the periphery (DeMattos et al., 2001; DeMattos et al., 2002a). It is 
interesting to note that peripherally injected Aß is rapidly cleared by the liver in 
nontransgenic mice, but not in apoE knockout mice (Hone et al., 2003). Thus, it 
could be that our finding of reduced amyloid deposition in parabiosed PS1+/-
,APP+/+,apoE-KO mice is due to apoE in the periphery clearing Aß.  The 
peripheral clearance of Aß would then shift the equilibrium towards efflux of Aß 
out of the brain and thereby reduce/delay amyloid deposition in the brains of 
parabiosed PS1+/-,APP+/+,apoE-KO mice.  ApoE could thereby act as a sink to 
drain Aß out of the brain and into the peripheral circulation for subsequent 
clearance by the liver. The sink hypothesis of Aß metabolism in APP transgenic 
mice was introduced as a model to explain the effects of passive vaccination 
against Aß.  Anti-Aß, but also apoE, was found to sequester Aß in a dialysis 
system (DeMattos et al., 2002a).  A similar mechanism might also explain the 
tendency of reduced Aß and amyloid burden in the brains of parabiosed PS1+/-
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,APP+/+,apoE+/- mice as compared to their unoperated siblings. Thus, drainage of 
apoE in the blood of the parabiosed PS1+/-,APP+/+,apoE+/- mice, through the 
shared circulation with the apoE KO mice, could be compensated for by an efflux 
of apoE from the brain to the periphery in these mice. Such transfer of apoE 
would tend to transport Aß out of the CNS compartment in the parabiosed PS1+/-
,APP+/+,apoE+/- mice, and thereby slow amyloid deposition. Previous transgenic 
experiments do suggest that human apoE can shift the equilibrium of Aß 
between different compartments and favor transport of Aß out of the brain. The 
mechanisms of Aß efflux from the brain might be both by bulk flow of ISF into the 
CSF, as well as across the blood brain barrier (Shibata et al., 2000; Silverberg et 
al., 2003). The low-density lipoprotein receptor-related protein, which is an apoE 
receptor, is a suspected receptor for Aß efflux (Zlokovic, 2004). No apoE-Aß 
complexes relevant to such transport mechanism could be shown in these 
experiments (Shibata et al., 2000), however other findings are strongly 
suggestive of apoE-Aß complexes existing in the ISF and also regulating Aß 
clearance.  Microdialysis experiments have shown that the presence of apoE 
extends the half-life of Aß in the ISF, which could be due to the existence of a 
reservoir of Aß as apoE-Aß complexes in the ISF (DeMattos et al., 2004).  
Furthermore, the human glial fibrillary acidic protein promoter GFAP-apoE3 
transgene, when crossed to an APP/apoE-KO genotype, lowered both soluble 
Aß levels in the brain and the ratio of CSF/plasma Aß42 in a dose dependant 
manner prior to onset of amyloid deposition (DeMattos, 2002).  The latter findings 
strongly suggest that apoE exerts dual functions with respect to Aß metabolism 
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by both facilitating amyloid deposition, but also by clearing Aß from the CNS to 
plasma through efflux mechanisms.  In sum, our findings suggest that apoE in 
the peripheral circulation does not promote Aß deposition in the brain, but clears 
Aß by favoring its efflux from the brain into the periphery.  These findings 
reinforce the idea that agents that are able to strongly sequester and clear 
soluble Aß monomers in the periphery, such as Aß antibodies (DeMattos et al., 
2001) or other high-affinity Aß binders (Matsuoka et al., 2003), could be 
promising novel therapeutics in AD.  
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Table 1 – Apolipoprotein E (ApoE) derived from the blood through 
parabiosis restores hypercholesterolemia in Aß-producing ApoE Knockout 
Mice 
 
Genotype    Age  Total Cholesterol (mg/dl) n 
 
Control 
Nontransgenic    7 months   105 ± 6           15 
PS1-/-APP+/+apoE+/-   7 months     73 ± 8  7 
PS1+/-APP+/+apoE+/-   7 months     79 ± 6  8 
PS1+/-APP+/+apoE-/-   7 months   392 ± 121  3 
ApoE-/-                               7 months   501 ± 39           13 
 
Parabiosed pairs 
1a. PS1+/-APP+/+apoE+/-   5 months   118   1 
1b. PS1+/-APP+/+apoE-/-   5 months   125   1 
2a. PS1+/-APP+/+apoE+/-   7 months     87   1 
2b. PS1+/-APP+/+apoE-/-   7 months     86   1 
3a. PS1+/-APP+/+apoE+/-   7 months   106   1 
3b. PS1+/-APP+/+apoE-/-   7 months     90   1 
4a. PS1+/-APP+/+apoE+/-   5 months     89   1 
4b. PS1+/-APP+/+apoE-/-   5 months     90   1 
 
Table 1 - Total plasma cholesterol measurements in randomly 
selected parabiosed pairs compared to control mice of various 
genotypes.  Apolipoprotein E derived from peripheral circulation can 
restore the hypercholesterolemia typical of Apolipoprotein E knockout 
(PS1+/-,APP+/+,apoE-/-) mice. 
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Figure 1 - (A) Apolipoprotein E can be detected in a parabiosed apoE-knockout 
mouse (lane 7) but not in a apoE knockout mouse that has not been parabiosed 
(lane 5). Lane 6 shows parabiosed partner that is heterozygous for the apoE 
gene. Lanes 1-4 are ten-fold dilutions of plasma from a nontransgenic mouse. 
(B) Parabiosed PS1+/-,APP+/+,apoE-/- and PS1+/-, APP+/+,apoE+/- mice show an 
equal extent of murine apoE and neo DNA in blood cells indicating successful 
and efficient white blood cell transfer between parabiosed partners.  
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Figure 2. Aß-immunoreactive (6E10) staining in parabiosed  or control PS1+/-
,APP+/+apoE-/- and PS1+/-,APP+/+,apoE+/- mice. The staining in PS1+/-
,APP+/+,apoE-/- mice, which is essentially only diffuse Aß deposition, is extensive 
in the hippocampus (B and D).In contrast, PS1+/-,APP+/+,apoE+/- mice show an 
abundance of amyloid plaques (A and C). The Aß immunostaining is essentially 
unaffected by parabiosis (n=6) (A and B) in both the cerebral cortex (E) and the 
hippocampus (F), as compared to unoperated mice (n=3) (C and D). No Aß-
immunoreactive staining was detected in nontransgenic mice (data not shown).  
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Fig. 3 – Apolipoprotein E immunostaining in parabiosed and control PS1+/- 
,APP+/+,apoE-/- and PS1+/-,APP+/+,apoE+/- mice.  ApoE is detected in amyloid 
plaques in parabiosed PS1+/-,APP+/+,apoE+/- mice (A and B) and PS1+/-
,APP+/+,apoE+/- controls (not shown) as well in astrocytes of nontransgenic 
control animals (C and D). In PS1+/-,APP+/+,apoE-/- control mice, no apoE 
immunoreactivity is detrected (F), but parabiosed mice of the same genotype 
present with a small amount of staining in choroid plexus, while none is present 
in the brain parenchyma (E).    
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Fig. 4 – Thioflavine S tissue staining for the detection of filamentous Aß.  (A) 
There is no statistical significant difference in the area of thioflavine S staining, as 
determined by densitometric analysis, in PS1+/-,APP+/+,apoE+/- between 
parabiosed (n=6) and control (n=3) mice in either the hippocampus or cerebral 
cortex.  (B) The number of plaques counted per brain section in parabiosed 
PS1+/-,APP+/+apoE-/- (n=6) mice is significantly smaller than that of 
nonparabiosed control (n=3) mice of the same genotype in both hippocampus 
and cerebral cortex.   
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ABSTRACT  
 Although lifelong cognitive stimulation is associated with lower risk of 
Alzheimer’s disease (AD), prospective long-term human studies needed to prove 
that environmental enrichment (EE) protects against AD are impractical.  We 
therefore sought to investigate the preventative potential of EE using mice 
expressing both human mutant presenilin-1 and amyloid precursor protein 
(PS1/PDAPP).  At weaning, mice were placed into either an enriched or standard 
housing (SH) environment.  Behavioral testing at 4½-6 months showed that EE-
PS1/PDAPP mice outperformed mice in SH, and were behaviorally 
indistinguishable from NT mice.  PS1/PDAPP mice given both EE and behavioral 
testing showed greater than 50% less brain ß-amyloid (Aß), but did not exhibit 
changes in dendritic morphology.  Microarray analysis using hippocampal tissue 
revealed large EE-induced changes in the expression of genes/proteins related 
to memory, neuroprotection, and Aß sequestration.  Inhibition of one such 
protein, PDE4, a cAMP-phosphodiesterase, by Rolipram treatment for two 
weeks, mimicked the cognitive benefits of EE. 
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INTRODUCTION 
 Alzheimer’s disease (AD) is a common neurodegenerative disorder 
characterized by parenchymal ß-amyloid deposition, neurofibrillary tangle 
formation, neuronal loss, and cognitive decline.  A lifelong pattern of high mental 
activity (Wilson et al., 2002) and educational attainment (Stern et al., 1994) 
correlates with lower risk of AD and may be protective.  Furthermore, high levels 
of linguistic ability early in life are associated with a reduced risk of the disease 
(Snowdon et al., 1996; Riley et al., 2005).  These studies suggest that extra 
“cognitive reserve” developed throughout life may help buffer against the 
consequences of later dementia.  However, despite some encouraging results 
(Loewenstein et al., 2004) the extent to which cognitive stimulation (i.e. 
environmental enrichment, EE) protects against AD remains difficult to assess in 
humans because: 1) retrospective studies cannot unequivocally isolate 
environmental enrichment from other factors affecting cognition over a lifetime, 
and 2)  long-term intervention in humans is impractical.  Furthermore, 
epidemiological human studies give no insights about the potential mechanisms 
by which EE may protect against AD.   
 The key question about whether EE intervention can protect against AD 
pathology, or its associated mental decline, was addressed in the present study 
using a transgenic mouse model of the disease.  The mice chosen express both 
the human mutant amyloid precursor protein (hAPPV717F) and mutant Presenilin 1 
(hPS1M146L) genes, which result in moderate brain ß-amyloid plaque deposition 
and significant behavioral impairment by 5-6 months of age.  At weaning, mice 
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were placed into either standard housing or an enriched environment, and were 
behaviorally tested between 4½-6 months of age.  It is known from previous 
studies that non-transgenic rodents subjected to cognitive stimulation (i.e. EE) 
perform better in water mazes, exhibit increased dendritic branching and 
dendritic spine formation (Globus et al., 1973; Comery et al., 1995; Turner et al., 
2003), increased synaptogenesis (Ramirez-Amaya et al., 1999), and increased 
neuronal plasticity-related gene expression (Pinaud et al., 2001), while exhibiting 
decreased levels of apoptotic cell death (Young et al., 1999). 
Our previous experiments determined that an EE paradigm used 
therapeutically in aged AD transgenic mice with severe Aß plaque deposition 
provided cognitive benefits without affecting the amyloid plaque burden 
(Arendash et al., 2004a).  Here we sought to determine the extent to which pre-
emptive EE protects memory, impacts Aß deposition, and affects dendritic 
morphology.  To characterize these changes at the molecular level, hippocampal 
gene expression was analyzed using a whole mouse genome microarray.  
 We found that PS1/PDAPP mice raised in EE outperformed those raised 
in SH across a variety of behavioral/memory tasks, in which they were 
statistically indistinguishable from non-transgenic (NT) mice.  Interestingly, brain 
Aß deposition in Tg+ mice was not affected by EE alone, but in combination with 
behavioral testing (an additional enriching experience), EE resulted in large 
reductions in brain Aß deposition.  Although the extent of dendritic branching and 
dendritic spine numbers in cortex/hippocampus were unchanged by enrichment, 
Tg+ mice given EE did exhibit increased expression of multiple memory-related 
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genes, a number of neuroprotective genes involved in anti-apoptotic BAD 
phosphorylation, as well as increased  expression of transthyretin (a known Aß 
sequestering molecule). 
 
RESULTS 
 Behavioral Testing.  Cognitive performance for both standard-housed (SH) 
and environmentally-enriched (EE) mice was determined between 4½-6 months 
of age through five cognitive-based tasks (Radial Arm Water Maze, Platform 
Recognition, Morris maze, Y-maze, and Circular Platform) – each measuring 
discreet cognitive domains.  Although we found significant effects of EE on 
multiple tasks and measures therein, two of the tasks were particularly important.  
Mice were tested in the radial arm water maze (RAWM), a task designed to 
assay working memory.  Over days 7-9 of testing, transgenic mice raised in 
environmental enrichment (Tg+/EE) had significantly lower escape latencies than 
their SH counterparts for the last acquisition trial (T4; p<0.001) and also the 
memory retention trial (T5; P<0.00001) (Figure 1A).  Interestingly, EE also 
improved the overall RAWM performance of non-transgenic (NT) mice, as 
evidenced by their significantly lower escape latencies on T4 compared to their 
SH counterparts (p<0.02).  The only other task in which EE improved upon the 
already fine performance of NT/SH mice was the circular platform task of spatial 
learning, wherein NT/EE mice had significantly shorter escape latencies overall 
compared to NT/SH mice (data not shown).  Since mice raised in an enriched 
environment had larger cages and access to mazes and running wheels, their 
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potential athletic ability could have been superior to mice raised in standard 
housing.  This was not the case, however, since analysis of the number of 
seconds taken per arm choice revealed no statistical differences in swim speed 
between SH and EE groups for either NT or Tg+ mice.  Furthermore, Tg+/EE 
mice made significantly fewer RAWM errors than Tg+/SH mice, and again were 
not statistically different from NT mice (SH or EE) (Data not shown).  In the 
platform recognition task, which requires mice to use a search/identification 
strategy rather than the spatial strategy of Morris maze and RAWM, similar 
behavioral benefit was observed for Tg+ mice.  Tg+/EE mice had significantly 
lower escape latencies than Tg+/SH mice over all days of testing (p<0.005), as 
well as on all but the initial day of testing (P<0.01) (Figure 1B).  Furthermore, 
Tg+/EE mice were not statistically significantly different from both NT groups in 
this task. 
 To determine the effects of EE on overall cognitive performance, we 
performed discriminant function analysis (DFA) across 8 cognitive measures 
taken from our test battery that represent multiple cognitive domains (working 
memory, reference learning/memory, identification/recognition).  DFA determines 
whether groups can be distinguished from one another based on their overall 
behavioral performance across multiple cognitive measures.  As shown in Figure 
1C, DFA was easily able to distinguish the impaired overall cognitive 
performance of Tg+/SH mice from the much better performance of both Tg+/EE 
mice and NT/SH controls (p<0.001 for both comparisons).  The latter two groups 
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could not be distinguished from one another by DFA.  Thus, the effect of EE in 
Tg+ mice was global in spanning multiple cognitive domains.  
 Alzheimer’s Disease Pathology. To study the effect of environmental 
enrichment on AD pathology, overall Aß immunoreactivity and mature ß-amyloid 
(Aß) deposition were measured.  In order to eliminate behavioral testing as an 
interfering form of cognitive stimulation that could alter brain pathology, we raised 
two cohorts of mice in both SH and EE conditions through 6 months of age.  
Aß immunohistochemistry was measured in both cohorts, but only one cohort 
underwent behavioral testing between 4½-6 months of age.  Total Aß 
immunoreactivity, using the 6E10 monoclonal antibody, revealed that there was 
no difference in total Aß load between Tg+/EE and Tg+/SH mice in either 
cerebral cortex or hippocampus for the “non-behaviorally tested” group (Figure 
2A,B).  Aß 1-42 enzyme linked immunosorbent assay (ELISA) further verified 
that the Aß levels (either soluble or insoluble) were not statistically significantly 
different between non-behaviorally tested SH vs. EE transgenic groups (Data not 
shown).  Since some pathological chaperones, such as apolipoprotein E, exert 
their contributory effect on AD pathology by promoting compact plaque formation 
rather than overall Aß levels (Costa et al., 2004), it is not unreasonable to expect 
EE to affect a change in only mature (compact) Aß deposition.  We find however, 
that mature Aß plaque loads (as measured by thioflavine S staining) were also 
not significantly different between non-behaviorally tested EE and SH transgenic 
groups in either cerebral cortex or hippocampus (Figure 2C,D).   
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Importantly, we did observe that behaviorally-tested EE mice had 
significantly lower Aß deposition than those mice that underwent only EE.  This 
was true for both total and compact Aß deposition and for both cortex and 
hippocampus (Figure 2A-D).  For behaviorally-tested Tg+/EE mice, their 57.6% 
and 69.0% decreases in compact Aß deposition in cortex and hippocampus, 
respectively, compared to non-behaviorally tested Tg+EE mice are particularly 
noteworthy.  Our Aß deposition results from both cohorts thus indicate that EE or 
behavioral testing alone is not sufficient to alter Aß pathology, but when they are 
combined there is a large statistically significant effect provided by both of these 
forms of cognitive stimulation in concert with one another.  Although Aß 
deposition was reduced by a combination of EE and cognitive testing, there were 
no statistically significant correlations in the Tg+/EE mice between such AD 
pathology and any behavioral measure (data not shown), indicating that the mice 
had experienced EE-induced cognitive improvement that was at least partially 
independent of any reduction in Aß pathology. 
 The extent and distribution of dendritic arborization in Layer V cortical 
neurons was measured in behaviorally tested mice through Golgi staining.  Using 
the Sholl method of quantification, there was no observed difference in dendritic 
branching between transgenic EE and SH groups (Figure 2E).  However, both 
Tg+/SH and Tg+/EE groups had significantly reduced dendritic arborization 
compared to non-transgenic single-housed (NT/SH) mice (p<0.001), indicating 
that EE could not increase dendritic arborization in Tg+ mice to the level of NT 
controls.  Additional evidence that EE did not affect dendritic morphology is 
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provided by analysis of dendritic spine counts in both cortex and hippocampus of 
Tg+ mice (Figure 2F).  No EE-induced increase in dendritic spines was evident in 
Tg+ mice for either cortical Layer V pyramidal neurons or for hippocampal CA1 
neurons.  Thus, Tg+/EE mice performed identically to NT/SH controls despite 
having reduced dendritic branching and synaptic spine counts that were identical 
to Tg+/SH mice. Evidentially, EE must induce changes in the brains of 
PS1/PDAPP Tg+ mice that allow them to compensate for any cognitive damage 
that may be imparted by the dendritic branching deficits and the Aß pathology 
typical of these transgenic mouse lines.  
 Microarray.  To begin to investigate the mechanism(s) by which EE 
protects against AD-induced cognitive decline, we used microarray analysis to 
examine gene expression changes in the hippocampus that might contribute to 
the aforementioned memory enhancement.  Non-behaviorally tested EE (n=4) 
and SH (n=4) transgenic mice were analyzed using an Affymetrix GeneChip 
designed for the mouse genome.  In all, over 120 genes showed statistically 
significant expression changes in response to EE. Of these genes, roughly 70 
were changed by a factor of 2.0 or more.  Many of the more robust changes 
occurred in genes already implicated in one or more aspects of memory or AD 
(TABLE 1).  For example, insulin-like growth factor (IGF-2), which has also been 
shown to play a neuroprotective role against Aß (Dore et al., 1997) was up-
regulated in EE mice by 2.5 fold.  This gene, along with Insulin-like growth factor 
binding protein-2 (IGFBP-2) (up-regulated 3.0 fold in EE), and the prolactin 
receptor (PRLR) (up-regulated 21.1 fold in EE) have all been implicated as 
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neuroprotective molecules acting in concert upstream of the Akt and Erk1/2 
pathways that ultimately lead to BAD phosphorylation, an event shown to be both 
neuroprotective and anti-apoptotic (Bonni et al., 1999; Thompson and 
Thompson, 2004).  A 10-fold increase in transthyretin (TTR), an Aß binding 
protein shown to sequester Aß and inhibit amyloid formation, was also observed 
in the EE mice.  These microarray results were verified by quantitative real-time 
PCR (Table 2).   Two genes involved in memory improvement, phospholipase A2 
and cytochrome C oxidase were up-regulated in EE mice by 6.7 and 3.1 fold 
respectively.  Furthermore, phosphodiesterase 4B was down-regulated 2.2 fold 
and the cholecystokinin B receptor was down-regulated 3.2 fold.  Both of these 
genes, when experimentally inhibited, are known to improve memory (Lemaire et 
al., 1994; Zhang et al., 2000; Bourtchouladze et al., 2003; Zhang et al., 2004).  
Calcineurin knockout mice exhibit increased tau phosphorylation, abnormal 
neuronal cytoskeleton, and cognitive deficits, making the increased expression of 
this gene by EE also interesting (Kayyali et al., 1997; Zeng et al., 2001).  
An examination of the functions of the proteins whose expression is 
changed by EE reveals that many participate in a signaling pathway that can 
confer neuroprotection in several experimental systems (See Figure 3).  The 
benefit of deriving such a neuroprotective pathway from the microarray results is 
that potential targets of therapeutic intervention can be identified.  For example, if 
the down-regulated genes identified by microarray analysis are responsible for 
the improvement in cognitive function, we would predict that pharmacological 
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inhibition of the products of one or more of these genes should have similar 
beneficial effects. 
To test this hypothesis, we attempted to pharmacologically intervene in 
the pathway shown in Figure 3 in hopes of emulating the beneficial memory 
effects of EE.  In our initial experiments, we chose to inhibit PDE4 since it is 
down-regulated by EE, and a there exists a highly specific PDE4 inhibitor, 
Rolipram, which has already been found to alleviate memory deficits in rodent 
models.   
To test this possibility, we initiated experiments in which Rolipram, a 
specific inhibitor of cAMP phosphodiesterase 4 (PDE4) (Figure 3, Purple), has 
been injected over a two-week period into.  Cognitively deficient PS1/PDAPP 
mice were injected with Rolipram over a two-week period, and then subjected to 
6 days of RAWM testing.  The injected mice had significantly lower escape 
latencies than those mice receiving vehicle alone for the last acquisition trial (T4; 
p<0.05) and also the memory retention trial (T5; P<0.05), indicating that Rolipram 
treatment effectively mimics the cognitive benefits of environmental enrichment 
(Figure 4).  Indeed, a comparison of the results shown in Figures 1 and 4 reveals 
that only two weeks of Rolipram treatment is able to restore normal function to 
severely impaired AD mice.  
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DISCUSSION 
 Our previous studies, and studies from others, have shown that mice that 
overexpress a mutant human APP gene linked to AD are significantly impaired in 
a number behavioral tasks (Arendash et al., 2001b; Arendash et al., 2004b; 
Nilsson et al., 2004; Jensen et al., 2005; Ognibene et al., 2005).  Here we show 
that doubly transgenic PS1/PDAPP Alzheimer’s mice raised in a mentally-
stimulating environment were “protected” from otherwise certain cognitive 
impairment, as evidenced by their superior performance in a variety of behavioral 
tasks compared to transgenic mice raised in standard housing conditions.  In 
fact, long-term EE produced transgenic mice whose “overall” performance across 
multiple cognitive measures was indistinguishable from non-transgenic mice.  
Thus, the cognitive benefits of EE were global in nature, affecting multiple 
cognitive domains.  Only by adding subsequent behavioral-testing to EE were 
profound reductions in brain Aß deposition achieved, suggesting an Aß 
limiting/sequestering action of EE.  Moreover, EE produced beneficial changes in 
expression of multiple genes involved with Aß sequestration, memory, and 
neuroprotection.  Our results not only provide the first unequivocal evidence that 
EE can protect against Alzheimer’s-like cognitive impairment, but also provide 
insight into the multi-faceted mechanisms involved in that protection.  
 Our previous work has shown that the levels of amyloid deposition in AD 
(i.e. APP) transgenic mice correlate with extent of cognitive impairment 
(Arendash et al., 2004b; Leighty et al., 2004; Nilsson et al., 2004).  For example, 
when different Aß promoting genes, namely Apolipoprotein E (apoE) and α-1 
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antichymotrypsin (ACT) are introduced into a mouse with an APP, apoE-KO, 
ACT-/- background, the severity of amyloid deposition depends on the presence 
of these promoters, and, more importantly, directly correlates with the levels of 
cognitive decline (Nilsson et al., 2004).  In our current study, we determined that 
neither EE nor the 6-week behavioral test period alone was sufficient to affect 
brain Aß deposition.  However, combining both these forms of cognitive 
stimulation (i.e. long-term EE and intense behavioral testing during the final 6 
weeks) resulted in dramatic (up to 69%) reductions in both total and mature 
(compact) Aß deposition.  Since it is unlikely that Aß deposition during the final 6 
weeks of EE would have increased by 2-3 fold in non-tested mice, it is 
reasonable to conclude that the combination EE experience actually resulted in 
removal/sequestration of brain Aß from both diffuse and compact deposits.  We 
hypothesize that long-term EE primed molecular/genetic pathways in the brain 
(see below) for complementary and/or synergistic actions provided by behavioral 
testing, resulting in profound reductions in brain Aß deposition.  These results are 
in direct conflict with another recent study (Jankowsky et al., 2003) that focused 
on Aß deposition changes in another transgenic mouse model of AD 
(APPsw/PS1dE9), and reported that EE promotes Aß burden and deposition.  
Since Jankowsky et al. (2003) did not behaviorally test their animals and used an 
atypical EE methodology, a direct comparison between the two studies is not 
practical.  In contrast to our EE methodology of maintaining the same stable 
group of animals in any given EE cage, Jankowsky et al. (2003) continually 
introduced young animals and removed older animals from their EE cages.  This 
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likely added a continual source of stress, which could have contributed to their 
observed increase in Aß burden. 
EE was not able to protect against the dendritic branching defects 
observed in PS1/PDAPP mice despite cognitive benefits observed in the same 
animals.  Analysis of Golgi-stained Layer V pyramidal cells in cortex revealed 
Tg+/SH and Tg+/EE were nearly identical in their extent of dendritic branching, 
with both groups having significantly less dendritic branching than NT/SH 
controls.  Dendritic spine counts in both cortex and hippocampus further 
underscored the lack of EE effects on dendritic morphology in Tg+ mice.  By 
contrast, prior studies involving normal rodents have provided evidence for EE-
induced changes in dendritic/synaptic morphology.  In those studies, EE induced: 
1) greater synaptophysin levels (an index of synaptic surface area, but not 
number of synapses) in hippocampus and neocortex (Frick and Fernandez, 
2003), and 2) an increase in Golgi-stained dendritic branches and dendritic 
spines in neocortex (Comery et al., 1995; Turner et al., 2003).  The inability of EE 
in the present study to increase dendritic branching or dendritic spines in 
Alzheimer’s Tg+ mice suggests that EE’s protective effect in those same mice 
does not primarily involve changes in dendritic/synaptic morphology.  
Nonetheless, subtle morphologic changes may have occurred or neuronal 
populations, other than those presently evaluated, may have been effected by 
EE. 
 To study possible biochemical/genetic changes that might be independent 
of, or additive to, Aß reducing/sequestering effects of EE in transgenic mice, we 
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performed microarray analysis using an Affymetrix 430 2.0 mouse GeneChip® 
which probes over 39,000 known unique transcripts of the mouse genome.  
Hippocampal RNA from eight non-behaviorally tested transgenic mice (EE n=4, 
SH n=4) was pooled in pairs, and used to probe four microarrays.  The resultant 
expression should reflect the effects of environmental enrichment and identify 
genes that are either up- or down-regulated by EE and that may underlie the 
cognitive protection evident in behaviorally-tested transgenic mice.  Of the 
approximately 70 known genes that were either up or down regulated by at least 
2-fold due to EE, we focused our attention on those that were most likely to 
impact AD and/or cognitive function.  
 A number of genes known to enhance or inhibit memory were up-
regulated or down-regulated, respectively.  In particular, phospholipase A2 
(PLA2), a protein involved in the inflammatory response, membrane remodeling, 
and phospholipid metabolism (Sun et al., 2004) and a proposed target for the 
treatment of inflammatory brain related disorders (Strokin et al., 2004) was up-
regulated approximately 6.7-fold in AD mice raised in EE conditions.  Expression 
of a mutated PLA2 homolog in drosophila introduces memory defects (Chiang et 
al., 2004), as does treatment of mice with bromoenol lactone, a potent PLA2 
inhibitor (Fujita et al., 2000).  Furthermore, reduced PLA2 expression has been 
reported in human AD brains (Gattaz et al., 2004).  We also observed a 3.1 fold 
increase in cytochrome C oxidase (CO) message.  Often used as a metabolic 
marker for neuronal activity, CO, an important enzyme involved in mitochondrial 
electron transport, is reportedly lowered in AD patients (Mutisya et al., 1994).  In 
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addition, mice trained in spatial working memory tasks show increased CO 
activity in the mammillary bodies, a region of the brain closely related to the 
hippocampus and memory formation. It is also interesting that transthyretin was 
up-regulated between 6- and 10-fold in transgenic mice raised in EE.  TTR is a 
plasma and CSF protein that is known to bind to (Tsuzuki et al., 1997; Tsuzuki et 
al., 2000) and sequester (Schwarzman et al., 1994) Aß, thus inhibiting plaque 
formation.  It is hypothesized that high levels of kidney TTR prevent Aß plaque 
formation despite the fact that kidneys have the highest levels of Aß 1-40 and 1-
42 in the body, after the brain (Tanzi et al., 1987; Tsuzuki et al., 2000).  In vitro 
work has shown that TTR co-localizes with amyloid plaques, and in vivo inhibition 
of TTR increases Aß deposition (Stein et al., 2004).  Previous microarray 
experiments have shown an increase in TTR in an APPsw mouse model of AD 
as compared to NT mice, and this is hypothesized to be partly responsible for the 
lack of neurodegeneration typically characteristic of AD mouse models (Stein and 
Johnson, 2002).  Similarly, we show an increase in TTR expression due to EE.  
Perhaps the reduced levels of TTR in human AD patients (Serot et al., 1997) 
contribute to their neurodegeneration and may therefore be alleviated by 
cognitive stimulation.  Despite TTR’s known Aß−sequestering activity, the 6-10x 
expression increase in non-behaviorally tested transgenics was unable to 
limit/decrease their brain amyloid deposition.  
 Converse to EE-induced gene up-regulation, two genes associated with 
memory repression - phosphodiesterase 4B and cholecystokinin B - were down-
regulated by 2.2- and 3.2-fold, respectively, in transgenic mice raised in EE.  
91 
Inhibiting PDE4 in a mouse model of Rubinstein-Taybi syndrome, a disease 
characterized by mental retardation, ameliorates the long-term memory deficits 
typical of this disorder.  Similarly, a recent study has shown that specifically 
inhibiting PDE4 in an APPsw/PS mouse model of AD ameliorates both deficits in 
long-term potentiation and memory (Gong et al., 2004).  Likewise, CCK-B 
receptor antagonists are shown to enhance memory in rats (Lemaire et al., 
1994).  In sum, the data show that environmental enrichment increases relative 
levels of memory enhancing transcripts while lowering the levels of multiple 
known inhibitors of memory.  Together, these genetic changes may help explain 
the cognitive enhancement induced by environmental enrichment. 
 The change in PDE4 suggests that the ERK/MAPK signaling 
cascade, known to be essential for memory consolidation (Impey et al., 1999; 
Schafe et al., 2000) may contribute to the observed EE effect.  MEK inhibition-
induced memory impairment in a mouse model can be reversed by treatment 
with a PDE4 inhibitor (Zhang et al., 2004), indicating the potential involvement of 
PDE4 in MEK/ERK signaling.  In addition, inhibition of PDE4 has been shown to 
increase cAMP concentrations (Barad et al., 1998), and the cAMP/PKA pathway 
is also known to modulate memory formation (Frey et al., 1993).  Environmental 
enrichment significantly lowers PDE4 levels, and therefore likely promotes both 
the ERK/MAPK and cAMP/PKA pathways.  We noticed a pattern emerge, in that 
many of the genes changed on the microarray (i.e. PDE4, PRLR, IGF-2, and 
IGFBP2) fit into a few related metabolic pathways with a common end-point 
(Figure 3).  Interestingly, these kinase cascade pathways culminate in the 
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phosphorylation of BAD, an event known to suppress apoptosis and promote cell 
survival.  The neuroprotective nature of BAD is evidenced by mouse experiments 
in which high dietary levels of docosahexanoic acid (DHA; an essential omega-3-
fatty acid whose consumption is associated with a reduced risk of AD) increased 
PI3-K, BAD phosphorylation, and provided some protection against behavioral 
deficits found in mice fed a DHA-deficient diet (Calon et al., 2004).  Activation of 
PI3-K is an IRS-1 mediated event.  We have found that the PRLR, IGF-2, and 
IGFBP-2 are all up-regulated in the EE mice.  IGF-2 and IGFBP-2 bind to the 
IGF-1 receptor and, together with the action of the PRLR, are able to activate 
IRS-1, leading to AKT-mediated BAD phosphorylation.  Our findings that 
PS1/PDAPP mice raised in EE have altered expression of PDE4, PRLR, IGF-2, 
and IGFBP-2 suggests that these proteins and the pathway linking them together 
(See Figure 3) may constitute a neuroprotective mechanism that is inducible by 
environmental enrichment. 
Finally, we determined that the combination of two forms of mental 
stimulation (long-term EE and intense behavioral testing) resulted in dramatic 
reductions in both total and mature (compact) Aß deposition occurring over the 6 
week period of behavioral testing.  Since neither EE nor behavioral testing alone 
was sufficient to decrease Aß deposition, the EE-induced changes in gene 
expression depicted in Figure 3 may have primed the brain for “behavioral 
testing-induced” synergistic and/or complementary effects that resulted in 
reduced brain Aß and increases cognitive function.  We propose that both Aß-
lowering and favorable gene expression pathways are involved in the cognitive 
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protection afforded by EE.  Thus, therapeutics designed to impact these 
pathways may provide cognitive protection against, or viable treatment for, 
Alzheimer’s disease.  This prediction has been strikingly supported by the finding 
that pharmacological inhibition of PDE4 by Rolipram can mimic the cognitive 
benefits of EE.    
 
EXPERIMENTAL PROCEDURES 
 Construction of transgenic mice.  All procedures involving experimentation 
on animal subjects were done in accord with the guidelines set forth by the 
University of South Florida’s Institutional Animal Care and Use Committee.  
Heterozygous PDGF-hAPP(V717F) mice [Swiss-Webster x C57BL/6] were 
crossed with PDGF-hPS1(M146L) heterozygotes [Swiss-Webster x C57BL/6] to 
generate mice with an APP+/-,PS1+/- genotype.  All offspring were screened by 
PCR to identity the PDGF-hAPP (Games et al., 1995)  and the PDGF-hPS1 gene 
(Duff et al., 1996).  
 Environmental Enrichment.  At weaning, mice were place into two groups 
that were exposed to standard single housing (PS1/PDAPP n=32; NT=23) or 
environmentally enriched housing (PS1/PDAPP n=27; NT n=19) for 4½-5½  
months.   All SH animals were housed in shoe box cages with static microisolator 
tops under climate-controlled conditions on a 12 hour light/12 hour dark cycle, fed 
Harlan Teklad Global Diet #2018 and provided with tap water ad libitum.  Although 
some enrichment studies in normal rodents have involved socially-housed animals 
as the standard housing control, we have found that both single- and socially-
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housed double transgenic mice are equally impaired across all of our cognitive-
based tasks vs. NT mice, and have elected to utilize standard single housing as 
our housing control for this study.  Enriched mice had the same diet and light cycle 
as SH mice, but were socially housed by sex (6-8 to a cage) in cages containing 
toys, tunnels, running wheels, etc. (Arendash et al., 2004a).  In addition to their 
enriched housing, EE mice were placed in novel complex environments 3 times 
weekly for several hours over the enrichment period. 
Behavioral Testing.  Beginning at 4.5 to 6 months of age, while continuing in 
either EE or SH housing, approximately half of the mice (n=57) were tested in five 
cognitive-based tasks as previously described in detail (Arendash et al., 2001a): Y-
maze, Morris water maze, circular platform, platform recognition, and radial arm 
water maze (RAWM) in that order. All testing was conducted during the light 
phase.  Because this report only presents results from platform recognition and 
RAWM in detail, the methodology of those tasks is described.  The platform 
recognition task measures the ability to search for and identify/recognize a 
variably-placed elevated platform.  It requires animals to ignore the spatial cues 
present around a 100 cm circular pool, which was the same pool used in earlier 
Morris water maze testing.  Mice were given four successive trials/day over a 4-
day period.  Latencies to find an elevated platform (9 cm dia.), bearing a prominent 
cone-shaped Styrofoam ensign on a wire pole, were determined.  For each trial (60 
sec. max.), animals were placed into the pool at the same location and the platform 
was moved to a different one of four possible locations. 
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For the RAWM task of working memory, an aluminum insert was placed into 
the above pool to create 6 radially-distributed swim arms emanating from a central 
circular swim area.  The latency to locate which one of the 6 swim arms contained 
a submerged escape platform (9 cm dia.) was determined for 5 trials/day over 9 
days of testing.  There was a 30 min. time delay between the 4th trial (T4; final 
acquisition trial) and 5th trial (T5; memory retention trial).  The platform location was 
changed daily to a different arm, with different start arms for each of the 5 trials 
semi-randomly selected from the remaining 5 swim arms.  During each trial (60 
sec. max.), the mouse was returned to that trial’s start arm upon swimming into an 
incorrect arm.  If the mouse did not find the platform within a 60s trial, it was guided 
to the platform for the 30s stay.  Escape latencies during Trials 4 and 5 are both 
considered indices of working memory. 
For both of the above tasks, statistical analysis involved either one-way or 
two-way repeated measure ANOVAs, followed by post-hoc planned comparisons 
between groups using the Fisher LSD test.  Discriminant Function Analysis (DFA) 
was performed across all 8 cognitive measures, from multiple tasks, that loaded 
together as the primary cognitive factor in Factor Analysis.  DFA was performed 
using the DISCRIM subroutine of the Systat software package. Following 
completion of the behavioral testing at 6 to 7.5 months of age, mice were then 
anesthetized with Nembutal (0.1mg/g).  The animals were intracardially perfused 
with 0.9% NaCl (25ml), and their brains were removed.   
   Immunohistochemical Procedures. Brains were immersion fixed for 24 
hours in 4% paraformaldehyde in 1x Sorenson’s phosphate buffer, followed by 
96 
cryoprotection via three sequential overnight sucrose immersions, ending in 30% 
sucrose.  25μm sections were cut using a sliding microtome (Spencer Lens Co.) 
and a freezing stage (Physitemp).  The sections were mounted and processed 
through antigen retrieval in prewarmed 25mM citrate buffer (pH 7.3) at +82°C for 
5 min. and further processed as previously described (Nilsson et al., 2004). The 
sections were incubated with primary antibodies against Aß (6E10, dil. 1:5000) 
overnight at +4°C. Secondary antibody was anti-mouse IgG developed with 
NovaRED substrate kit (Vector). Thioflavine S staining was accomplished using a 
5 min. incubation in 1% Thioflavine S followed by 5 min. differentiation in 70% 
ethanol.  
 Image Analysis. Data were collected from three equally spaced coronal 
tissue sections for both dorsal hippocampus and overlying parietal cortex 
(Bregma -1.30 to -2.30 mm) for each mouse.  The sections were examined with a 
Nikon Eclipse E1000 microscope using either 4X or 10X Plan Fluor objective 
lenses.  A Retiga 1300 CCD (QImaging) with a QImaging RGB LCD-slider was 
used to capture images.  For thioflavine S, a Nikon BV-2B fluorescence filter 
cube was utilized.  Customized software written in Visual Basic 6.0 (Microsoft) 
utilizing Auto-Pro function calls (Image Pro Plus, Media Cybernetics) was used to 
segment and quantify images.  Aß deposition was calculated as percent area of 
interest (=Area Stainedtot/Area Measuredtot).  Results were analyzed using a two-
tailed, unpaired student’s t test with Welch’s correction. 
 Golgi Staining. Coronal brain slices 2-3 mm thick were stained en bloc 
using the Rapid Golgi modification of (Valverde, 1993).  Tissue blocks were 
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initially immersed in a mixture of osmium tetroxide and potassium dichromate for 
5-6 days, then rinsed and blotted, and then subsequently immersed in a silver 
nitrate solution for 36-48 hours.  The blocks were then dehydrated and 
embedded in nitrocellulose. The stained blocks were then cut at 120 µm on a 
sliding microtome, cleared in alpha-terpineol, rinsed in xylene, and coverslipped 
under Permount.  All slides were coded for subsequent quantitative analyses. For 
dendritic branching analysis, randomly selected layer V pyramids of the parietal 
cortex (6 neurons per brain) had camera lucida drawings prepared of their basilar 
dendritic arbors.  These were subsequently quantified for the amount and 
distribution of their dendritic domains using the Sholl analysis (Method of 
Concentric Circles; (Sholl, 1953)).  Pair-wise statistical comparisons of the Sholl 
profiles utilized the repeated measures ANOVA with the post-hoc tuckey test.  
For dendritic spine analysis, from the coded slides, spines were counted directly 
on the Zeiss research microscope using 100x long-working distance oil-
immersion objectives.  Spines were counted from two neuronal populations: 
along 30 micron terminal tip segments of the basilar tree of the layer V pyramids, 
and along 30 micron long terminal tip segments of the basilar tree of CA1 
pyramids of the hippocampus.  Spines were counted on 3-5 terminal tip 
segments from each of 6 neurons per brain in each brain region.  Only flanking 
dendritic spines were counted, e.g., spines which were not obscured by the 
dendritic branch itself.  Statistical analysis of the spine counts was carried out 
using ANOVA with a post-hoc tukey test. 
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ELISA Analysis of Aß levels.  Protein extracts from the above eight 
hippocampi were used for ELISA and western blot analysis.  ELISA was 
performed as previously described (Dodart et al., 2002), with the modification 
that PBS rather that TBS was used to extract soluble Aß. 
 Microarray. Both experimental groups, EE and SH, were represented by 
two microarrays each, and each microarray had RNA pooled from two mice (n=8 
total).  Immediately following saline perfusion, brains were micro-dissected and 
the hippocampus isolated and frozen in liquid nitrogen.  Total RNA was isolated 
from each hippocampus using an RNeasy kit (Qiagen).  The microarray used, 
GeneChip 430 2.0 Mouse Expression Set, contains over 45,000 probe sets 
designed from GenBank, dbEST, and RefSeq sequences clustered based on 
build 107 of the UniGene database.  The clusters were further refined by 
comparison to the publicly available draft assembly of the mouse genome.  An 
estimated 39,000 distinct transcripts are detected including over 34,000 well 
substantiated mouse genes.  Five micrograms of total RNA pooled from each 
brain sample served as the mRNA source for microarray analysis.  The poly(A) 
RNA was specifically converted to cDNA and then amplified and labeled with 
biotin following a previously described procedure (Van Gelder et al., 1990).  
Hybridization with the biotin labeled RNA, staining, and scanning of the chips 
followed the proscribed procedure outlined in the Affymetrix technical manual 
and has been previously described (Warrington et al., 2000).  Scanned output 
files were visually inspected for hybridization artifacts and then analyzed using 
Affymetrix Microarray 5.1 software. Signal intensity was scaled to an average 
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intensity of 500 prior to comparison analysis.  Using the default settings, MAS 5.1 
software identifies the increased and decreased genes between any two samples 
with a statistical algorithm that assesses the behavior of 16 different 
oligonucleotide probes designed to detect the same gene (Liu et al., 2002).  
Probe sets that yielded a change p-value less than 0.0045 were identified as 
changed (increased or decreased) and those that yielded a p-value between 
0.0045 and 0.006 were identified as marginally changed.  A gene was identified 
as consistently changed if it was identified as changed in all replicate 
experiments.   
 Rolipram Administration. Twelve-month-old PS1/PDAPP/APOE+/- were 
subcutaneously injected daily with either 0.03 mg/kg Rolipram (n=5) or vehicle 
only (n=4) for two weeks.  After one day without treatment, all mice were 
behaviorally tested 6 for days in the radial arm water maze.   
 Real-Time quantitative PCR.  RNA samples were treated with DNase 
(DNA-free, Ambion), to reduce the chance of genomic DNA contamination.  
cDNA synthesis was achieved using the SuperScript III First-Strand Synthesis 
SuperMix kit (Invitrogen) according to the manufacturer’s instructions.  Primer 
pairs for real-time PCR were designed using the web-based applications Primer3 
(http://fokker.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and the Oligo Toolkit 
(Operon Technologies).  The following primer pairs were used: Prolactin 
Receptor primer 1-ATCATTGTGGCCGTTCTCTC, Primer 2-
TGGAAAGATGCAGGTCATCA;  Transthyretin, primer 1-
ATGGCTTCCCTTCGACTCTT, primer 2-GCATCCAGGACTTTGACCAT;  Insulin 
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like growth factor 2, primer 1-CCCTCAGCAAGTGCCTAAAG, primer 2-
TTAGGGTGCCTCGAGATGTT;  Insulin-like growth factor binding protein 2, 
primer 1-GCCGGTACAACCTTAAGCAG, primer 2- 
GTGTTGGGGTTCACACACC; 18s RNA, primer 1-
GTAACCCGTTGAACCCCATT, primer 2- CCATCCAATCGGTAGTAGCG.  25μl 
PCR reactions were prepared using iQ SYBR Green Supermix (Bio-Rad), and 
repeated in triplicate.  A two-step PCR reaction was run using an iCycler iQ Real-
Time PCR detection system (Bio-Rad) as follows: 1 cycle of 95°C for 3 min. 
followed by 40 cycles of 95°C for 30 s. and 60°C for 30 s.  All primer sets yielded 
a single fluorescence peak via melt curve analysis, indicating a lack of mis-
priming or primer-dimer artifacts.  Fold-change values were calculated for all 
experimental wells using the comparative CT method (2-ΔΔCt) (Livak, 1997).  
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Figure 1.  Environmental enrichment (EE) protects PS1/PDAPP mice 
against cognitive impairment across multiple behavioral tasks 
administered between 4½-6 months of age.   
(A) In the radial arm water maze task of working memory, SH Tg+ mice given 
showed impaired performance across days 7-9 of testing on working memory 
Trials 4 and 5 (T4, T5), while EE Tg+ mice exhibited working memory on trials 4 
and 5 that was indistinguishable from non-transgenic standard-housed (Tg-/SH) 
mice.  On working memory T4, EE also significantly improved performance of 
non-transgenic mice raised in EE compared to NT/SH mice.  All groups were 
similar in escape latencies during the semi-randomized initial trial (T1) (B)  In the 
platform recognition task of search/identification, the performance of Tg+/EE 
mice over all 4 days of testing was significantly better than impaired Tg+/SH 
controls and identical to Tg-/SH mice.  This effect was evident on individual Days 
2-4 of testing.  (C)  Environmental enrichment completely protected mice from 
overall cognitive impairment across 8 behavioral measures evaluated by 
discriminant function analysis (DFA).  This Canonical Scores Plot depicts a linear 
representation of the two functions resulting from DFA (Wilks’ lambda for overall 
discrimination was p<0.0001), representing the overall poorer cognitive 
performance of control Tg+/SH mice relative to both enriched Tg+/EE mice and 
control NT/SH mice, which could not be discriminated from one another.  In (A) 
and (B), means±SEM’s are plotted.   * = p<0.002 or higher level of significance 
for Tg+/SH vs. both Tg+/EE and NT/SH; # = p<0.02 for NT/SH vs. NT/EE; ** = 
p<0.05 or higher level of significance for Tg+/SH vs. all other groups for that day.      
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Figure 2.  Aß and compact amyloid plaque levels are severely reduced in 
Tg+ mice both environmentally enriched and behaviorally tested despite 
dendritic deficits.  
(A)  Immunohistochemical analysis, using the monoclonal antibody 6E10, reveals 
a 51.5% reduction in area immunostained cerebral cortex (P=0.025) in those 
mice behaviorally tested and raised in EE (n=8) vs. mice only raised in EE 
(n=11). (B)  Similarly, in hippocampus, mice behaviorally tested and raised in EE 
had a 44.1% (P=0.022) reduction in immunostaining vs. those only raised in EE.  
There was no statistically significant difference in immunostaining in either cortex 
or hippocampus between EE and SH mice in either tested or non-tested cohorts. 
(C)  Compact plaque deposition, as measured by thioflavine S staining, shows, in 
cerebral cortex, a 57.6% reduction in mature plaque deposition (p=0.008) and (D) 
a 69.0% reduction (P<0.0001) in hippocampal deposition in mice behaviorally 
tested and raised in EE vs. those only raised in EE.  As with 6E10 
immunostaining, there was no statistically significant difference in thioflavine S 
staining in either cortex or hippocampus between EE and SH mice in either 
tested or non-tested cohorts. (E) EE does not rescue the transgene-induced 
dendritic arborization deficits, as shown by Golgi staining (p<0.0001) (Sholl 
method). (F) Dendritic spine counts further verify that EE has no affect on 
dendritic morphology.   
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Figure 3.  Environmental Enrichment results in a set of genetic changes 
that culminate in anti-apoptotic/neuroprotective BAD phosphorylation.   
A number of proteins (represented as red in this figure) that affect BAD 
phosphorylation were changed in their expression due to EE.  Insulin-like growth 
factor (IGF-2) was up-regulated 2.5 fold, and Insulin-like growth factor binding 
protein-2 (IGFBP-2) was up-regulated 3.0 fold in Tg+/EE mice, which acts 
through the Akt and Erk1/2 pathways to phosphorylate BAD.  Working only 
through the Akt pathway, the prolactin receptor (PRLR) was up-regulated 21.1 
fold in Tg+/EE mice. Phosphodiesterase 4B was down-regulated 2.2 fold, 
resulting in a diminishing of cAMP inhibition and a resultant increase in Mek/Erk 
mediated BAD phosphorylation.  Also shown is Rolipram, a specific PDE4 
inhibitor, whose ability to mimic EE was tested (Figure 4).  A 10-fold increase in 
transthyretin (TTR) was also observed in the Tg+/EE mice, an Aß binding protein 
known to sequester Aß and inhibit amyloid formation.  (Bole-Feysot et al., 1998; 
Bergmann, 2002; Stein and Johnson, 2002).  The figure shows how the 
protective affects of BAD phosphorylation and TTR may inhibit neuronal 
degeneration and dysfunction caused by Alzheimer’s-related changes in Aß 
peptide and τ-phosphorylation. 
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Figure 4.  Administration of Rolipram to Tg+ mice results in memory 
improvement which mimics environmental enrichment.   
(A) In the radial arm water maze task of working memory, Tg+ mice injected with 
Rolipram showed significantly improved performance across days 4-6 of testing 
on working memory Trials 4 and 5 (T4, T5), while Tg+ injected with vehicle only 
exhibited working memory deficits typical of PS/PDAPP mice.  Both groups were 
similar in escape latencies during the semi-randomized initial trial (T1). 
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Table 1.  Comparative microarray analysis of hippocampal gene expression 
between environmentally enriched and standard housed PS1/PDAPP mice  
Classification Gene 
Accession 
 Number Affymetrix ID SLR FC 
      
Amyloid Sequestration      
 Transthyretin NM_013697 1451580_a_at 3.425 10.7 
   1455913_x_at 3.075 8.4 
   1454608_x_at 2.575 6.0 
   1459737_s_at 2.5 5.7 
Neuroprotection      
 Prolactin Receptor NM_008932 1448556_at 4.4 21.1 
   1425853_s_at 2.2 4.6 
   1421382_at 1.875 3.7 
 Insulin-like growth factor binding protein 2 NM_008342 1454159_a_at 1.575 3.0 
 Insulin-like growth factor 2 NM_010514 1448152_at 1.325 2.5 
Memory Related      
 Phospholipase A2, group V NM_011110 1417814_at 2.75 6.7 
 Cytochrome c oxidase, subunit VIIIb NM_007751 1449218_at 1.625 3.1 
 Cholecystokinin B receptor NM_007627 1454770_at -1.675 -3.2 
 Phosphodiesterase 4B, cAMP specific NM_019840 1442700_at -1.125 -2.2 
Plasticity Related      
 
Calcium/calmodulin-dependent protein kinase 
II α NM_009792 1452453_a_at 0.475 1.4 
Aging Related      
 Klotho NM_013823 1423400_at 2.175 4.5 
Extracellular Matrix      
 Procollagen, type VIII, α 1 NM_007739 1418441_at 1.975 3.9 
   1418440_at 1 2.0 
 Procollagen, type IX, α 3 NM_009936 1460693_a_at 1.875 3.7 
   1420280_x_at 1.425 2.7 
 Procollagen C-proteinase enhancer protein NM_008788 1437165_a_at 1.4 2.6 
 Procollagen C-endopeptidase enhancer 2 NM_029620 1451527_at 1 2.0 
Immediate Early Genes      
 Arc NM_018790 1418687_at -0.825 -1.8 
 Egr1 NM_007913 1417065_at -0.825 -1.8 
Presynaptic Proteins      
 Doc2a BB543070 1436862_at -2.075 -4.2 
 Synaptotagmin-like 2 NM_031394 1421594_a_at -0.55 -1.5 
 Syntaxin 1A (brain) NM_016801 1437390_x_at -0.35 -1.3 
   1448366_at -0.325 -1.3 
 
Calcium/calmodulin -dependent protein 
kinase II γ NM_178597 1423941_at -0.3 -1.2 
   1423942_a_at -0.25 -1.2 
AD Related      
 ß-site APP cleaving enzyme (BACE) NM_011792 1455826_a_at -0.225 -1.2 
 amyloid ß (A4) precursor-like protein 2 NM_009691 1432344_a_at 0.325 1.3 
 Calcineurin NM_024459 1450368_a_at 0.35 1.3 
Other      
 
Steap (six transmembrane epithelial antigen 
of the prostate) NM_027399 1424938_at 5.425 43.0 
 growth hormone NM_008117 1460613_x_at -4.225 18.7 
   1437522_x_at -3.05 8.3 
      1460310_a_at -1.725 3.3 
      
SLR, Signal log ratio; FC, Fold change (approximate) = 2(SLR)    
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Table 2.  qRT-PCR verification of select transcripts from hippocampal 
microarray analysis. 
 
Gene ΔΔCT   Fold Change (2-ΔΔCT) 
    
Prolactin Receptor -3.59 ± 1.02   12.06 
    
Transthyretin -5.39 ± 1.28  41.98 
    
Insulin-like growth factor 2 -1.1 ± 0.86  2.144 
    
Insulin like growth factor binding protein 2 -0.99 ± 0.75   1.99 
    
Comparative threshold cycle: ΔΔCT = ΔCT(EE) - ΔCT(SH)  
ΔCT = CT (target) - CT(reference)    
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DISCUSSION 
 
In vitro (Ma et al., 1994) and in vivo (Nilsson et al., 2001) studies have found 
that the chief pathogenic chaperone found in amyloid ß plaques, apoE,  is able to 
catalyze the polymerization of Aß into neurotoxic amyloid filaments and change 
the anatomical distribution of immunoreactivity in the brain. Furthermore, the 
deposition of brain AD pathology is strongly influenced, both in intensity and age 
of onset, by the gene dosage of apoE.  Specific binding experiments, site 
directed mutagenesis, and structural analysis have identified the primary 
molecular interactions between the pathological chaperone, apoE, and Aß 
(Potter, 1991; Strittmatter et al., 1993; Ma et al., 1996; Janciauskiene et al., 
1998).  A previous study from our laboratory provides the first in vivo 
demonstration that the increased Aß immunoreactive and mature plaque 
deposition caused by expression of the amyloid promoter, apoE, is associated 
with impaired spatial learning (Nilsson et al., 2004, APPENDIX B). 
We found that apoE promotes the development of both diffuse, 
immunoreactive, Aß deposits and mature amyloid plaques in Aß-overexpressing 
mice without affecting the levels of monomeric Aß itself and that impaired 
cognitive performance in two different spatial tasks requires both Aß peptide and 
either ApoE or ACT as an amyloid promoter, with apoE showing a higher 
catalytic activity.  Furthermore, both diffuse Aß deposits and mature amyloid 
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plaques were correlated with impaired spatial learning ability.  Indeed, 18 month 
old APP mice that didn’t express ApoE deposited very little Aß and displayed no 
cognitive deficits in the RAWM or Morris Water Maze, similar to nontransgenic 
mice.  These findings imply that the process and/or product of ApoE catalyzed 
amyloid formation is more critical for the cognitive decline in AD than is the 
amount of monomeric Aß-peptide.  In sum, our previous findings of a strong 
association between cognitive decline and both diffuse Aß deposits and mature 
amyloid plaques in transgenic mice indicate that a major pathological role of 
ApoE in Alzheimer’s disease is to promote Aß polymerization and deposition, 
possibly with slightly different effects in terms of time course and anatomical 
distribution of the pathology.    
 Given that the doubly transgenic AßPP/PS1 mouse model used in the 
currently reported study expresses severely elevated levels of brain Aß1-42, most 
likely superseding any possible effect of apolipoprotein E on Aß peptide 
production or clearance (if there are indeed any), we offer clear proof that apoE 
directly catalyzes the polymerization of Aß into ß-sheet fibrils and its consequent 
aggregation to form mature, Thioflavine S-positive, amyloid plaques.  This 
directly contrasts with previous publications only utilizing singly transgenic, 
PDAPP, animals, whereby apoE had been shown to promote both total Aß 
deposition and amyloid formation (Nilsson et al., 2004, APPENDIX B). 
 Transgenic mice expressing both human PS1M146L and AßPPV717F 
mutations do not develop significant fibrillar amyloid deposits by 7 months of age, 
in the absence of apoE, despite copious amounts of immunoreactive Aß 
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deposition.  We find that mature, Thioflavine-S positive, amyloid deposits are 
allowed to form only the presence of apoE, and are the first authors, to our 
knowledge, to describe the gross morphological chages of amyloid plaques, 
using electron microscopy, due to apoE.        
Although we find that ApoE clearly promotes Aß polymerization directly, 
this protein likely has additional roles to play in AD and other brain diseases.  For 
example, other authors have shown that ApoE affects the level or location of 
APP processing so as to generate fewer Aß peptides and more potentially toxic 
C-terminal fragments (in animals slightly older than ours’ and at an age known to 
show the initial stages of amyloid deposition) (Dodart et al., 2002).  Particularly 
interesting is the finding that ApoE4 is less neuroprotective than ApoE3 both in 
vitro and in vivo (Buttini et al., 2002).   
ApoE is also known to affect cholesterol metabolism (Poirier, 2000), for 
ApoE knockout mice develop hypercholesterolemia and atherosclerosis that 
could have an effect on amyloid formation.  It is therefore wise to consider the 
possible direct and compensatory consequences of expressing or not expressing 
ApoE during development.  However, heterozygous PDAPP/ApoE+/- mice have 
normal serum cholesterol levels and develop amyloid deposits at a rate 
intermediate between full PDAPP/ApoE-KO and PDAPP/ApoE+/+ animals (Bales 
et al., 1999), suggesting that the lower amyloid deposition induced by knocking 
out ApoE is not caused by high serum cholesterol due to ApoE deficiency.  
Furthermore, except for hypercholesterolemia in ApoE-KO mice, we have not 
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observed gross differences in physiology or brain morphology due to knocking 
out ApoE.  
 Preventing apoE from binding to Aß and stimulating its polymerization into 
ß-sheet filaments may prove to be a promising therapeutic approach for AD drug 
development.  It is possible that the process of amyloid formation, or an 
intermediate formed therein, rather than the end product (mature plaques), 
causes the typical neuronal dysfunction and cognitive decline of AD. These 
results showing the essential role of ApoE in amyloid fibril formation, together 
with the previous findings that apoE promotes cognitive decline and does not 
alter the steady state level of Aß, suggest that pharmacologic inhibition of 
Aß/ApoE interactions should be a prime target for therapeutic intervention in AD.  
Previous experiments indicate that such an approach may be effective, for small 
fragments of the Aß peptide were shown to effectively prevent ApoE-catalyzed 
polymerization in vitro (Ma et al., 1994; Ma et al., 1996).  
 A pharmacological target in the periphery as a therapy against AD has 
clear pharmacological and clinical advantages. There is much debate in the field 
of Alzheimer’s disease regarding the contribution of peripheral circulating 
proteins to disease pathology.  The fact that disease-related proteins such as Aß 
and apoE are elevated in the serum of AD patients, and that there exists a 
notable prevalence of vascular cerebral amyloid angiopathy indicates that 
circulating proteins are at least linked causally to the disease process.  Since we 
observed such a drastic catalytic affect of apoE on the polymerization of Aß, and 
since apoE is known to shuttle Aß across the blood brain barrier, we surmised 
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that if circulating apoE has an affect on brain pathology it would be easily 
detectable in our AßPP/PS1 transgenic mouse model.   
 We demonstrate here that the unorthodox surgical technique of parabiosis 
is a feasible approach for studying the contribution of circulating proteins and 
hormones to Alzheimer’s disease pathology.  We found that apoE is efficiently 
transferred from one parabiont to another using PCR analysis of white blood 
cells.  Though transferred efficiently, the levels of circulating apoE protein 
determined via western blot were only 5% of that found in a nontransgenic 
mouse.  These low steady state levels of apoE in the apoE-KO parabiont are 
most likely due to massive sequestration of apoE for use in lipoprotein particles 
and cholesterol transport.  This is suggested by the fact that the 
hypercholesterolemic phenotype of apoE-knockout mice is rescued in these 
same mice when parabiosed to a mouse expressing apoE.  It should be 
mentioned that work by other authors has shown that it takes less than 3% of 
normal levels of apoE to prevent atherosclerotic plaque deposition and to 
maintain typical cholesterol levels (Thorngate et al., 2002).    
 Based upon our findings regarding apoE-mediated thioflavine-S catalysis, 
we anticipated that even minute amounts of apoE entering the central nervous 
system of PS1/APP/apoE-KO mice could promote large amounts of fibrillar 
amyloid deposition.  Surprisingly, there was no increase in Aß deposition, diffuse 
or fibrillar, whatsoever. Conversely, we found fewer fibrillar, Thioflavine S-
positive, deposits in the parabiosed mice that expressed apoE as compared to 
control mice.  Immunohistochemical analysis reveals that peripheral apoE is only 
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detectable in the choroids plexus which is in agreement with another previous 
study (Martel et al., 1997).     
 Since Aß injected into the circulation of mice is cleared rapidly, the 
observed lowering of Aß deposition in parabiosed PS1+/-,APP+/+,apoE+/- mice 
may be due to apoE-mediated peripheral Aß clearance.  It has been shown that 
there exists a dynamic equilibrium between brain Aß levels and the levels in the 
CSF, which was demonstrated by using a peripheral antibody injection to 
sequester Aß (DeMattos et al., 2002).  Besides apoE’s known role as a promoter 
of fibrillization, there is increasing evidence for a dual role of apoE, in that it may 
also promote the clearance of Aß.  For example, in vitro astrocytic internalization 
and degradation of Aß is found to be dependent on the presence of apoE 
(Koistinaho et al., 2004).  Furthermore, intra-venous injections of Aß, which 
would normally be quickly cleared by the liver, are not detectably cleared in mice 
devoid of apoE (Hone et al., 2003).  Therefore our study, and those of others, 
suggests that apoE may be involved in the peripheral clearance/sequestration of 
Aß, acting as a sink which may change the equilibrium between brain and 
peripheral Aß.  This could therefore alter the circulating:CSF/brain Aß 
equilibrium, shifting it towards the blood, resulting in an efflux of Aß from the 
brain, consequently resulting in the observed reduction in amyloid deposition.  
This shift in Aß equilibrium between discreet compartmentalized pools has also 
been suggested by the work of others (Silverberg et al., 2003). 
 We conclude that peripheral apolipoprotein E does not contribute to the 
brain pathology found in Alzheimer’s disease, and may actually help promote the 
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clearing/efflux of brain Aß by a mechanism that remains open to speculation.  
Based on the amelioration of hypercholesterolemia due to parabiosis, we are 
confident that this uncommon technique has merit for studying the contribution of 
circulating factors to Alzheimer’s and other neurodegenerative diseases. 
 Another, seemingly unrelated, primary topic of study in our laboratory is 
that of environmental enrichment as an intervention strategy for the treatment of 
AD.  Initial environmental enrichment studies from our laboratory indicate that a 
long-term period of EE in aged AD transgenic mice results in superior overall 
cognitive performance as determined by a number of behavioral measures 
(Arendash et al., 2004, APPENDIX B).  Although a reduction in brain Aß 
deposition has been associated with behavioral benefit of Aß immunotherapy in 
similar AD transgenic mice (Corder et al., 1993), our initial results indicated that 
mechanisms independent of Aß deposition are sufficient for behavioral benefit, 
for we observed no changes in brain pathology in EE mice.  Along this line, EE-
induced enhancements in neurogenesis (Anderson et al., 1998), synaptogenesis 
(Anderson and Higgins, 1997), growth factor levels (Arendash et al., 2001b), and 
gene expression (Arendash et al., 2001a) have all been seen in normal mice and 
are thus potentially involved in the behavioral benefits of EE we reported in aged 
APPsw mice (Arendash et al., 2004, APPENDIX B). 
In this prior study, designed to evaluate the potential of EE as a 
therapeutic means in aged AD transgenic mice, our results suggested that long-
term intensive enrichment/cognitive stimulation could be useful in stabilizing or 
slowing the cognitive decline of AD and it’s predecessor, mild cognitive 
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impairment (MCI) without a need to reduce Aß burden.  Largely because of 
practical considerations, prospective longitudinal studies have not been done in 
humans to confirm controversial retrospective studies reporting AD risk reduction 
with “lifelong” education/occupation-related intellectual activity (Bales et al., 1997; 
Bales et al., 1999).  A recent 5-year longitudinal study involving non-demented 
75+ year olds did find participation in cognitively-stimulating leisure activities to 
be associated with a lower risk of dementia (Dodart et al., 2002).  However, a 
cause and effect relationship can not be established because the leisure 
activities were self-chosen. 
The current study sought to both eliminate any cause/effect ambiguity by 
randomly assigning transgenic mice destined to develop AD and their NT 
counterparts to either EE or SH and to ascertain the preventative benefits of long 
term enrichment.  We find that mice raised in a cognitively stimulating 
environment were protected from certain cognitive decline as measured by 
multiple behavioral assays.  Our results also indicate that, alone, neither 
environmental enrichment nor behavioral testing could alter brain Aß levels.  The 
cognitive benefits of preventative EE are therefore at least partly independent of 
AD brain pathology, for we observed what may be a cognitive stimulation 
threshold for the clearance of Aß that does not affect cognitive measures 
performance, for only the combination of both long-term environmental 
enrichment and intense behavioral testing resulted in a lowered level of brain Aß 
deposition.  In fact, we observed up to 69% decreases in both diffuse and 
compact Aß levels, and surmise that a decrease of this magnitude could not 
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possibly be from only a halting in Aß deposition, but from an as yet unknown 
removal or sequestration mechanism.  EE has been shown to prime the brain for 
increased maze training-induced choline acetyltransferase activity (Levi et al., 
2003), and we observe what is most likely a similar priming by EE for behavioral 
testing-induced pathology changes.  Additionally, microarray analysis revealed a 
number of beneficial gene expression changes related to memory, 
neuroprotection, and Aß sequestration.  
Previous studies have revealed that EE is capable of inducing beneficial 
structural changes such as increases in the number of dendritic spines and 
branching complexity (Comery et al., 1995; Turner et al., 2003).  In our 
experiment, we observed no such changes due to EE.  In fact, all the transgenic 
mice in our study displayed dendritic defects, as determined by Golgi staining, 
and these were unaffected by EE, indicating that 1) these physical defects could 
not be rescued by EE, and 2) that the observed memory improvement due to EE 
in these mice was independent of dendritic structural changes.   
Microarray analysis was performed to study the possible genetic changes 
that could be responsible for the improved cognitive performance and the 
observed lowering of AD brain pathology due to cognitive stimulation.  We 
focused on the roughly 70 known genes that were significantly changed, either 
up or down, by at least 2-fold due to EE, and provided an in-detail inquiry for 
those transcripts most likely to affect Alzheimer’s disease or cognitive function. 
We found that a number of genes known to be involved in pathways which 
culminate in the phosphorylation of BAD, an event known to be anti-apoptotic 
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and neuroprotective, had altered expression levels.  Previous experiments 
wherein mice where fed a diet rich in a compound (docosahexanoic acid) known 
to promote BAD phosphorylation helped protect mice against cognitive deficits 
(Calon et al., 2004).  In particular, we found four transcripts upstream of bad 
phosphorylation that were changed due to EE: phosphodiesterase 4B, insulin-like 
growth factor-2, insulin-like growth factor binding protein-2, and the prolactin 
receptor.  Docosahexanoic acid-induced BAD phosphorylation is an IRS-1/PI3-K 
mediated event, and three transcripts for the proteins, IGF-2, IGFBP2, and PRLR 
which are also known to promote BAD phosphorylation via the IRS-1/PI3-K 
pathway were significantly upregulated.  IGF-2 and IGFBP2 are also able induce 
BAD phosphorylation through an alternative MEK/ERK mediated pathway which 
has been show to be imperative in the formation of long term memory (Impey et 
al., 1999; Schafe et al., 2000).  Interestingly, PDE4, which was downregulated by 
EE, acts as an inhibitor of this same pathway (Zhang et al., 2004), and its 
inhibition has recently been shown to promote both memory and LTP in a mouse 
model of AD (Gong et al., 2004).  By injecting Rolipram, an inhibitor of PDE4, into 
8-month-old transgenic mice we have rescued the transgene-induced cognitive 
deficits, effectively mimicking the effect of environmental enrichment.  Taken as a 
whole, the changes in these related transcripts suggest the memory 
improvement in mice that were exposed to EE may be due an inducible 
mechanism that confers neuroprotection.               
A molecule know to bind to (Tsuzuki et al., 1997; Tsuzuki et al., 2000) and 
sequester (Schwarzman et al., 1994) Aß, transthyretin, was up-regulated roughly 
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10-fold in transgenic mice raised in EE.  TTR binds to Aß and is thought to inhibit 
Aß aggregation, for inhibition of TTR has been shown to increase Aß deposition 
(Stein et al., 2004).  In fact, TTR is thought responsible for the prevention of 
peripheral Aß deposition, for the kidney’s level of this protein is quite high.  
Furthermore, TTR levels are reduced in human AD patients, and are 
hypothesized to be at least partly responsible for the accumulation of Aß and the 
resultant neurodegeneration, so there exists a discrepancy, for in those mice only 
undergoing EE there was no decrease in pathology despite cognitive 
improvements. 
Besides these changes, some transcripts were altered due to EE that are 
known to improve memory.  For example, CCK-B was down-regulated, and past 
experiments have shown that inhibiting the CCK-B receptor enhances memory in 
rats (Lemaire et al., 1994).  Another protein, which is known to be reduced in 
human AD patients, phospholipase A2, was upregulated due to EE, and memory 
defects are known to be induced by its pharmacological inhibition. 
 A number of other genes or gene groups experienced significant changes, 
but their direct relevance to our model and AD is unclear.  For example, STEAP 
(six transmembrane epithelial antigen of the prostate), a seemingly AD- and 
memory-unrelated transcript was up-regulated by approximately 43-fold, the 
largest observed change on the microarray.  Also a number of procollagen and 
procollagen-related transcripts were also up-regulated.  These proteins are 
potentially important for Schwann-cell extracellular matrix (Greenberg et al., 
1980; Roytta et al., 1988), but their role in memory formation or improvement is 
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unknown.  Klotho, a gene encoding a membrane protein known to cause 
premature aging in mice when mutated (Kuro-o et al., 1997), was also up-
regulated by 4.5-fold.  This could be an EE-induced compensatory mechanism 
against an aspect of aging that has yet to be determined.   
A recent report of a similar experiment run in parallel by another group 
(Lazarov et al., 2005) using a different mouse model (APPsw/PS1dE9), further 
confirms our findings that EE reduces amyloid deposition.  It should be noted that 
we do not see any changes in the levels of neprilysin, an Aß degrading enzyme 
that these authors attribute to the EE-induced lowering of Aß, therefore indicating 
that other sequestration/degradation mechanisms are most likely responsible for 
the changes in pathology that we observed.  Furthermore, a differential sensitivity 
to Aß reduction due to EE likely depends on genotype, possibly explaining the 
lowered Aß deposition only in animals that underwent EE and intense behavioral 
testing.  Jankowsky et al., in direct contrast to both of the above findings, 
reported that EE promotes Aß deposition in an APPsw/PS1dE9 mouse model of 
AD.  Unfortunately, these authors chose an unusual enrichment methodology 
whereby new mice were continually introduced to the cages, adding a 
confounding source of stress which may explain the observed increase in 
pathology.  This therefore makes comparisons between this study and ours’ of 
little value.  
In conclusion, we found that the combination of both long-term EE and 
intense behavioral testing, both forms of cognitive stimulation, can reduce the 
levels of Aß deposition.  Furthermore, the gene expression changes due to EE 
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may prime the brain for further changes in AD pathology induced by additional 
intense cognitive stimulation.  Therefore, pharmacological alteration of these 
genetic pathways, as exemplified by our inhibition of PDE4 by Rolipram, may 
prove to be valuable targets in the fight against the cognitive decline of 
Alzheimer’s disease.   
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FUTURE DIRECTIONS 
 
The paths for a number of future avenues of study have been cleared by 
the recent research of our laboratory.  For example, we show that parabiosis is a 
useful method for determining the contribution of a circulating protein (in the case 
of our current research, apoE) to AD pathology.  Further experiments should be 
repeated with different parabiont combinations.  For example, a mouse 
expressing circulating Aß, such as our PS1/APP mouse, should be parabiosed to 
a non-transgenic mouse, for any brain pathology present in the transgenic 
partner would be a result of circulating Aß, therefore answering the question of 
whether peripheral Aß contributes to brain pathology.  If so, antibody injections or 
the administering of Aß-sequestering agents may prove useful as a stand-alone, 
or more likely as an adjunct AD therapy.  If on the other hand there is no affect 
on brain pathology, efforts to curb brain pathology via the peripery should 
possibly be reevaluated.  Similarly, experiments using mice which overexpress 
peripheral α1-antichympotrypsin, another pathogenic chaperone, should also be 
initiated for the same reasons.           
Since our environmental enrichment paradigm has a number of differing 
aspects which may be responsible for the observed memory improvement and 
genetic changes, it will be useful to parse out the aspect or aspects of EE which 
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are most responsible for these beneficial changes.  Our “whole” EE setting 
entails social, physical, and cognitive elements, and by systematically isolating 
and differentiating which element exerts the greatest cognitive and genetic 
benefits, using behavioral testing and further microarray analysis, both 
recommendations for using enrichment therapy in humans and more appropriate 
pharmacological targeting can be devised with greater accuracy.   
Since pharmacological inhibition of PDE4 using Rolipram rescued the 
cognitive deficits in our transgenic mouse model of AD, further animal trials using 
other available phosphodiesterase inhibitors (e.g. Aminophylline, cilomilast, 
etc…) should be initiated, and if successful should lead to eventual clinical trials 
for the treatment or prevention of Alzheimer’s disease.  This strategy should 
furthermore be applied to the pathways and proteins whose expression changed 
due to EE that converge in BAD phosphorylation such as IGF-2, IGFBP2, and 
PRLR. 
Lastly, it has been shown that environmental enrichment-induced memory 
and learning improvements in transgenic mice are apoE allele-dependant (Levi et 
al., 2003), so future studies should therefore concentrate on combining the two 
main foci of my work, apolipoprotein E and environmental enrichment, in order to 
elucidate the differing genetic changes and behavioral changes of the various 
apoE alleles among varying environmental enrichment conditions so as to 
develop a clearer understanding of the relevant pathways and define the most 
efficacious and personalized treatment regimens possible in relation to ones’  
given apoE allele. 
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'IPPMACRO.frm 
 
' HOMER Version 1.0 
' DAVID COSTA 2003 
' 
Option Explicit 
'File Management Variables 
Dim vstrBackgroundImage As String 
Dim vstrSegmentationImage As String 
Dim vstrSegmentationFile As String 
Dim vstrExcelFile As String 
Dim vstrTargetImageDirectory As String 
Dim vstrTargetImage As String * 255 
Dim vstrtxtIcComment As String 
Dim vintRangeMin As Integer 
Dim vlngRangeMax As Long 
Dim vsngExcelArray(10) As Single 
'Dim vintTweakChoice As Integer 
Dim vintExcelRow As Integer         'index for ron number for Excel data export 
 
Dim vintDirectoryIndex As Integer   'in cmdCalculate - loop index for 
IpStSearchDir() 
Dim vintDirectoryStatus As Integer  'in cmdCalculate - return value for 
IpStSearchDir() 
 
'Excel Variables 
Dim xlapp As Object 
Dim xlbook As Object 
Dim xlSheet As Object 
Dim xlRange As Object 
 
Dim n As Integer 'Index for excel export of data 
 
Dim i As Integer 
Dim j As Integer 
Dim xlData() As Single 
Dim xlLabels() As String 
Dim dInfo As IPDOCINFO 
 
'InitExcel() initializes the OLE link to Excel and returns the Object 
'in the xlApplication parameter.  Return value: 0 = success; -1 = failure 
Function InitExcel(ByRef xlApplication As Object) As Integer 
159 
    APPENDIX A (Continued) 
 
 
InitExcel = 0    ' Make sure the function is initialized 
     
    On Error Resume Next ' continue if an error is generated 
    Err.Clear                       ' clear the error flag 
     
    Set xlApplication = GetObject(, "Excel.Application") 
     
    ' GetObject will return an error if Excel isn't open 
    If Err.Number <> 0 Then 
        ' Start Excel with CreateObject.  If this fails, we exit the macro. 
        Err.Clear 
        Set xlApplication = CreateObject("Excel.Application") 
        If Err.Number <> 0 Then 
            MsgBox "Can't find Excel.", vbOKOnly + vbCritical, "OLE Error" 
            InitExcel = -1 
            Exit Function 
        End If 
    End If 
     
    'show Excel (don't run in background) 
    xlApplication.Visible = True 
     
    If Err.Number <> 0 Then 
        MsgBox "Error showing Excel!", vbOKOnly + vbCritical, "OLE Error" 
        InitExcel = -2 
    End If 
     
     
End Function 
 
' Opens Excel spreadsheet and defines rows and columns for data input 
Function fncOpenExcel() 
     
'startup Excel for OLE data dump 
    If InitExcel(xlapp) < 0 Then 
        Exit Function 
    End If 
     
    'create a new workbook for your data 
    Set xlbook = xlapp.Workbooks.Add 
        xlbook.Activate 
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    Set xlSheet = xlbook.ActiveSheet 
        xlSheet.Activate 
        xlapp.Visible = True 
        xlapp.WindowState = vbMaximized 
     
    'Note: due to the design of OLE, it is much faster to transfer data 
    '      to Excel in a 2 dimensional array, even if you are only filling 
    '      one cell 
    ReDim xlLabels(1 To 1, 1 To 3) As String        '(row,column) 
     
    'Adds Summary sheet to excel file 
    xlapp.worksheets.Add 
    Set xlSheet = xlbook.ActiveSheet 
        xlSheet.Activate 
        xlSheet.Name = "Result Summary" 
 
    'Adds AOI sheet to excel file if area is checked 
    If chkArea.value = vbChecked Then 
        xlapp.worksheets.Add 
        Set xlSheet = xlbook.ActiveSheet 
        xlSheet.Activate 
        xlSheet.Name = "AOI" 
     
        'Labels and Formats "AOI" Sheet 
        With xlapp 
            .ActiveWindow.Zoom = 75 
            .Range("A1").Select 
            .ActiveCell.FormulaR1C1 = "Image" 
            .Range("B1").Select 
            .ActiveCell.FormulaR1C1 = "Sum" 
            .Range("C1").Select 
            .ActiveCell.FormulaR1C1 = "Std. Deviation" 
            .Range("D1").Select 
            .ActiveCell.FormulaR1C1 = "Num. of Objects" 
            .Range("E1").Select 
            .ActiveCell.FormulaR1C1 = "Comments" 
            '.Columns("E:E").Select 
            '.selection.ColumnWidth = 50 
             
            .Rows("1:1").Select 
             
            With .Selection 
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               .Font.Underline = 2 'xlUnderlineStyleSingle 
               .Font.Bold = True 
               .ColumnWidth = 22 
               .HorizontalAlignment = 3 'xlCenter 
            '   .VerticalAlignment = xlBottom 
               .WrapText = False 
               .Orientation = 0 
               .AddIndent = False 
               .IndentLevel = 0 
               .ShrinkToFit = False 
            '   .ReadingOrder = xlContext 
               .MergeCells = False 
            End With 
             
        .Range("C6").Select 
         '.Columns("E:E").ColumnWidth = 23.57 
        End With 
    End If 
     
    'Adds % Area sheet to excel file if area is checked 
    If chkArea.value = vbChecked Then 
        xlapp.worksheets.Add 
        Set xlSheet = xlbook.ActiveSheet 
        xlSheet.Activate 
        xlSheet.Name = "% Area" 
    
        'Labels and Formats "% Area" Sheet 
        With xlapp 
            .ActiveWindow.Zoom = 75 
            .Range("A1").Select 
            .ActiveCell.FormulaR1C1 = "Image" 
            .Range("B1").Select 
            .ActiveCell.FormulaR1C1 = "Mean Value" 
            .Range("C1").Select 
            .ActiveCell.FormulaR1C1 = "Std. Deviation" 
            .Range("D1").Select 
            .ActiveCell.FormulaR1C1 = "Min. Measurment" 
            .Range("E1").Select 
            .ActiveCell.FormulaR1C1 = "Maximum Measurement" 
            .Range("F1").Select 
            .ActiveCell.FormulaR1C1 = "Range" 
            .Range("G1").Select 
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            .ActiveCell.FormulaR1C1 = "Sum" 
            .Range("H1").Select 
            .ActiveCell.FormulaR1C1 = "Num. of Objects" 
            .Rows("1:1").Select 
             
            With .Selection 
                .Font.Underline = 2 'xlUnderlineStyleSingle 
                .Font.Bold = True 
                .ColumnWidth = 22 
                .HorizontalAlignment = 3 'xlCenter 
             '   .VerticalAlignment = xlBottom 
                .WrapText = False 
                .Orientation = 0 
                .AddIndent = False 
                .IndentLevel = 0 
                .ShrinkToFit = False 
             '   .ReadingOrder = xlContext 
                .MergeCells = False 
            End With 
         
        .Range("C6").Select 
        .Columns("E:E").ColumnWidth = 23.57 
      
        End With 
    End If 
     
    'Adds Density sheet to excel file if Density is checked 
    If chkDensity.value = vbChecked Then 
        xlapp.worksheets.Add 
        Set xlSheet = xlbook.ActiveSheet 
        xlSheet.Activate 
        xlSheet.Name = "Density" 
         
        With xlapp 
            .ActiveWindow.Zoom = 75 
            .Range("A1").Select 
            .ActiveCell.FormulaR1C1 = "Image" 
            .Range("B1").Select 
            .ActiveCell.FormulaR1C1 = "Density Mean: Mean" 
            .Range("C1").Select 
            .ActiveCell.FormulaR1C1 = "Density Mean: Std.Dev" 
            .Range("D1").Select 
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            .ActiveCell.FormulaR1C1 = "Density Mean: Sum" 
            .Range("F1").Select 
            .ActiveCell.FormulaR1C1 = "Density Sum: Mean" 
            .Range("G1").Select 
            .ActiveCell.FormulaR1C1 = "Density Sum: Std.Dev" 
            .Range("H1").Select 
            .ActiveCell.FormulaR1C1 = "Density Sum: Sum" 
             
                            
            .Rows("1:1").Select 
            With .Selection 
                .Font.Underline = 2 'xlUnderlineStyleSingle 
                .Font.Bold = True 
                .ColumnWidth = 22 
                .HorizontalAlignment = 3 'xlCenter 
             '   .VerticalAlignment = xlBottom 
                .WrapText = False 
                .Orientation = 0 
                .AddIndent = False 
                .IndentLevel = 0 
                .ShrinkToFit = False 
             '   .ReadingOrder = xlContext 
                .MergeCells = False 
            End With 
             
             
                         
            .Columns("E:E").Select 
            .Selection.ColumnWidth = 5 
            End With 
             
    End If 
     
    'Delete Unwanted sheets 
  '  With xlapp 
   '     .Sheets("Sheet1").Select 
    '    .SendKeys "Y" 
     '   .ActiveWindow.SelectedSheets.Delete 
      '  .Sheets("Sheet2").Select 
       ' .ActiveWindow.SelectedSheets.Delete 
        '.Sheets("Sheet3").Select 
        '.ActiveWindow.SelectedSheets.Delete 
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    'End With 
     
     'Label the columns 
'    xlLabels(1, 1) = "Data 1" 
'    xlLabels(1, 2) = "Data 2" 
'    xlLabels(1, 3) = "Data 3" 
        
'    Set xlSheet = Nothing 
'    Set xlbook = Nothing 
'    Set xlapp = Nothing 
            
            
End Function 
 
Function fncExcelDataExport(vstrSheetName As String, vintYindex As Integer) 
 
Select Case vstrSheetName 
 
    Case "% Area" 
     
        'declare n as index integer 
        n = 0 
         
        'Get statistics from current AOI and send to Array 
        ret = IpBlbGet(GETSTATS, 0, BLBM_AREA, vsngExcelArray(n)) 
              
        'make % area active sheet and sends area data to excel 
        xlapp.Sheets(vstrSheetName).Select 
                Set xlSheet = xlbook.ActiveSheet 
         
            'Mean, Std.Dev,Min, Max, Range, Sum 
            For n = 0 To 5 
                With xlSheet 
                    .Range(.cells(vintYindex, 2 + n), .cells(vintYindex, 2 + n)).value = 
vsngExcelArray(n) 
                End With 
            Next n 
            '# of Objects 
            n = n + 2 
                With xlSheet 
                    .Range(.cells(vintYindex, n), .cells(vintYindex, n)).value = 
vsngExcelArray(n) 
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                End With 
            n = 0 
             'name of current file to excel 
                With xlSheet 
                    .Range(.cells(vintYindex, 1), .cells(vintYindex, 1)).value = 
vstrTargetImage 
                End With 
     
    Case "AOI" 
 
        n = 0 
        'Get statistics from current AOI and send to Array 
        ret = IpBlbGet(GETSTATS, 0, BLBM_AREA, vsngExcelArray(n)) 
          
        'make AOI active sheet and sends area data to excel 
        xlapp.Sheets(vstrSheetName).Select 
          
        Set xlSheet = xlbook.ActiveSheet 
             
            'Sum 
                With xlSheet 
                    .Range(.cells(vintYindex, 2), .cells(vintYindex, 2)).value = _ 
                          vsngExcelArray(5) 
                End With 
            'Std.Dev 
                With xlSheet 
                    .Range(.cells(vintYindex, 3), .cells(vintYindex, 3)).value = _ 
                          vsngExcelArray(1) 
                End With 
             
            '# of Objects 
                With xlSheet 
                    .Range(.cells(vintYindex, 4), .cells(vintYindex, 4)).value = _ 
                           vsngExcelArray(8) 
                End With 
                 
                If txtIcComment.text <> "" Then 
                    vstrtxtIcComment = txtIcComment.text 
                        With xlSheet 
                        .Range(.cells(vintYindex, 5), .cells(vintYindex, 5)).value = _ 
                               vstrtxtIcComment 
                        End With 
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                End If 
                            
            n = 0 
             
            'name of current file to excel 
                With xlSheet 
                    .Range(.cells(vintYindex, 1), .cells(vintYindex, 1)).value = _ 
                           vstrTargetImage 
                End With 
      
     Case "Density" 
        n = 0 
         
        'Get statistics from current AOI and send to Array 
        ret = IpBlbGet(GETSTATS, 0, BLBM_DENSITY, vsngExcelArray(n)) 
         
        'make % area active sheet and sends area data to excel 
        xlapp.Sheets(vstrSheetName).Select 
         
        Set xlSheet = xlbook.ActiveSheet 
         
            'Mean, Std. Dev 
            For n = 0 To 1 
                With xlSheet 
                    .Range(.cells(vintYindex, 2 + n), .cells(vintYindex, 2 + n)).value = _ 
                          vsngExcelArray(n) 
                End With 
            Next n 
             
            With xlSheet 
                    .Range(.cells(vintYindex, 4), .cells(vintYindex, 4)).value = _ 
                           vsngExcelArray(5) 
                End With 
             
             
             
         n = 0 
        'Get statistics from current AOI and send to Array 
        ret = IpBlbGet(GETSTATS, 0, BLBM_DENSSUM, vsngExcelArray(n)) 
         
        'make % area active sheet and sends area data to excel 
        xlapp.Sheets(vstrSheetName).Select 
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        Set xlSheet = xlbook.ActiveSheet 
         
            'Mean, Std. Dev 
            For n = 0 To 1 
                With xlSheet 
                    .Range(.cells(vintYindex, 6 + n), .cells(vintYindex, 6 + n)).value = _ 
                          vsngExcelArray(n) 
                End With 
            Next n 
                 
        With xlSheet 
                    .Range(.cells(vintYindex, 8), .cells(vintYindex, 8)).value = _ 
                           vsngExcelArray(5) 
                End With 
                 
End Select 
 
 
End Function 
 
'Determines percent area of segmented portions of image 
Function fncPercentArea() 
 
    'loads segmentation file 
    ret = IpSegLoad(vstrSegmentationFile) 
    ret = IpSegShow(0) 
    ret = IpSegSetAttr(SETCURSEL, 0) 
    ret = IpSegSetAttr(Channel, 0) 
    ret = IpSegPreview(ALL_C_T) 
    ret = IpSegShow(0) 
     
    ret = IpBlbShow(1) 
    'selects manual autorange 
    ret = IpBlbSetAttr(BLOB_AUTORANGE, 0) 
    'Green Fill Color 
    ret = IpBlbSetAttr(BLOB_OUTLINECOLOR, 3) 
    'Style = Filled 
    ret = IpBlbSetAttr(BLOB_OUTLINEMODE, 3) 
    'Set Label Mode to NONE 
    ret = IpBlbSetAttr(BLOB_LABELMODE, 0) 
    'Sets Cleanborder Mode 
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    ret = IpBlbSetAttr(BLOB_CLEANBORDER, 0) 
     
    If chkApplyRanges.value = vbChecked Then 
        vlngRangeMax = txtSizeMax.text 
        vintRangeMin = txtSizeMin.text 
             
        'set filter ranges 
         ret = IpBlbSetFilterRange(BLBM_AREA, vintRangeMin, vlngRangeMax) 
        'apply filter ranges 
         ret = IpBlbSetAttr(BLOB_FILTEROBJECTS, 1) 
    Else 
        vlngRangeMax = 10000 
        vintRangeMin = 10 
     
        'set filter ranges 
         ret = IpBlbSetFilterRange(BLBM_AREA, vintRangeMin, vlngRangeMax) 
        'apply filter ranges 
         ret = IpBlbSetAttr(BLOB_FILTEROBJECTS, 1) 
    End If 
     
    ret = IpBlbCount() 
    ret = IpBlbUpdate(0) 
     
 
End Function 
 
'Determines Integrated Optical Density 
Function fncDensity() 
 
 
End Function 
 
'Determines total area of chosen AOI 
Function fncAOI() 
     
    'set large filter range 
    vlngRangeMax = 10000000 
    vintRangeMin = 0 
 
    'selects manual autorange 
    ret = IpBlbSetAttr(BLOB_AUTORANGE, 0) 
    'Green Fill Color 
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    ret = IpBlbSetAttr(BLOB_OUTLINECOLOR, 3) 
    'Style = Filled 
    ret = IpBlbSetAttr(BLOB_OUTLINEMODE, 3) 
    'Set Label Mode to NONE 
    ret = IpBlbSetAttr(BLOB_LABELMODE, 0) 
    'Sets Cleanborder Mode 
    ret = IpBlbSetAttr(BLOB_CLEANBORDER, 0) 
 
 
    'set filter ranges 
    ret = IpBlbSetFilterRange(BLBM_AREA, vintRangeMin, vlngRangeMax) 
    'apply filter ranges 
    ret = IpBlbSetAttr(BLOB_FILTEROBJECTS, 1) 
      
    'Set segmentation to Max 
    ret = IpBlbShow(1) 
    ret = IpSegShow(1) 
    ret = IpSegSetAttr(SETCURSEL, 0) 
    ret = IpSegSetAttr(Channel, 0) 
    ret = IpSegPreview(ALL_C_T) 
    ret = IpSegShow(2) 
    ret = IpSegSetAttr(SETCURSEL, 0) 
    ret = IpSegPreview(ALL_C_T) 
    ret = IpSegShow(1) 
    ret = IpSegSetAttr(SETCURSEL, 0) 
    ret = IpSegSetAttr(Channel, 0) 
    ret = IpSegPreview(ALL_C_T) 
    ret = IpSegShow(2) 
    ret = IpSegSetAttr(SETCURSEL, 0) 
    ret = IpSegPreview(ALL_C_T) 
    ret = IpSegShow(0) '1 
    ret = IpSegSetAttr(SETCURSEL, 0) 
    ret = IpSegSetAttr(Channel, 0) 
    ret = IpSegPreview(ALL_C_T) 
    ret = IpSegSetRange(0, 0, 255) 
    ret = IpSegPreview(ALL_C_T) 
    ret = IpSegSetAttr(Channel, 1) 
    ret = IpSegSetRange(1, 0, 255) 
    ret = IpSegPreview(ALL_C_T) 
    ret = IpSegSetAttr(Channel, 2) 
    ret = IpSegSetRange(2, 0, 255) 
    ret = IpSegPreview(ALL_C_T) 
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    ret = IpSegShow(0) 
     
    ret = IpBlbCount() 
    ret = IpBlbUpdate(0) 
     
    ret = fncExcelDataExport("AOI", vintExcelRow) 
     
      
End Function 
 
'measurment function that calls Area, Density, and AOI functions 
Function fncMeasure() 
 
    'capture AOI 
    ret = IpMacroStop("Please select Area of Interest", 0) 
     
    'open count/size dialog 
    ret = IpBlbShow(1) 
     
    'Percent Area 
    If chkArea.value = vbChecked Then 
        fncPercentArea 
    End If 
 
 
End Function 
 
 
 
Private Sub Capture_Click() 
     
Dim y As Integer 
y = 1 
 
    ret = IpAcqShow(ACQ_SNAP, 1) 
    ret = IpAcqShow(ACQ_SNAP, 3) 
    ret = IpAcqShow(ACQ_LIVE, 1) 
     
    Load frmAutoName 
    frmAutoName.Show 
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End Sub 
 
'MAIN SUB 
Private Sub cmdCalculate_Click() 
 
vintExcelRow = 3            'These 3 vars. are initialized here. 
vintDirectoryIndex = 0      'For IpStSearch function - Load image index for Dir 
vintDirectoryStatus = 1     'For IpStSearch function - if 1, images still in Dir 
 
    vstrSegmentationFile = txtSegmentationFile.text 'segmentation file path to 
variable 
     
    '--------------------------------Input Checks 
    'Checks to see if user entered file path in background text box 
     
     
    If txtBackgroundImage = "" Then 
        MsgBox ("Please Enter Background Image") 
        Exit Sub 
    End If 
     
    If txtSegmentationImage = "" Then 
        MsgBox ("Please Enter Segmentation Image") 
        Exit Sub 
    End If 
     
    If txtSegmentationFile = "" Then 
        MsgBox ("Please Enter or Create New Segmentation File") 
        Exit Sub 
    End If 
     
    If txtExcelFile = "" Then 
        MsgBox ("Please Enter Name of Excel Spreadsheet") 
        Exit Sub 
    End If 
     
    If txtTargetImageDirectory = "" Then 
        MsgBox ("Please Enter Target Image Directory") 
        Exit Sub 
    End If 
    '--------------------------------End Input Checks 
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    cmdCalculate.Visible = False 
    lblCurrentImageLabel.Visible = True 
    lblCurrentImage.Visible = True 
     
    IPPMACRO.Height = 6855 
     
    'sends targetimagedir text box to string variable 
    vstrTargetImageDirectory = txtTargetImageDirectory.text 
     
    'sends background text box to string variable and loads it using IPbasic 
function 
    vstrBackgroundImage = txtBackgroundImage.text 
    ret = IpWsLoad(vstrBackgroundImage, "tif") 
     
    ret = IpBlbEnableMeas(BLBM_DENSITY, 1) 
    ret = IpBlbEnableMeas(BLBM_DENSSUM, 1) 
    ret = IpBlbEnableMeas(BLBM_AREA, 1) 
     
    fncLoadDir 
     
    If vintDirectoryStatus = 1 Then 
        fncMeasure 
    End If 
     
 
End Sub 
 
Function fncLoadDir() 
 
    vintDirectoryStatus = IpStSearchDir(vstrTargetImageDirectory, "*.tif", _ 
                                        vintDirectoryIndex, vstrTargetImage) 
    If vintDirectoryStatus <> 1 Then 
        ret = IpMacroStop("No More Images in Directory", MS_STOP) 
        cmdIcContinue.Enabled = False 
        cmdIcContinue.Font.Strikethrough = True 
        Exit Function 
    End If 
     
    lblCurrentImage.caption = vstrTargetImage 
       
    'sends background text box to string variable and loads it using IPbasic 
function 
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  '  vstrBackgroundImage = txtBackgroundImage.text 
  '  ret = IpWsLoad(vstrBackgroundImage, "tif") 
     
    'loads target image to IPP 
    ret = IpWsLoad(vstrTargetImage, "tif") 
     
    'Background Correction 
    ret = IpOpShow(3) 
    ret = IpOpBkgndSubtract(0, 0) 
    ret = IpOpShow(2) 
     
         
    'Apply Filters if Applicable 
     
    'Index (1) is for HighGauss 
    If optFilter.Item(1) Then 
        ret = IpFltConvolveKernel("HIGAUSS.7x7", 10, 1) 'HiGauss Filter Size:5x5; 
Strength:100%; Passes:1 
    End If 
     
    'Index (2) is for Lar's Amyloid Macro Filters 
    If optFilter.Item(2) Then 
        ret = IpFltFlatten(0, 20) 
        ret = IpWsConvertToGray() 
        ret = IpFltConvolveKernel("HIGAUSS.7x7", 2, 1) 'HiGauss Filter Size:5x5; 
Strength:100%; Passes:1 
        ret = IpHstEqualize(EQ_BESTFIT) 
        ret = IpSegLoad(vstrSegmentationFile) 
         
     
    Else 
        'loads segmentation file 
        ret = IpSegLoad(vstrSegmentationFile) 
        ret = IpSegShow(0) 
        ret = IpSegSetAttr(SETCURSEL, 0) 
        ret = IpSegSetAttr(Channel, 0) 
        ret = IpSegPreview(ALL_C_T) 
        ret = IpSegShow(0) 
         
        ret = IpBlbShow(1) 
 
    End If 
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End Function 
 
'Allows user to create segmentation file from segmentation image if non existant 
Private Sub cmdCreateSegmentationFile_Click() 
 
    ret = IpAppCloseAll 
     
    'Checks to see if user entered file path in background text box 
    If txtBackgroundImage = "" Then 
        MsgBox ("Please Enter Background Image") 
        Exit Sub 
    End If 
     
    'Checks to see if user entered file path in background text box 
    If txtSegmentationImage = "" Then 
        MsgBox ("Please Enter Segmentation Image") 
        Exit Sub 
    End If 
     
        If MsgBox("Are you using Lars-HiGauss Filter Option?", vbYesNoCancel, 
"Create Sementation File") = vbYes Then 
            optFilter(2) = True 
        End If 
         
    'Load Background Image 
    vstrBackgroundImage = txtBackgroundImage.text 
    ret = IpWsLoad(vstrBackgroundImage, "tif") 
     
    'Load Segmentation Image 
    vstrSegmentationImage = txtSegmentationImage.text 
    ret = IpWsLoad(vstrSegmentationImage, "tif") 
     
    'Background Subtraction 
    ret = IpOpShow(3) 
    ret = IpOpBkgndSubtract(0, 0) 
    ret = IpOpShow(2) 
     
    If optFilter.Item(2) Then 
        ret = IpBlbShow(1) 
        ret = IpFltFlatten(0, 20) 
        ret = IpBlbShow(0) 
        ret = IpWsConvertImage(IMC_GRAY, CONV_SCALE, 0, 0, 0, 0) 
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        ret = IpFltShow(1) 
        ret = IpFltConvolveKernel("HIGAUSS.7x7", 2, 1) 
        ret = IpFltShow(0) 
        ret = IpHstEqualize(EQ_BESTFIT) 
         
        ret = IpBlbShow(1) 
        ret = IpSegShow(1) 
        ret = IpSegSetAttr(SETCURSEL, 0) 
        ret = IpSegSetAttr(Channel, 0) 
        ret = IpSegPreview(CURRENT_C_T) 
         
        ret = IpMacroStop("Adjust Segmentation and Press Continue to Save 
Segmentation File", 0) 
     
        With CommonDialog1 
            .FileName = "" 
            .Filter = "Color Segmentation Files (*.rge)|*.rge|All Files|*.*" 
            .FilterIndex = 1 
            .ShowSave 
            vstrSegmentationFile = .FileName 
            txtSegmentationFile = .FileName 
        End With 
         
    Else 
         
     
        ret = IpSegShow(1) 
        ret = IpSegSetAttr(SETCURSEL, 0) 
        ret = IpSegSetAttr(Channel, 0) 
        ret = IpSegPreview(ALL_C_T) 
        ret = IpMacroStop("Adjust Segmentation and Press OK to Save 
Segmentation File", 0) 
         
        With CommonDialog1 
            .FileName = "" 
            .Filter = "Color Segmentation Files (*.rge)|*.rge|All Files|*.*" 
            .FilterIndex = 1 
            .ShowSave 
            vstrSegmentationFile = .FileName 
            txtSegmentationFile = .FileName 
        End With 
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    End If 
     
    ret = IpSegSave(vstrSegmentationFile, 0) 
    ret = IpSegShow(0) 
    ret = IpAppCloseAll 
         
         
End Sub 
 
Private Sub cmdExit_Click() 
 
    Unload Me 
 
 
End Sub 
 
Private Sub cmdIcContinue_Click() 
 
  ret = fncExcelDataExport("% Area", vintExcelRow) 
 
    'Density Measurement 
    If chkDensity.value = vbChecked Then 
        fncDensity 
        ret = fncExcelDataExport("Density", vintExcelRow) 
    End If 
     
    'Area of Interest Total Area 
    fncAOI 
     
    'index for directory image 
    vintDirectoryIndex = vintDirectoryIndex + 1 
     
    'index for Excel Row 
    vintExcelRow = vintExcelRow + 1 
     
    'Reset Comment Box 
    txtIcComment.text = "" 
     
    ret = IpDocClose() 
     
    fncLoadDir 
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    If vintDirectoryStatus = 1 Then 
        fncMeasure 
    Else 
    ret = IpAppCloseAll() 
    End If 
 
 
End Sub 
 
Private Sub cmdIcDeselectItem_Click() 
 
    ret = IpAoiShow(FRAME_NONE) 
    ret = IpTemplateMode(1) 
    ret = IpBlbHideObject(0, 0, 0) 
    ret = IpTemplateMode(0) 
    ret = IpAoiShow(FRAME_IRREGULAR) 
 
 
End Sub 
 
Private Sub cmdIcModifySegmentation_Click() 
     
    ret = IpSegShow(1) 
    ret = IpSegShow(1) 
    ret = IpSegSetAttr(SETCURSEL, 0) 
    ret = IpSegSetAttr(Channel, 0) 
    ret = IpSegPreview(ALL_C_T) 
    ret = IpSegShow(2) 
    ret = IpSegSetAttr(SETCURSEL, 0) 
    ret = IpSegPreview(ALL_C_T) 
    ret = IpSegShow(1) 
    ret = IpSegSetAttr(SETCURSEL, 0) 
    ret = IpSegSetAttr(Channel, 0) 
    ret = IpSegPreview(ALL_C_T) 
    ret = IpSegShow(1) 
    ret = IpSegSetAttr(SETCURSEL, 0) 
    ret = IpSegSetAttr(Channel, 0) 
    ret = IpSegPreview(ALL_C_T) 
     
    ret = IpMacroStop("Adjust Segmentation and Press OK", 0) 
    ret = IpSegShow(0) 
    ret = IpBlbCount() 
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    ret = IpBlbUpdate(0) 
     
     
End Sub 
 
'Opens CommonDialog1 "Open File" dialog and sends file to appropriate textbox 
 
Private Sub cmdOpenBackground_Click() 
    With CommonDialog1 
         .Filter = "TIF|*.tif|JPEG (.jpg)|*.jpg|All Files|*.*" 
         .FilterIndex = 1 
         .ShowOpen 
         txtBackgroundImage = .FileName 
    End With 
 
 
End Sub 
 
'Opens CommonDialog1 "Open File" dialog and sends file to appropriate textbox 
 
Private Sub cmdOpenExcel_Click() 
 
    With CommonDialog1 
         .Filter = "Excel Spreadsheet File (.xls)|*.xls|All Files|*.*" 
         .FilterIndex = 1 
         .ShowOpen 
         txtExcelFile = .FileName 
    End With 
 
 
End Sub 
 
'Opens "Browse Directory Structure" dialog and allows one to choose directory 
and 
'sends chosen directory to textbox 
 
Private Sub cmdOpenImageDirectory_Click() 
 
Dim udtBrowseInfo As BROWSEINFO 
Dim lRet As Long 
Dim lPathID As Long 
Dim sPath As String 
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Dim nNullPos As Integer 
     
    txtTargetImageDirectory.SetFocus 
     
    'Specify the window handle for the owner of the dialog box 
    udtBrowseInfo.hOwner = Me.hwnd 
     
    'Specify the root to start browsing from; 
    'if null, My Computer is the root 
    udtBrowseInfo.pidlRoot = 0& 
     
    'Specify a title.  This is not the caption of the dialog.  Useful for 
    'adding any kind of additional information or instructions 
    udtBrowseInfo.lpszTitle = "Select a folder" 
     
    'Specify any flags; See Declarations section 
    udtBrowseInfo.ulFlags = BIF_RETURNONLYFSDIRS 
     
    'Call the function. 
    'The return value is a pointer to an item identifier list that 
    'specifies the location of the selected folder. 
    'If the user cancels the dialog box, the return value is 0. 
    lPathID = SHBrowseForFolder(udtBrowseInfo) 
     
    sPath = Space$(512) 
    lRet = SHGetPathFromIDList(lPathID, sPath) 
     
    If lRet Then 
        nNullPos = InStr(sPath, vbNullChar) 
        txtTargetImageDirectory = Left(sPath, nNullPos - 1) 
    End If 
 
 
End Sub 
 
'Opens CommonDialog1 "Open File" dialog and sends file to appropriate textbox 
 
Private Sub cmdOpenSegmentationFile_Click() 
 
    With CommonDialog1 
        .Filter = "Color Segmentation Files (*.rge)|*.rge|All Files|*.*" 
        .FilterIndex = 1 
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        .ShowOpen 
        txtSegmentationFile = .FileName 
    End With 
 
 
End Sub 
 
'Opens CommonDialog1 "Open File" dialog and sends file to appropriate textbox 
Private Sub cmdOpenSegmentationImage_Click() 
 
    With CommonDialog1 
        .Filter = "TIF|*.tif|JPEG (.jpg)|*.jpg|All Files|*.*" 
        .FilterIndex = 1 
        .ShowOpen 
        txtSegmentationImage = .FileName 
    End With 
 
 
End Sub 
 
 
Private Sub Exit_Click() 
Unload Me 
End Sub 
 
Private Sub Form_Load() 
     
  
    'Both "WinExec" and "SetWindowPos" require API calls - The real WinAPI file 
is too 
    'large to be included in a VB executable, so a modified API file, DCmodAPI.rtf, 
is 
    'used instead. 
     
    'Loads IPP on start of program 
    ret = WinExec("c:\ipwin4\ipwin32.exe", 1) 
     
    'keeps VB controls on top of IPP 
    '-1 = HWND_TOPMOST 
    '&H2 = SWP_NOMOVE 
    '&H1 = SWP_NOSIZE 
    '4 Numbers between are screen coordinates 
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    ret = SetWindowPos(IPPMACRO.hwnd, -1, 0, 0, 0, 0, &H2 + &H1) 
     
    ret = IpAppCloseAll 
    chkArea.value = vbChecked 
     
    IPPMACRO.Height = 5840 
     
    'opens excel using user defined function 
    fncOpenExcel 
     
        
     
End Sub 
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'IpUtil32.bas 
 
Function iprint(mystring As Variant) 
        ' Replaces the print command in IP-Basic v. 3.0. 
        ' Sends the string argument to the output window. 
        IpOutput (mystring + Chr$(13) + Chr$(10)) 
End Function 
 
Function IpTrim(mystring As String) As String 
        ' Replaces RTrim$ command in IP-Basic v.3.0. 
        ' The old command used to trim zeros as well as spaces. 
        Dim Index% 
        Index = InStr(mystring, Chr$(0)) 
        If Index > 0 Then IpTrim = Trim$(Left$(mystring, Index - 1)) Else IpTrim = 
Trim$(mystring) 
End Function 
 
Function IpDocActive() As Integer 
        ' Returns the document Id of the active image 
        ' Returns -1 if no image is displayed. 
        Dim docid As Integer 
        ret = IpDocGet(GETACTDOC, 0, docid) 
        If ret < 0 Then IpDocActive = -1 Else IpDocActive = docid 
End Function 
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'ModBrowse.bas 
 
 
Option Explicit 
 
'Function Declarations, type structure, and constants to use the 
'Browse for Folder dialog box.  For more information on these, 
'consult the SDK, included with VB 4.0 Pro or Ent editions as 
'part of the MSDN/VB Starter Kit. 
 
Public Declare Function SHGetPathFromIDList Lib "shell32.dll" _ 
Alias "SHGetPathFromIDListA" (ByVal pidl As Long, _ 
ByVal pszPath As String) As Long 
 
Public Type BROWSEINFO 
    hOwner As Long 
    pidlRoot As Long 
    pszDisplayName As String 
    lpszTitle As String 
    ulFlags As Long 
    lpfn As Long 
    lParam As Long 
    iImage As Long 
End Type 
 
Public Declare Function SHBrowseForFolder Lib "shell32.dll" _ 
Alias "SHBrowseForFolderA" (lpBrowseInfo As BROWSEINFO) As Long 
 
'Below are the constants which can be specified in the ulFlags member 
'of the BROWSEINFO structure. 
 
'Only returns file system directories. If the user selects folders 
'that are not part of the file system, the OK button is grayed. 
Public Const BIF_RETURNONLYFSDIRS = &H1 
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'Does not include network folders below the domain level in the 
'tree view control. 
Public Const BIF_DONTGOBELOWDOMAIN = &H2 
 
'Only returns file system ancestors. If the user selects anything 
'other than a file system ancestor, the OK button is grayed. 
Public Const BIF_RETURNFSANCESTORS = &H8 
 
'Only returns computers. If the user selects anything other than 
'a computer, the OK button is grayed. 
Public Const BIF_BROWSEFORCOMPUTER = &H1000 
 
'Only returns printers. If the user selects anything other than 
'a printer, the OK button is grayed. 
Public Const BIF_BROWSEFORPRINTER = &H2000 
 
'Includes a status area in the dialog box. The callback function can set the status 
text by sending messages to the dialog box. 
Const BIF_STATUSTEXT = &H4 
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'ModFileO.BAS 
 
 
Option Explicit 
 
'Function Declarations, type structure, and constants for the Open and Save 
'common dialog boxes.  For more information on these, consult the SDK, 
'included with VB 4.0 Pro or Ent editions as part of the MSDN/VB Starter 
'Kit. 
 
Public Type OPENFILENAME 
    lStructSize As Long 
    hwndOwner As Long 
    hInstance As Long 
    lpstrFilter As String 
    lpstrCustomFilter As String 
    nMaxCustFilter As Long 
    nFilterIndex As Long 
    lpstrFile As String 
    nMaxFile As Long 
    lpstrFileTitle As String 
    nMaxFileTitle As Long 
    lpstrInitialDir As String 
    lpstrTitle As String 
    Flags As Long 
    nFileOffset As Integer 
    nFileExtension As Integer 
    lpstrDefExt As String 
    lCustData As Long 
    lpfnHook As Long 
    lpTemplateName As String 
End Type 
 
'Functions and constants for the common dialog boxes 
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Public Declare Function GetOpenFileName Lib "comdlg32.dll" _ 
Alias "GetOpenFileNameA" (pOPENFILENAME As OPENFILENAME) As Long 
 
Public Declare Function GetSaveFileName Lib "comdlg32.dll" _ 
Alias "GetSaveFileNameA" (pOPENFILENAME As OPENFILENAME) As Long 
 
'These constants must be declared since the Common Dialog control is not 
'part of the project and, therefore, the intrinsic constants are not 
'defined. 
Public Const OFN_READONLY = &H1 
Public Const OFN_OVERWRITEPROMPT = &H2 
Public Const OFN_HIDEREADONLY = &H4 
Public Const OFN_NOCHANGEDIR = &H8 
Public Const OFN_SHOWHELP = &H10 
Public Const OFN_ENABLEHOOK = &H20 
Public Const OFN_ENABLETEMPLATE = &H40 
Public Const OFN_ENABLETEMPLATEHANDLE = &H80 
Public Const OFN_NOVALIDATE = &H100 
Public Const OFN_ALLOWMULTISELECT = &H200 
Public Const OFN_EXTENSIONDIFFERENT = &H400 
Public Const OFN_PATHMUSTEXIST = &H800 
Public Const OFN_FILEMUSTEXIST = &H1000 
Public Const OFN_CREATEPROMPT = &H2000 
Public Const OFN_SHAREAWARE = &H4000 
Public Const OFN_NOREADONLYRETURN = &H8000 
Public Const OFN_NOTESTFILECREATE = &H10000 
Public Const OFN_NONETWORKBUTTON = &H20000 
Public Const OFN_NOLONGNAMES = &H40000         '  force no long names for 
4.x modules 
Public Const OFN_EXPLORER = &H80000            '  new look commdlg 
Public Const OFN_NODEREFERENCELINKS = &H100000 
Public Const OFN_LONGNAMES = &H200000          '  force long names for 3.x 
modules 
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'DCmodAPI.rtf 
 
Const STARTF_USESHOWWINDOW = &H1 
 
Declare Function WinExec Lib "kernel32" (ByVal lpCmdLine As String, ByVal 
nCmdShow As Long) As Long 
 
'  error values for ShellExecute() beyond the regular WinExec() codes 
Const SE_ERR_SHARE = 26 
Const SE_ERR_ASSOCINCOMPLETE = 27 
Const SE_ERR_DDETIMEOUT = 28 
Const SE_ERR_DDEFAIL = 29 
Const SE_ERR_DDEBUSY = 30 
Const SE_ERR_NOASSOC = 31 
 
'  ShellExecute() and ShellExecuteEx() error codes 
 
'  regular WinExec() codes 
Const SE_ERR_FNF = 2                     '  file not found 
Const SE_ERR_PNF = 3                     '  path not found 
Const SE_ERR_ACCESSDENIED = 5            '  access denied 
Const SE_ERR_OOM = 8                     '  out of memory 
Const SE_ERR_DLLNOTFOUND = 32 
 
 
'  Note CLASSKEY overrides CLASSNAME 
Const SEE_MASK_CLASSNAME = &H1 
Const SEE_MASK_CLASSKEY = &H3 
'  Note INVOKEIDLIST overrides IDLIST 
Const SEE_MASK_IDLIST = &H4 
Const SEE_MASK_INVOKEIDLIST = &HC 
Const SEE_MASK_ICON = &H10 
Const SEE_MASK_HOTKEY = &H20 
Const SEE_MASK_NOCLOSEPROCESS = &H40 
Const SEE_MASK_CONNECTNETDRV = &H80 
Const SEE_MASK_FLAG_DDEWAIT = &H100 
Const SEE_MASK_DOENVSUBST = &H200 
Const SEE_MASK_FLAG_NO_UI = &H400 
 
Type SHELLEXECUTEINFO 
        cbSize As Long 
        fMask As Long 
188 
APPENDIX A (Continued) 
 
        hwnd As Long 
        lpVerb As String 
        lpFile As String 
        lpParameters As String 
        lpDirectory As String 
        nShow As Long 
        hInstApp As Long 
        '  Optional fields 
        lpIDList As Long 
        lpClass As String 
        hkeyClass As Long 
        dwHotKey As Long 
        hIcon As Long 
        hProcess As Long 
End Type 
 
Declare Sub WinExecError Lib "shell32.dll" Alias "WinExecErrorA" (ByVal hwnd 
As Long, ByVal error As Long, ByVal lpstrFileName As String, ByVal lpstrTitle As 
String) 
 
Const SW_HIDE = 0 
Const SW_SHOWNORMAL = 1 
Const SW_NORMAL = 1 
Const SW_SHOWMINIMIZED = 2 
Const SW_SHOWMAXIMIZED = 3 
Const SW_MAXIMIZE = 3 
Const SW_SHOWNOACTIVATE = 4 
Const SW_SHOW = 5 
Const SW_MINIMIZE = 6 
Const SW_SHOWMINNOACTIVE = 7 
Const SW_SHOWNA = 8 
Const SW_RESTORE = 9 
Const SW_SHOWDEFAULT = 10 
Const SW_MAX = 10 
 
' Old ShowWindow() Commands 
Const HIDE_WINDOW = 0 
Const SHOW_OPENWINDOW = 1 
Const SHOW_ICONWINDOW = 2 
Const SHOW_FULLSCREEN = 3 
Const SHOW_OPENNOACTIVATE = 4 
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' Identifiers for the WM_SHOWWINDOW message 
Const SW_PARENTCLOSING = 1 
Const SW_OTHERZOOM = 2 
Const SW_PARENTOPENING = 3 
Const SW_OTHERUNZOOM = 4 
 
Const WM_SHOWWINDOW = &H18 
Declare Function ShowWindow Lib "user32" (ByVal hwnd As Long, ByVal 
nCmdShow As Long) As Long 
Const SWP_SHOWWINDOW = &H40 
 
Declare Function ShowWindowAsync Lib "user32" (ByVal hwnd As Long, ByVal 
nCmdShow As Long) As Long 
'---------------------------------------------------- 
'Set Window Pos 
Declare Function SetWindowPos Lib "user32" (ByVal hwnd As Long, ByVal 
hWndInsertAfter As Long, ByVal x As Long, ByVal y As Long, ByVal cx As Long, 
ByVal cy As Long, ByVal wFlags As Long) As Long 
 
' SetWindowPos Flags 
Const SWP_NOSIZE = &H1 
Const SWP_NOMOVE = &H2 
Const SWP_NOZORDER = &H4 
Const SWP_NOREDRAW = &H8 
Const SWP_NOACTIVATE = &H10 
Const SWP_FRAMECHANGED = &H20        '  The frame changed: send 
WM_NCCALCSIZE 
'Const SWP_SHOWWINDOW = &H40 
Const SWP_HIDEWINDOW = &H80 
Const SWP_NOCOPYBITS = &H100 
Const SWP_NOOWNERZORDER = &H200      '  Don't do owner Z ordering 
 
Const SWP_DRAWFRAME = SWP_FRAMECHANGED 
Const SWP_NOREPOSITION = SWP_NOOWNERZORDER 
 
' SetWindowPos() hwndInsertAfter values 
Const HWND_TOP = 0 
Const HWND_BOTTOM = 1 
Const HWND_TOPMOST = -1 
Const HWND_NOTOPMOST = -2 
 
Type DLGTEMPLATE 
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        style As Long 
        dwExtendedStyle As Long 
        cdit As Integer 
        x As Integer 
        y As Integer 
        cx As Integer 
        cy As Integer 
End Type 
 
Type DLGITEMTEMPLATE 
        style As Long 
        dwExtendedStyle As Long 
        x As Integer 
        y As Integer 
        cx As Integer 
        cy As Integer 
        id As Integer 
End Type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
191 
APPENDIX B 
 
Previous Publications 
 
Cognitive impairment in PDAPP mice depends on ApoE ans ACT-catalyzed  
amyloid formation..............................................................................192 
 
Environmental enrichment improves cognition in aged Alzheimer’s 
 Transgenic mice despite stable ß-amyloid deposition.......................250 
 
 
 
 
APPENDIX B (Continued) 
192 
Previously Published 
Neurobiology of Aging  25 (2004) 1153-1167 
 
 
Cognitive impairment in PDAPP mice depends on ApoE and ACT-
catalyzed amyloid formation 
 
 
Lars N.G.Nilsson1,6,8, Gary W. Arendash3,8, Ralph E. Leighty3, David A. 
Costa1, Mark A. Low3, Marcos F. Garcia3, Jennifer R. Cracciolo3,Amyn 
Rojiani2, Xin Wu4, Kelly R. Bales4, Steven M. Paul4 & Huntington 
Potter1,5,7 
 
1Suncoast Gerontology Center and Department of Biochemistry and Molecular 
Biology, 1,2Moffitt Cancer Center, 2Department of Pathology, College of 
Medicine, MDC07, University of South Florida, 12901 Bruce B. Downs Blvd., 
Tampa, FL 33612, USA  
3Memory and Aging Research Laboratory, Department of Biology SCA112, 
College of Arts and Sciences, University of South Florida, Florida, FL 33620, 
USA 
 4Neuroscience Discovery Research, Lilly Research Laboratories, Indianapolis, 
Indiana, 46285, USA 
5The Florida Alzheimer’s Center and Research Institute 
6Present address: Department of Public Health and Caring Sciences, Uppsala 
University, Dag Hammarskjölds Väg 20, S-75185 Uppsala, Sweden  
7Correspondence: hpotter@hsc.usf.edu 
8These authors contributed equally to this work 
 
Corresponding author: Dr. Huntington Potter, Department of Biochemistry and 
Molecular Biology, College of Medicine, MDC 7, University of South Florida, 
Tampa, FL 33612, tel. (813) 974-5369, fax (813) 974-7357, email. 
hpotter@hsc.usf.edu  
 
Acknowledgements 
We thank Jean-Paul Sorondo for assistance in behavioral analysis in this 
study, and Dr. Dave Morgan for providing access to a fluorescence microscope 
for photography. The research was supported by a grant AG09665 from the 
National Institute of Aging (HP), funding from USF Institute of Aging (GWA), a 
fellowship from the John Douglas French Alzheimer’s Foundation and grants 
from the Loo and Hans Osterman and the Swedish Alzheimer Foundation 
(LNGN). H.P. occupies the Eric Pfeiffer Chair for Research in Alzheimer’s 
disease at the Suncoast Gerontology Center at the University of South Florida 
and is acting director; Florida Alzheimer’s Center and Research Institute. 
 
 
 
APPENDIX B (Continued) 
193 
 
1.Abstract 
 
Biochemical and genetic studies indicate that the inflammatory proteins, 
Apolipoprotein E (ApoE) and α1-Antichymotrypsin (ACT) are important in 
the pathogenesis of Alzheimer’s disease (AD). Using several lines of 
multiply transgenic/knockout mice we show here that murine ApoE and 
human ACT separately and synergistically facilitate both diffuse Aβ 
immunoreactive and fibrillar amyloid deposition and thus also promote 
cognitive impairment in aged PDAPP(V717F) mice. The degree of 
cognitive impairment is highly correlated with the ApoE- and ACT-
dependent hippocampal amyloid burden, with PDAPP mice lacking ApoE 
and ACT having little amyloid and little learning disability. A analysis of 
young mice before the onset of amyloid formation shows that steady 
state levels of monomeric Aβ peptide are unchanged by ApoE or ACT.  
These data suggest that the process or product of amyloid formation is 
more critical than monomeric Aβ for the neurological decline in AD, and 
that the risk factors ApoE and ACT participate primarily in disease 
processes downstream of APP processing. 
 
Key words: α1-Antichymotrypsin, Apolipoprotein E, Alzheimer’s disease, 
amyloid deposition, learning, memory, inflammation, transgenic mice, amyloid 
β-peptide 
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1. Introduction 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized 
psychologically by progressive mental decline and defined histopathologically 
by parenchymal amyloid deposits and neurofibrillary tangles. Mutations within 
the amyloid precursor protein (APP) gene that cause inherited AD place APP 
and the Aβ peptide at the center of the disease process [52, 26, 58]. Whether 
Aβ per se or the process or product of its conversion into amyloid underlies AD 
neurodegeneration remains unknown.  
 Insight into the role of APP and Aβ in AD may be provided by genetic and 
biochemical studies showing other proteins to be involved in the disease 
process. For example, Aβ amyloid deposits also contain α1-antichymotrypsin 
(ACT; [1]) and apolipoprotein E (ApoE; [43, 73]), which are over-expressed in 
affected regions of the AD brain as part of an inflammatory process [74, 1].  
ACT levels are also increased in AD serum and CSF ([15]for data and 
discussion).  It was proposed at the time of their discoveries that ApoE and 
ACT might function as amyloid promoters or “Pathological Chaperones”, and 
both in vitro and in vivo studies support this model [36, 56, 72, 8, 7, 28, 41, 45].   
As with APP, the importance of inflammation and specifically ApoE and ACT in 
AD is supported by genetics. Inheritance of ApoE4 is the strongest risk factor 
for AD besides age [13, 59], and an ACT/A signal peptide variant that 
increases mature glycosylated ACT available for secretion [46] increases AD 
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susceptibility and pathology [30, 75] (for discussion see [44, 51]). Similarly, 
polymorphisms in the IL-1 promoter greatly increase the risk of AD [40]. These  
genetic variations increase IL-1 expression during inflammation and would 
therefore be expected to promote amyloid formation by increasing the 
production of both APP and ACT [24, 10, 22, 14, 46, 55].  
Although genetic and biochemical studies have identified key proteins in 
the AD pathogenic pathway, it remains unclear what role Aβ, inflammation, and 
amyloid formation play in the cognitive dysfunction of AD. To answer this 
question, cognitive studies should be performed with AD mouse models in 
which the inflammatory proteins and the Aβ deposition they influence can be 
regulated without changing the level of monomeric Aβ peptide. To this end, we 
have generated and analyzed four mouse models of AD and find that 1) ApoE 
and ACT independently and synergistically promote Aβ immunoreactive and 
mature amyloid deposition without initially affecting Aβ levels and 2) cognitive 
impairment in aged AD mice depends on the amyloid promoting effect of ApoE 
and/or ACT. 
   
2. Materials and methods 
Construction of transgenic mice. A 1.5kbp full-length human ACT-cDNA-
clone was subcloned into a modified GFAP-expression vector construct as 
previously described [45]. Heterozygous mice from one of these founder lines 
(#8784, FVB/N) were crossed with homozygous PDGF-hAPP(V717F) mice 
[Swiss-Webster x C57BL/6 x DBA/2] to generate mice with genotypes APP+/-
 
 
 
APPENDIX B (Continued) 
196 
/ApoE+/+/ACT+/- and APP+/-/ApoE+/+/ACT-/-. Heterozygous ACT mice were also 
crossed with ApoE-/- mice [Swiss-Webster x C57BL/6 xDBA/2] to generate 
mice with genotype ApoE+/-/ACT+/-. These mice were then crossed with APP+/+, 
ApoE-/- mice [(Swiss-Webster x C57BL/6 x DBA/2) x  C57BL/6] to generate 
mice with genotypes APP+/-/ApoE-/-/ACT+/- and APP+/-/ApoE-/-/ACT-/-. All 
offspring were screened by PCR for identity of the GFAP-ACT gene [45], the 
PDGF-hAPP gene [23], as well as the mouse ApoE gene and neo gene [8]. 
The basal ACT protein expression in the transgenic mice was 12 pmol/g wet 
weight in the cerebral cortex and 24pmol/g wet weight in the hippocampus, 
which is at least ten-fold lower than the levels detected in human AD brain 
tissue [1, 32, 45]. The presence or absence of proper ACT protein expression 
in astrocytes was further verified by ACT-immunohistochemistry in all of the 
pathologically and behaviorally examined animals. The genetic background of 
the nontransgenic mice was Swiss-Webster. For the ease of reading, a single 
plus sign immediately following APP or ACT genotype refers to heterozygosity 
unless otherwise stated in the text. The presence of the normal complement of 
two murine ApoE genes in a strain is indicated in parenthesis as (mApoE+) 
and the absence of the human ACT transgene by (ACT-) for the sake of clarity.  
The four lines are therefore designated: 
 
APP+(mApoE+), ACT+   (heterozyg PDAPP/homozyg murine ApoE/heterozyg ACT) 
APP+(mApoE+)(ACT -)  (heterozyg PDAPP/homozyg murine ApoE/no ACT) 
APP+, mApoE-KO, ACT+  (heterozyg PDAPP/murine ApoE knockout/heterozg ACT) 
APP+, mApoE-KO (ACT-)  (hetrozyg PDAPP/murine ApoE knockout/no ACT) 
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ELISA Analysis of Aβ levels.  At two months of age, animals of each genotype 
were sacrificed and their brains prepared for ELISA as previously described 
[18], with the modification that PBS rather that TBS was used to extract soluble 
Aβ. 
 
General Protocol and Behavioral Analysis. The four groups of transgenic mice, 
along with three strains of non-transgenic mice (Swiss-Webster, B6D2/F1, and 
FVBJ) were maintained on a 12-hr light-dark cycle. The animals were provided 
free access to water and rodent chow, with behavioral testing always done 
during the light phase and by investigators unaware of animal genotypes. 
Beginning at 16 months of age, all animals were tested in a 6-week battery of 
sensorimotor, anxiety and cognitive tasks, which included the Morris water 
maze and the radial arm water maze (RAWM) as previously described [6, 38]. 
Two groups of animals, APP+ (mApoE+) (ACT-) and nontransgenic littermates, 
were behaviorally tested in the same battery of tasks at two months of age to 
determine whether animals destined to deposit amyloid were impaired at an 
early age before deposition began. 
Briefly, the RAWM consisted of a circular pool, 1 meter in diameter, with 
six swim arms (19 cm wide) radiating from an open central area (40 cm in 
diameter). A variety of spatial cues were present on the walls and ceiling in the 
immediate vicinity of the pool for RAWM testing (as well as for Morris water 
maze testing), in order to spatially orient the animals while swimming. The 
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submerged escape platform was positioned near the end of a different arm for 
each of the 9 days of testing, thus forcing the animals to use spatial working 
memory to decrease their escape latency to find a given days “goal” arm over 
5 trials per day. Four consecutive acquisition trials were done (T1-T4), followed 
by a retention trial (T5) 30 minutes later. The five arms not containing the 
platform were designated as start arms for each of the one-minute trials, in a 
varied semi-randomized sequence for each day of testing. For any given trial, 
the animal was placed in a start arm and allowed to make arm choices, with 
each incorrect choice resulting in the animal being gently pulled back to the 
start arm for that trial. The time required to locate the submerged platform was 
recorded and the animal was allowed to remain on the escape platform for 30 
seconds. Animals that did not find the platform within any 60 sec trial were 
guided to the platform and the maximal 60 sec time was recorded. RAWM 
latency data were analyzed over three 3-day blocks. Because unimpaired 
animals generally require the first two blocks to learn this task’s procedural 
aspects, block 3 of testing (days 7-9) is most indicative of cognitive 
performance.  
The Morris water maze consisted of an open circular pool, with a 
diameter of 1 meter, which was divided in four quadrants. An indiscernible 9-
cm platform was positioned in quadrant 2 (Q2) 1.5cm below the water surface. 
Acquisition testing involved four trials per day for 9 days wherein an animal 
was placed successively into each of the four quadrants to initiate a 60 sec 
trial. The time to locate the platform was recorded for each trial and the 
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average latency to find the submerged platform was calculated for these four 
trials. Upon locating and ascending the platform (or after 60 sec) the animal 
was allowed a 30 sec inter-trial resting period on the platform. 
  
Histology and Immunohistochemistry. At 18 months of age, brains were 
dissected from anesthetized and intracardially perfused mice and 25μm 
coronal tissue sections were processed as previously described [45]. The 
mounted sections were processed through antigen retrieval in prewarmed 
25mM citrate buffer (pH 7.3) at +82°C for 5 min and further processed as 
previously described [45]. The sections were incubated with primary antibodies 
rabbit anti-ACT (AXL-145, dil 1:1000, Accurate) and mouse anti-Aβ (6E10, dil 
1:5000, Senetek) overnight at +4°C. Secondary antibodies were anti-rabbit IgG 
(BA-1000, 1:300, Vector) or anti-mouse IgG and developed with NovaRED 
substrate kit (Vector). Congo Red-staining and Thioflavine S was performed 
according to well-established protocols[16].  
 
Image analysis. Data were collected from five equally spaced coronal tissue 
sections for both dorsal hippocampus and overlying parietal cortex (Bregma -
1.06 to -2.30mm; [45]. The sections were examined with a Nikon Eclipse E600 
microscope at 100X  (6E10 immunostaining) and 200X (Congo Red) 
magnification at a constant predefined light setting and video images captured 
with a color CCD-camera. All images were then processed through shading 
correction. The 6E10 immunostaining was converted to a grayscale image and 
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segmented with an auto threshold function (Image Pro Plus, Media 
Cybernetics). Diffuse immunoreactive Aβ deposition (6E10) was estimated as 
area fraction (=stained areatot/measured areatot, expressed in %). Congo Red 
positive amyloid plaques were circled at 200X magnification, and their location 
noted on an anatomic atlas. The captured image was segmented with respect 
to threshold settings for RGB that had been specified prior to analysis so as to 
distinguish specific signals from background. The area occupied by amyloid 
within each circle, as defined by the image segmentation, was then quantitated 
and an area fraction calculated from the total measured area as previously 
described [45]. 
 
Statistical analysis. The histopathological results were analyzed with factorial 
ANOVA and post hoc Fisher LSD test. The behavioral data were evaluated 
with One-way ANOVA and post-hoc Fisher LSD test of each separate trial. 
Repeat-measures ANOVA across all trials yielded almost identical results. The 
correlations between histopathological and behavioral analysis were examined 
with linear regression. Discriminant analysis was performed to determine 
whether groups of mice with different strain backgrounds, different genotypes 
or varying amyloid depositing capacity, could be distinguished from one 
another behaviorally. The analysis, which was based on the performance of 7-
19 measures from our behavioral test battery, was performed with the 
DISCRIM subroutine of the SYSTAT software package. The discriminant 
analysis was based on the following measures:  
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1. Open field activity (line crossings during a 5 minute trial),  
2. Balance Beam (time before falling during 3 successive trials, in seconds),  
3. String Agility (agility to put hindpaws and/or tail around a suspended string during 
a 1 minute trial),  
4. Y-maze choices (number of arm choices in a single 5 minute trial),  
5. Y-maze percent alternation (in a single 5 minute trial),  
6. Morris maze acquisition (averaged daily latencies over 9 days of testing),  
7. Morris maze acquisition (averaged latency for the last day of testing),  
8. Morris maze retention (percent of time spend in former platform quadrant during a 
probe trial done the day following acquisition),  
9. Circular platform errors (averaged over 8 days of testing),  
10. Circular platform errors (last day of testing),  
11. Circular platform escape latency (averaged over 8 days of testing),  
12. Circular platform escape latency (last day of testing),  
13. Platform recognition (averaged daily latencies over 4 days of testing),  
14. Platform recognition (averaged latency for the last day of testing),  
15. Radial arm water maze - Trial 4 latency over all 3 blocks of testing,  
16. Radial arm water maze - Trial 5 latency over all 3 blocks of testing,  
17. Radial arm water maze - Trial 1 latency for the last block of testing,  
18. Radial arm water maze - Trial 4 latency for the last block of testing,  
19. Radial arm water maze - Trial 5 latency for the last block of testing.  
Discriminant analysis forms new variables called “discriminant functions”, 
which are linear composites of the multiple original measures that are used to 
evaluate the overall performance of groups of animals. The number of such 
functions generated always equals the number of groups analyzed minus one. 
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Thus, if at least three groups are being compared, any two “discriminant 
functions” can be graphed to visually illustrate the presence or absence of 
group discrimination, as mathematically evaluated through the statistical 
analysis (Pillai’s trace).  
 
3. Results 
To study the effect of ApoE and ACT on Aβ immunoreactive and mature 
amyloid formation and cognitive decline, we have generated and analyzed four 
transgenic mouse lines: APP+(mApoE+)(ACT-) (n=11), APP+,(mApoE+),ACT+ 
(n=17), APP+,mApoE-KO,ACT- (n=8), and APP+,mApoE-KO,ACT+ (n=9). 
Animals from these heterozygous transgenic lines were behaviorally analyzed 
along with a group of nontransgenic mice (n=5) at 16 months of age and 
subsequently sacrificed at 18 months of age for histopathological evaluation.  
Other mice from these four lines were also sacrificed at two months of age to 
determine the effect(s) of ApoE and ACT on the steady state levels of 
monomeric Aβ before amyloid deposition begins.  Some were also behaviorally 
analyzed to determine whether animals destined to deposit amyloid were 
impaired at this early age.  
 
ApoE and ACT expression in the brain do not increase the steady state 
levels of Aβ1-40   or Aβ1-42  prior to amyloid deposition in PDAPP 
transgenic mice  
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All of the APP and presenilin mutations that have been found to cause 
familial Alzheimer’s disease with an autosomal dominant mode of inheritance 
appear to act by increasing the amount of the Aβ(1-42) peptide, which displays 
a high propensity to polymerize into amyloid filaments [57, 20]. If ApoE or ACT 
were to similarly influence AD by affecting Aβ production or clearance, one 
would predict that steady state levels of monomeric Aβ should be altered in 
young PDAPP/ACT transgenic or PDAPP/mApoE-KO mice in comparison to 
unaltered PDAPP mice. In contrast, if the main role of ApoE and ACT is to 
promote the formation of amyloid deposits, the presence or absence of these 
genes would not necessarily affect monomeric Aβ levels. 
To investigate the potential role of ApoE and ACT in the 
formation/clearance of Aβ, we first used ELISA to quantify both water soluble 
(defined as PBS-extractable) and membrane-bound (defined as guanidine-
extractable) Aβ1-40 and Aβ1-42 in the hippocampus and cerebral cortex of young 
APP transgenic mice prior to the onset of amyloid deposition (2 month old 
transgenic mice). No consistent, statistically significant genotype-dependent 
difference in either water soluble or membrane-bound Aβ1-40 or Aβ1-42 were 
observed between our four lines of transgenic mice in the hippocampus. In 
general, transgenic mice expressing ApoE tended to display lower levels of 
water soluble Aβ, and mice expressing ACT tended to show reduced levels of 
membrane-bound Aβ in the hippocampus (Table 1 and Figure 1). Similar 
results and trends were observed in the cerebral cortex tissue extracts, where 
the level of water soluble Aβ was found to be more clearly reduced by ApoE 
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expression (Table 1). The ability of ApoE to reduce soluble Aβ levels in young 
APP mice has been reported in other studies [21, 18], and previous findings 
have shown that young APP/ACT mice have unchanged or slightly increased 
Aβ levels using different antibodies [41, 45].  
In sum there is little evidence that either murine ApoE or human ACT 
increase Aβ levels in very young APP mice, but rather there is a trend toward 
ApoE and ACT reducing Aβ levels. Thus any increases in Aβ immunoreactive 
and mature amyloid deposition observed in the presence of ApoE or ACT in 
older mice is likely to be due to amyloid-promoting mechanisms other than 
merely increasing production or decreasing clearance of monomeric Aβ prior to 
amyloid deposition and the inflammation that it induces.  
Young Adult (2 month old) APP transgenic mice are not impaired in either the 
Morris Water Maze or the RAWM  
 To determine whether animals genetically destined to deposit amyloid 
later in life show early behavioral deficits that could be attributed to expression 
of the transgene or the production of human Aβ peptide, we tested APP+ 
(mApoE+)(ACT-) and nontrangenic littermates in the same battery of tasks that 
would be used to assess the behavior of aged animals.  The young animals 
showed no deficits in non-cognitive tasks.  Furthermore, as shown in Figure 
1e,f, the 2 month old APP-expressing and non-transgenic animals were also 
not significantly different in either Morris Maze acquisition or radial arm water 
maze (RAWM) working memory. 
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ApoE and ACT separately and in combination increase Aβ deposition in 
PDAPP transgenic mice 
Amyloid deposition is a complex process consisting of several stages.  
In order to develop the most effective therapies for Alzheimer’s disease, it is 
important to know which proteins contribute to which stages of the amyloid 
cascade and which stages cause cognitive decline.  The histopathological 
analysis of our mice was designed to distinguish the individual and synergistic 
contributions of ApoE and ACT to both diffuse Aβ deposition and fibrillar 
amyloid formation and, together with the behavioral analysis described below, 
to distinguish the relative impact of these forms of Aβ deposition on cognitive 
decline. 
Total Aβ deposition was measured as area (in %) occupied by Aβ 
immunoreactivity with the 6E10 antibody. Figure 2 shows that total Aβ  
deposition was markedly reduced in the hippocampus and absent in the 
cerebral cortex in PDAPP transgenic mice lacking ApoE expression [APP+, 
mApoE-KO, (ACT-)], consistent with previous findings [8]. Furthermore there 
was increased deposition in APP+(mApoE+),ACT+ transgenic mice, as 
compared to APP+,(mApoE+)(ACT-) transgenic mice, in the cerebral cortex 
(4.8±0.6% vs. 2.8±0.6%, P<0.05) and a modest elevation in the hippocampus 
(8.7±0.6% vs. 7.4±0.7%, n.s.), due to the presence of the ACT transgene 
(Figure 2a-b and 2e). The difference between APP+,(mApoE+),ACT+ and 
APP+,(mApoE+)(ACT-) transgenic mice was greater in the lateral extension of 
the parietal cortex as compared to either the hippocampus or the retrosplenial 
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cortex, where immunoreactive Aβ deposition develops at an early age (Figure 
2a-b). Furthermore there was an almost fourfold higher Aβ load in the 
hippocampus of the ACT-expressing/ApoE knockout (APP+,mApoE-KO,ACT+) 
transgenic mice as compared to the ACT minus/ApoE knockout 
(APP+,mApoE-KO,(ACT-)) mice (3.1±1.3% vs. 0.8±0.8%, P<0.05, Figure 2c-e). 
In fact, only a single animal among the transgenic mice with genotype 
APP+,mApoE-KO,(ACT-) showed any immunoreactive Aβ deposition at 18 
months of age.  
Mature, filamentous amyloid deposition is facilitated by either ApoE or 
ACT expression in the PDAPP transgenic mice 
In addition to forming diffuse, immunoreactive Aβ deposits, as quantified 
with the 6E10 antibody as above, the Aβ peptide also deposits as mature 
filamentous amyloid distinguishable by its strong beta sheet character. Congo 
Red staining, which measures such compact Aβ deposition, was about twofold 
elevated in both the hippocampus and cerebral cortex of the 
APP+,(mApoE+),ACT+ mice (Figure 3a) as compared to 
APP+,(mApoE+)(ACT-) transgenic mice (Figure 3b). This increase was 
statistically significant both in the cerebral cortex (0.028±0.004% vs. 
0.014±0.0.004%, P<0.05) and the hippocampus (0.060±0.008% vs. 
0.037±0.006%, P<0.05, Figure 3c). The ACT-induced increase in congophilic 
amyloid load was due to increased plaque density in both the cerebral cortex 
(3.12±0.46 vs. 1.44±0.44 plaques/mm2, P<0.05) and the hippocampus 
(6.01±0.62 vs. 3.86±0.59 plaques/mm2, P<0.05, Figure 3d). Furthermore ACT 
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antibodies immunostained Congo Red positive plaques in 
APP+,(mApoE+),ACT+, but not APP+,mApoE+)(ACT-) mice (not shown). 
There were no congophilic Aβ deposits in the hippocampus and the cerebral 
cortex of either the APP+,mApoE-KO,ACT+ or the APP+,mApoE-KO,(ACT-) 
mice at 18 months of age (but see below).  
ApoE-immunoreactivity has previously been demonstrated to be 
associated with a subset of Aβ immunoreactive plaques, which are essentially 
always Thioflavine S positive [7, 62]. However, using a more sensitive 
immunostaining protocol we now can show that ApoE is localized in essentially 
every Aβ  immunoreactive plaque in an APP+,(mApoE+),ACT+ transgenic 
mouse (Fig 4a-b), while ACT-immunostaining is largely restricted to Thioflavine 
S positive amyloid plaques. Thioflavine S staining and ACT-immunostaining 
also correlate well in their relative intensity among individual amyloid plaques.  
These results suggest that ACT binds to Aβ peptide or an intermediate Aβ 
species, increases the extent of its beta sheet structure and thereby 
accelerates the formation of mature amyloid plaques (Fig 4c-d). In vitro binding 
and X-ray crystallography/structural modeling studies between ACT and Aβ 
support such a model of ACT function in AD [50, 70, 35, 34, 29]. 
At an advanced age (23 months) all (6/6) homozygous APP+,mApoE-
KO,ACT+ mice, but only some (6/10; 60%) age-matched APP+,mApoE-
KO,(ACT-) mice, developed Thioflavine S positive amyloid plaques in the 
hippocampus. The anatomical distribution of Aβ and Thioflavine S positive 
staining varied among individual animals, particularly among the 
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APP+,mApoE-KO,(ACT-) mice. The Aβ-immunoreactive staining included the 
cerebral cortex in some of these mice, both with and without the ACT 
transgene. The Thioflavine S positive amyloid plaques in APP+,mApoE-
KO,ACT+ mice were always Aβ-immunoreactive, and mostly ACT  
immunoreactive and were most frequently observed in the molecular layer of 
the dentate gyrus and the CA1 stratum lacunosum/moleulare, but were also 
present in the CA1 and CA3 stratum radiatum. ACT immunopositive staining 
was also observed in Aβ immunoreactive deposits that were not Thioflavine S 
positive in these aged APP+,mApoE-KO,ACT+ mice (Figure 4e-h). Thioflavine 
S was used in these experiments because we found it to be a more sensitive 
dye than Congo Red. 
 
 
 
 
ApoE expression in aged PDAPP transgenic mice is associated with impaired 
learning ability in the Morris Water Maze 
Gender and age-matched animals were randomly selected from the four 
transgenic groups and, along with a group of non-transgenic mice, were 
examined in a battery of standard behavioral tasks.  As will be discussed in 
detail below, the non-cognitive tasks in the battery indicated that the mice in 
each of our lines were functioning well and could not be distinguished from 
each other in general non-cognitive abilities. For example, animals of all 
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genotypes performed at a similar level in open field activity and string agility 
tasks that estimate exploratory behavior and muscle strength and all exhibited 
similar swim speeds and were able to see.  
Cognitive tasks, however, did reveal differences between the transgenic 
lines. The most common task for assessing cognition in mice is the standard 
Morris Water Maze which measures spatial learning ability. The escape 
latencies for the four experimental and the non-transgenic control mice during 
the first block of testing (Days 1-3) in the Morris Water Maze were the same 
(F4,38 =0.636; P=0.63). This result reinforced the conclusion from the non-
cognitive tasks that there is no essential difference between the four transgenic 
groups and the non-transgenic mice in ability to perform the non-cognitive 
aspects of the Morris Water Maze task.  However in the last block of testing 
(Days 7-9), significantly higher escape latencies were recorded for the 
APP+,(mApoE+)(ACT-) mice (41±5 sec) as compared to the APP+,mApoE-
KO,(ACT-) mice (26±3 sec, P<0.05) and the nontransgenic mice (21±3 sec, 
P<0.01). Similar inferior performance was displayed by the 
APP+,(mApoE+),ACT+ mice (36±4 sec) as compared to the APP+,mApoE-
KO,ACT+ mice (23±4 sec, P<0.05) and the nontransgenic mice (21±3 sec, 
P<0.05, Figure 5).  Thus cognitive dysfunction as measured by the Morris 
Water Maze is associated with ApoE-catalyzed amyloid formation in APP-
expressing mice.  
ApoE knockout mice have been reported to exhibit cognitive deficits and 
thigmotaxic behavior (a tendency to swim in the peripheral annulus of the pool) 
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in association with structural cytoskeletal and neurochemical deficits in the 
brain. However, the ApoE knockout mouse model we used shows no such 
defect [4, 3, 11, 64], and we did not observe any thigmotaxic behavior in our 
mice.   
The Morris Water Maze was unable to reveal any difference between, 
for example, APP+,mApoE-KO,(ACT-) and APP+,mApoE-KO,ACT+ mice, 
although these groups of mice display different extents of Aβ immunoreactive 
histopathology. We surmised that a more demanding behavioral task would be 
more informative and sensitive in its ability to reveal subtle cognitive 
differences between the transgenic mice. 
 
ApoE and ACT expression in aged PDAPP transgenic mice determine the 
extent of cognitive impairment in the Radial Arm Water Maze 
The Radial Arm Water Maze (RAWM) is a more challenging version of 
the Morris Water Maze that is designed to test both visual-spatial and working 
memory in mice [6]. Previous work has shown that the RAWM provides a very 
sensitive behavioral measure that correlates well with the level of Aβ 
immunoreactive and mature amyloid load in transgenic mouse models of AD 
[6, 25, 38].  Therefore all of the behaviorally-analyzed mice were examined 
over three blocks of testing in the RAWM (Figure 6). Each of the three blocks 
consists of three days in which four acquisition trials (T1-4) and a delayed 
retention trial (T5) are performed on each day, with the location of the 
submerged platform being altered daily. 
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The escape latencies in the RAWM did not differ between the five 
groups of mice (four experimental and one control, non-transgenic) in the first 
trials (T1) of the first block of testing (Days 1-3), when the animals were naive 
to the task (F4,31 = 0.60; P=0.67; Figure 6a), indicating that there was no 
inherent difference between the groups in basic swimming and other non-
cognitive performance (see further discriminant analysis below). However, over 
the full 3 blocks of testing, there developed group differences in both learning 
(Trial 1 compared to Trial 4 on each day) and memory (Trial 5). Of particular 
importance were group differences in average T5 performance across all three 
blocks, wherein APP+,(mApoE+) with or without ACT displayed substantially 
longer escape latencies (47±4 and 47±2 sec.) compared to APP+,mApoE-KO 
mice with or without ACT (36±4 and 29±2 sec., P<0.05, P<0.001) and 
nontransgenic controls (29±3 sec., P<0.01) (Figure 6b). In block 3, when 
cognitive learning processes are most distinguishable from the procedural 
learning that occurs during earlier testing blocks, APP+,(mApoE+) mice with or 
without ACT were impaired in their ability to reduce their escape latencies 
between trials T1 and T5. On both the final learning trial (T4) and the memory 
retention trial (T5), escape latencies for these two groups were significantly 
longer than those for APP+,mApoE-KO,(ACT-) mice and nontransgenic mice.  
Importantly, APP+,mApoE-KO,ACT+ mice displayed an intermediate 
RAWM performance. Although these mice were able to learn, as evidenced by 
their ability to reduce their escape latencies throughout the trials, their T4 
escape latencies were significantly longer compared to both APP+,mApoE-
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KO,(ACT-) mice and nontransgenic mice.  This result indicates that the ACT 
expression not only promoted amyloid formation, but also caused cognitive 
decline as measured in the RAWM. 
ACT transgene expression in APP transgenic mice expressing ApoE further 
increased amyloid deposition but did not further reduce the already very poor 
spatial learning ability of APP+,(mApoE+) mice, which we interpret as a ceiling 
effect in this difficult behavioral task. Interestingly, one of the APP+,mApoE-
KO,ACT+ transgenic mice lacking visible Aβ immunoreactive deposition 
performed poorly in the RAWM. It could be that biologically active Aβ 
intermediates that are detrimental to hippocampal function had already begun 
to form in this mouse, but had not yet reached the threshold level necessary to 
precipitate detectable Aβ immunoreactive deposits. 
The extent of ApoE/ACT-catalyzed Aβ deposition correlates with cognitive 
performance. 
The data clearly show that the process and/or the product of amyloid 
formation found in both groups of APP+,(mApoE+) transgenic mice is of prime 
importance for cognitive impairment in the RAWM. This conclusion is further 
reinforced by a strong correlation between the T5 retention trial escape latency 
over all three test blocks and the amount of both immunoreactive Aβ 
deposition (T5, r=0.68, P<0.001, Figure 6c) and mature congophilic amyloid 
(T5, r=0.60, P<0.001, Figure 6d) in the hippocampus.  
Furthermore, the correlation between escape latency and 
immunoreactive Aβ deposition in the hippocampus remains strong when the 
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statistical analysis is restricted to the high-depositing APP+,(mApoE+) mice 
with or without ACT (T5, r=0.59, P<0.01). Extrapolating this linear correlation to 
its intercept on the y-axis (i.e. the extrapolated, theoretical, escape latency of 
an APP+,(mApoE+) transgenic mouse with zero Aβ deposition) yields a 
predicted latency of 31±12sec, which is close to the average recordings of the 
APP+,mApoE-KO mice (33±3sec). This extrapolation indicates  that the main 
contribution of ApoE to cognitive decline is to promote Aβ immunoreactive  and 
mature amyloid formation.  Without such deposition, there would be no 
cognitive difference (i.e. difference in latency) between APP+,(mApoE+) mice 
and either APP+,mApoE-KO mice or non-transgenic mice.   
Diffuse Aβ deposition in the hippocampus is associated with cognitive 
impairment in PDAPP transgenic mice 
Thus far, the analysis has shown that ApoE and ACT catalyze Aβ 
immunoreactive  and mature amyloid deposition in PDAPP mice and that the 
extent of these deposits correlates with the cognitive dysfunction  of the mice, 
suggesting a cause and effect relationship. We then analyzed the data further 
to determine the relative impact of the two major forms of Aβ deposition, 
diffuse Aβ immunoreactivity  and compact/fibrillar amyloid on cognitive 
performance.   
All 18 months old PDAPP transgenic mice lacking ApoE and thus 
exhibiting only diffuse immunoreactive Aβ deposits with no compact Aβ 
amyloid deposition were stratified for the presence or absence of 
immunoreactive Aβ deposition in the hippocampus, and their behavior in the 
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RAWM was compared to that of nontransgenic mice (Fig. 6e). In the first trial 
(T1) of the first block of testing (Days 1-3), when the animals were naive to the 
RAWM, there were no differences between any of the experimental groups 
(F2,18 = 3.05; P=0.072). In block 3 (Days 7-9) it was found that working memory 
was worse in those APP+,mApoE-KO transgenic mice with diffuse 
hippocampal Aβ immunoreactive deposits as compared to APP+,mApoE-KO 
mice without diffuse Aβ  deposits (T5, P<0.05), which were indistinguishable 
from nontransgenic mice.   
 
Behavioral differences among the four groups of transgenic mice and the 
nontransgenic mice are not due to different genetic backgounds 
 Because of the multiple crosses during breeding that were necessary to 
generate our four lines of transgenic/knockout mice, it was not possible to 
assure that the strain backgrounds were identical short of many years of 
repeated backcrossing. Instead all of the mice have a uniform, mixed genetic 
background that should equally assure that any consistent difference between 
the lines must be due to the presence or absence of ApoE or ACT, which are 
the only genetic trait that the members of a particular line share. 
To experimentally demonstrate that the differential behavior of the transgenic 
mice is largely due to the inheritance of the transgenic/knockout loci, we 
performed a comprehensive comparison of all of the behavioral data using 
discriminant function analysis. As previous studies have shown, this statistical 
tool allows for the comparison and discriminating analysis of characteristic 
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behavioral profiles of specific mouse strains [54]. We applied such discriminant 
analysis to the performance of our transgenic mice and of three lines of non-
transgenic mice in the entire group of 19 different behavioral measures from 
multiple behavioral tasks in our test battery.  There were consistent behavioral 
differences between the three groups of nontransgenic mice of different strain 
background, including the strains from which our transgenic/knockout mice 
were derived (P<0.025, Pillai’s trace, Figure 7a), indicating the ability of this 
technique to distinguish different mouse strains. In contrast, we were not able 
to behaviorally discriminate our control nontransgenic and the four transgenic 
groups of mice based on the same 19 behavioral measures (P>0.05, Pillai’s 
trace, Figure 7b). When the analysis was limited to 10 cognitive-based 
measures, the two APP+,(mApoE+) (high Aβ depositing) lines could be 
discriminated from the two APP+,mApoE-KO (low Aβ depositing) lines, 
confirming that cognitive-based behavioral measures are associated with the 
amyloid pathology. In contrast, the high depositing lines could not be 
distinguished from the low depositing lines on the basis of non-cognitive 
behavioral measures (P>0.05, Pillai’s trace).  In sum, not only are the mice 
within each line that we have used more similar cognitively to each other than 
they are to mice in any other line, indicating that their differences are due only 
to ApoE or ACT, but no group can be distinguished by non-cognitive 
measures, indicating that they are all fundamentally similar in background. 
 
4. Discussion 
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Previously, we and others had hypothesized and then demonstrated the 
ability of ApoE and ACT to catalyze the polymerization of Aβ into neurotoxic 
amyloid filaments [1, 73, 36, 72, 56].  Specific binding experiments, site 
directed mutagenesis and structural analysis then identified the molecular 
interactions between these pathological chaperones and Aβ and outlined the 
likely mechanism of action of the amyloid promoting reaction [50, 60, 35, 29]. 
The present study provides the first in vivo demonstration that the increased 
Aβ immunoreactive and mature plaque deposition caused by expression of the 
amyloid promoters ApoE and ACT, is associated with impaired spatial learning. 
Our results show 1) that ApoE and ACT separately and synergistically promote 
the development of both diffuse, immunoreactive Aβ deposits and mature 
amyloid plaques in Aβ overexpressing mice without affecting the levels of 
monomeric Aβ  itself, 2) that impaired cognitive performance in two different 
spatial tasks requires both Aβ peptide and either ApoE or ACT as an amyloid 
promoter and 3) that both diffuse Aβ deposits and mature amyloid plaques are 
correlated with impaired spatial learning ability. Indeed, 18 month old APP 
mice that expressed neither ApoE nor ACT, deposited very little Aβ and 
displayed no cognitive deficits in the RAWM or Morris Water Maze, similar to 
nontransgenic mice. These findings imply that the process and/or product of 
ApoE or ACT-catalyzed amyloid formation is more critical for the cognitive 
decline in AD than is the amount of monomeric Aβ-peptide. 
Although these experiments do not directly address which aspect or 
intermediate/product of amyloid formation causes cognitive decline, they 
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indicate that it must be ApoE and/or ACT-dependent and may be either some 
intermediate step in the process, the final, mature product, or both.  
Specifically, APP+,mApoE-KO,ACT+ animals accumulate diffuse, 
immunoreactive amyloid deposits and have impaired cognition.  This finding 
suggests that diffuse Aβ immunoreactive deposition, or an even earlier, 
ApoE/ACT-dependent, step in the process of amyloid formation, may be 
equally important for the cognitive decline in these mouse models of AD as is 
mature congophilic amyloid.  This interpretation of the data is supported by 
previous findings that Aβ oligomers and/or protofibrils appear to be more 
neurotoxic than monomeric or filamentous Aβ both in vitro [66, 67, 27, 31] and 
in vivo [68, 65].  
The Morris water maze and the RAWM were chosen for these studies 
because the place learning that they assay depends on the hippocampus [39], 
which is pathologically and functionally affected early in AD. It has been 
suggested that there is some learning deficit of PDAPP mice in a working 
memory version of the Morris water maze that is age-independent and 
therefore unrelated to Aβ burden [12]. However, we observed no statistically 
significant cognitive deficits in young adult PDAPP mice (Figure 1e-f), 
indicating that most behavioral impairment in the PDAPP mice depends on 
later-developing Aβ deposition (and on the action of ApoE and ACT). Our data 
also indicate that the RAWM task is a more sensitive measure of Aβ deposition 
than is the traditional reference memory version of the Morris maze. 
 
 
 
APPENDIX B (Continued) 
218 
Both PDAPP+,mApoE-KO and PDAPP+(mApoE+) mice have been 
reported to be impaired in an object recognition task as compared to 
nontransgenic mice. These findings were attributed to the high levels of soluble 
Aβ shared by the transgenic mice and seem to contrast with our results [19]. 
However, the object recognition task and the RAWM measure different aspects 
of cognition (identification vs. working memory) that may, to a differential 
extent, be dependent on certain brain regions (cerebral cortex vs. 
hippocampus) and be sensitive to different forms of Aβ deposition.  Indeed, 
object recognition shows only weak correlation with Aβ-immunoreactive 
deposition or mature Thioflavine S positive Aβ deposition [19], while RAWM 
performance is strongly correlated with both diffuse and compact Aβ 
deposition, as demonstrated here and previously [5, 25]. In addition, clearance 
of soluble Aβ species from the brain through passive immunization conferred 
short-term cognitive benefits in the object recognition task [17]. However these 
were acute observations after an invasive procedure that alters the 
compartmentalization and equilibrium between soluble and insoluble Aβ 
concentrations and are thus difficult to compare to the present findings. It is 
also possible that acute cognitive benefits of passive vaccination derive from 
the resulting reduction in the vasoconstrictor activity of Aβ [63] or to alleviated 
hemodynamic responses [42], either of which could enhance cerebral blood 
flow and improve cognition without providing insight into the mechanism by 
which APP and Aβ normally cause cognitive decline. 
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  We have considered the possibility that a somewhat higher or lower 
proportion of the original strains in the various knockout/transgenic lines used 
in this study, and not differences in Aβ deposition, could have led to the 
observed differences in the cognitive test results. However such an explanation 
is highly unlikely because 1) Different behavioral characteristics of inbred 
mouse strains are often lost in F1 hybrid strains [48].  For example, the 
protocol for generating our mice required several crosses that assured that the 
mice of each line contained a random mixture of backgrounds, with the only 
common feature being the presence or absence of APP, ApoE or ACT.  
Therefore, if genetic traits attributable to differences in strain background had 
been the major determinant of cognitive function, the individual mice within 
each line would have been expected to show a widely variable performance on 
the cognitive tests, reflecting their different genetic backgrounds. Such 
variation would preclude us from being able to detect differences due to 
mApoE or the ACT transgene. Instead the mice within each line were very 
similar to each other and differed as a group from the mice of the other lines. 2) 
There is a strong correlation between escape latency and hippocampal Aβ-
immunoreactive deposition among the APP+(mApoE+) (with or without ACT) 
mice which all have an identical strain background. 3) APP+, mApoE-KO (with 
or without ACT) mice with hippocampal Aβ-immunoreactive deposition are 
impaired as compared to APP+, mApoE-KO mice without Aβ-immunoreactive 
deposition. These latter two groups of mice also have an identical strain 
background showing that the ApoE effect on behavior cannot be due to 
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background strain difference. 4) Discriminant analysis, which can compare and 
reveal differences among comprehensive behavioral profiles of different mouse 
strains, shows that the differences among the four groups of transgenic mice 
and the nontransgenic mice are restricted to those behavioral measures which 
are the most sensitive assays of cognitive performance. In contrast, different 
control mouse strains can be discriminated on the basis of both cognitive and 
non-cognitive behavioral tests.  
Although ApoE and ACT clearly promote Aβ polymerization directly, 
these proteins likely have additional roles to play in AD and other brain 
diseases. For example, it has been shown that ACT inhibits Aβ degrading 
enzymes [76], and ApoE affects the level or location of APP processing so as 
to generate fewer Aβ peptides  and more potentially toxic C-terminal fragments 
(in animals slightly older than ours and of an age to show initial stages of 
amyloid deposition; [18]). ApoE also affects cholesterol metabolism [49]. 
Particularly interesting is the finding that ApoE4 is less neuroprotective than 
ApoE3 both in vitro and in vivo [9].  
 It is also important to consider the possible direct and compensatory 
consequences of expressing or not expressing ApoE and/or ACT during 
development.  For example, ApoE knockout mice develop 
hypercholesterolemia and atherosclerosis that could have an effect on amyloid 
formation.  However, heterozygous PDAPP/ApoE+/- mice have normal serum 
cholesterol levels and develop amyloid deposits at a rate intermediate between 
full PDAPP/ApoE-KO and PDAPP/ApoE+/+ animals [7] (and Nilsson and 
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Potter unpublished).  This result suggest that the lower amyloid deposition 
induced by knocking out ApoE is not caused by high serum cholesterol due to 
ApoE deficiency. Similarly, the effect of long term expression of a protease 
inhibitor such as ACT could be deleterious or could be masked by 
developmental compensation that could itself have side effects.  If present, 
such effects of ACT would affect development only late since the GFAP 
promoter of the ACT transgene does not become active until the very latest 
stages of fetal development. Furthermore, except for hypercholesterolemia in 
ApoE-KO mice, we have not observed gross differences in physiology or brain 
morphology due to knocking out ApoE or expressing ACT.  
In sum, our findings of a strong association between cognitive decline 
and both diffuse Aβ deposits and mature amyloid plaques in transgenic mice 
indicate that a major pathological role of ApoE and ACT in Alzheimer’s disease 
is to promote Aβ polymerization and deposition, possibly with slightly different 
effects in terms of time course and anatomical distribution of the pathology. 
Furthermore, it may be the process of amyloid formation, or an intermediate 
formed there in, rather than the end product (mature plaques) that causes 
neuronal dysfunction and cognitive decline. These results showing the 
essential role of ApoE and ACT in both amyloid formation and cognitive 
decline, together with the finding that ApoE and ACT do not alter the steady 
state level of Aβ, suggest that inhibition of the Aβ/ApoE or Aβ/ACT interactions 
are prime targets for therapeutic intervention in AD.  Previous experiments 
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have shown that such interaction inhibitors effectively prevent ApoE and ACT-
catalyzed polymerization in vitro [41].  
Besides sharing the ability to promote Aβ polymerization, ApoE and ACT also 
share the feature of being inflammatory proteins whose mRNAs are 
overexpressed in affected areas of the AD and APP mouse brain. Thus, the 
present findings provide an explanation for the involvement of inflammation 
and the prophylactic benefit of NSAIDs in AD [37, 44, 2, 53] and point to novel 
targets for anti-inflammatory therapy. Specifically, inhibitors of glial 
overproduction and release of IL-1, ApoE, or ACT should prevent amyloid 
formation and cognitive decline. Both in vitro and in vivo experiments indicate 
the likely success of such approaches [14, 35, 33].  
Finally, we note that the concept of pathological chaperones playing a catalytic 
role in diseases of protein conformation is potentially quite general, as it 
appears to extend to both other AD proteins and other amyloid disorders [61, 
47, 69, 71, 16].   
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Table 1. ELISA measurements of Aβ(1-40) and Aβ(1-42) levels in the 
hippocampus of 2 months old mice.  
 
 
Genotype  n PBS-extractable Guanidine-extractable 
              (mean pg/mg tissue)  (mean pg/mg tissue) 
 
   Aβ1-40 Aβ1-42  Aβ1-40   Aβ1-42 
 
 
Hippocampus 
 
PDAPP+ApoE+ACT+ 20 103±21 65±7  312±18   238±10 
 
PDAPP+ApoE+ACT- 12 148±17 78±9  356±25   303±29*  
 
PDAPP+ApoE-ACT+ 17  167±29 91±11*  310±23   262±16 
 
PDAPP+ApoE-ACT- 19 151±33 92±9*  349±39   288±27 
 
Cerebral Cortex 
 
PDAPP+ApoE+ACT+ 20  18±2  10±1   181±12   165±12 
 
PDAPP+ApoE+ACT- 12  19±3  11±1   186±12   183±12  
 
PDAPP+ApoE-ACT+ 17   24±2  16±1**   115±5**   157±11 
 
PDAPP+ApoE-ACT- 19  27±3*  16±1**   133±11**  171±18 
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Values are mean±SEM; *P<0.05 as compared to PDAPP+ApoE+ACT+ 
transgenic mice for the hippocampal measurements. *P<0.05  and **P<0.01 as 
compared to PDAPP+ApoE+ACT+ as well as PDAPP+ApoE+ACT- transgenic 
mice for the measurements of the cerebral cortex. 
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6. Figure legends  
 
Figure 1. ELISA measurements of Aβ(1-40) and Aβ(1-42) levels in 
hippocampus and behavior analysis of cognitive ability in 2 months old mice 
before amyloid deposition has begun.  
(a-d) Quantitation of the levels of Aβ(1-40) and Aβ(1-42) in 
PDAPP+,(mApoE+),ACT+ (n=20, solid bar), PDAPP+(mApoE+)(ACT-) (n=12, 
open bar), PDAPP+,mApoE-KO,ACT+ (n=17, solid bar) and PDAPP+,mApoE-
KO,(ACT-) (n=19, open bar). The quantitative measurements refer to soluble 
(PBS-extractable) and membrane-bound (guanidine extractable) Aβ levels. 
*P<0.05.  
(e,f) Morris Water Maze and radial arm water maze performance of young 
adult APP+.(mApoE+)(ACT-) mice and non-transgenic littermates. 
 
Figure 2. Total amyloid load, diffuse and compact, in four strains of 18 months 
old transgenic/knockout mice, as measured by 6E10 immunostaining.  
Representative animals with genotypes (a) PDAPP+,(mApoE+),ACT+, (b) 
PDAPP+,(mApoE+)(ACT-), (c) PDAPP+,mApoE-KO,ACT+ and (d) 
PDAPP+,mApoE-KO,(ACT-).  
(e) Quantitative image analysis of total amyloid load from all investigated 
animals with genotype PDAPP+,(mApoE+),ACT+ (n=17, solid bar) and 
PDAPP+,(mApoE+)(ACT-) (n=11, open bar) in the hippocampus (left) and the 
cerebral cortex (middle), and PDAPP+,mApoE-KO,ACT+ (n=9, solid bar) and 
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PDAPP+m,ApoE-,(ACT-) (n=8, open bar) in the hippocampus (right). *P<0.05. 
Scale bar measures 335 μm. 
 
Figure 3. Compact amyloid deposition in four strains of 18 months old 
transgenic/ knockout mice as measured by Congo Red staining 
Representative animals of the experimental groups (a) 
PDAPP+,(mApoE+),ACT+  and (b) PDAPP+,(mApoE+)(ACT-).  
Quantitative compact amyloid load from all investigated animals with 
genotypes PDAPP+,(mApoE+),ACT+ (n=17, solid bar) and 
PDAPP+,(mApoE+)(ACT-) (n=11, open bar) in the hippocampus and the 
cerebral cortex. Congo positive amyloid load is expressed as  % compact Aβ 
load (c) and  plaque density (d). *P<0.05. Scale bar measures 115 μm. 
 
Figure 4. Amyloid pathology of an 18 months old heterozygous 
PDAPP+(mApoE+)ACT+ (a-d) and a 23 months old homozygous 
PDAPP+,mApoE-KO,ACT+ transgenic mouse (e-h). Aβ- (a and e), ApoE- (b 
and f), and ACT-immunostaining (d and h) and Thioflavine S staining (c and g). 
 
Figure 5. Analysis of spatial learning in the Morris Water Maze 
Average escape latency for four daily trials during block 1 (days 1-3), block 2 
(days 4-6) and block 3 (days 7-9) of testing. PDAPP+,(mApoE+),ACT+ (n=11; 
yellow squares), PDAPP+,(mApoE+)(ACT-) (n=10; green squares), 
PDAPP+,mApoE-KO,ACT+ (n=10; blue circles) and PDAPP+,mApoE-
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KO,(ACT-) (n=7; red circles) and nontransgenic mice (n=5; pink triangles). 
Statistical significance refers to P<0.05 or higher level of significance as 
compared to nontransgenic mice (*), PDAPP+,ApoE-,(ACT-) mice (#) or 
PDAPP+,ApoE-,ACT+ mice (≠). 
 
Figure 6. Analysis of working memory in the Radial Arm Water Maze 
(a) Escape latency during block 1 (days 1-3), block 2 (days 4-6) and block 3 
(days 7-9) of RAWM testing for the first and last acquisition trials (Trial 1, Trial 
4), and the delayed memory retention trial (Trial 5).  
(b) Combined average escape latencies of the memory retention (T5) trials 
over all three blocks of testing.  
(c) Correlation analysis of escape latency for Trial 5 over all three blocks and 
total hippocampal amyloid deposition (6E10 immunoreactivity).  
(d) Correlation analysis of escape latency for T5 over all three blocks and compact 
amyloid deposition (Congo Red staining).  
(e) Escape Latency during block 1 (days 1-3), block 2 (days 4-6) and block 3 
(days 7-9) of RAWM testing for PDAPP+,mApoE-KO transgenic mice stratified 
for the presence (n=5; green squares) or absence (n=11; blue squares) of 
diffuse hippocampal amyloid deposition as well as nontransgenic mice (n=5; 
pink triangles). 
Statistical significance in panels (a )and e refers to P<0.05 or higher level of 
significance as compared to PDAPP+,ApoE-,(ACT-) (#) or  nontransgenic mice (*). 
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Statistical significance in panel (b) refers to P<0.05 (*) and P<0.01 (**). Dashed lines 
in panels (c) and (d) indicate 95% confidence interval of regression line. 
 
 
Figure 7. Discriminant analysis 
(a)  Graphical demonstration of the ability of discriminant analysis to easily 
discriminate  three different nontransgenic mice strains based on 19 measures 
of behavior. 
(b) Lack of ability to behaviorally discriminate the four groups of APP 
transgenic mice and the nontransgenic mice based on the same 19 behavioral 
measures. 
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Fig. 4 
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Rodents undergoing cognitive stimulation (CS) by being placed in an 
“enriched environment” (e.g., socially-housed in large cages containing toys, 
tunnels, running wheels, etc.) exhibit improved cognitive performance1,2, as 
well as increased hippocampal neurogenesis3, synaptogenesis4, growth factor 
levels5, and cognition-linked gene expression6.  Although retrospective studies 
in humans have similarly found that a lifelong pattern of CS generally 
associated with educational/occupational attainment protects against 
Alzheimer’s Disease (AD)7-8, it is unclear to what extent long-term CS would 
benefit individuals who already have AD.  Here we show that long-term 
environmental enrichment (EE) in aged AD transgenic mice results in global, 
overall improvement in cognitive function without decreasing brain beta-
amyloid (Aβ) deposition, suggesting that long-term CS could provide cognitive 
stabilization or improvement to AD patients through mechanisms independent 
of Aβ deposition and clearance. 
Recently, several cognitive stimulation programs have been developed 
in an attempt to slow or reverse the cognitive decline in AD patients9,10.  These 
programs have generally involved a relatively short 4-12 week period of 
cognitive training classes and/or daily caregiver-directed mental activities, 
resulting in modest degrees of success. However, the therapeutic potential of 
intensive, “long-term” CS has not yet been evaluated in AD patients.  
Furthermore, retrospective/longitudinal studies cannot determine whether CS 
is a promotor or merely an indicator of intact cognition.  Therefore, the present 
study sought to elucidate the cognitive-enhancing potential of long-term EE in 
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aged APPsw transgenic mice, which overexpress the “Swedish” mutant 
amyloid precursor protein and bear moderate cortical/hippocampal Aβ 
deposition within mature AD-like neuritic plaques11. 
Beginning at 16 months of age, APPsw mice were put into either EE (n 
= 5) or standard housing (SH; n = 4) for four months (Fig. 1).  In addition to 
their enriched housing, EE mice were placed in novel complex environments 3 
times weekly for several hours over the 4 month period.  Beginning at 20 
months of age, all mice were tested in four cognitive-based tasks as previously 
described11: Morris water maze (reference learning and memory), circular 
platform (reference memory), platform recognition (search/identification), and 
radial arm water maze (working memory).  Following completion of the 
behavioral testing at 22 months of age, animals were euthanized and their 
brains processed for Aβ load determinations12.  During the course of 
enrichment, 2 EE mice died. 
 Over 10 days of Morris maze acquisition (learning), EE mice performed 
significantly better than SH mice by having lower escape latencies (Fig. 2a).  
During the subsequent memory retention (probe) trial (Fig. 2b), EE mice 
showed an exclusive preference for the former platform-containing quadrant (p 
= 0.01, ANOVA), while SH mice showed nominal quadrant preference (p = 
n.s., ANOVA).  In switching from the “reference” learning/memory strategy of 
the Morris maze to the search/identification strategy of platform recognition, SH 
mice showed obvious impairment, as evidenced by their high latencies over 
the first 3 days of platform recognition testing (Fig. 2c).  By sharp contrast, EE 
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mice effectively and immediately changed strategies by exhibiting low escape 
latencies even on the first day of platform recognition testing (p<0.05; Fig. 2c).  
Indeed, a comparison of the improved behavior of EE mice in the above tasks 
indicates that they had reacquired the cognitive ability of previously-studied 16 
month old non-transgenic mice with the same strain background11.  
To determine whether EE had an “overall” cognitive-enhancing effect 
encompassing all 4 tasks employed, we evaluated data from the two primary 
measures of each task.  As shown in Fig. 3a, the means of EE mice on all 8 
measures were better than those of SH mice.  An analysis of these data 
showed that EE mice had significantly better “overall” cognitive performance 
spanning all 8 cognitive measures (p <0.005; Fisher Sign test).  Moreover, 
discriminant function analysis (step-wise forward method), evaluating data from 
the same 8 behavioral measures, also revealed significantly better overall 
performance of EE vs. SH mice (F[4,2] = 33.57, p = 0.029; Wilks’ lambda = 
0.0147); the Systat program found four measures from 3 of the 4 tasks to 
collectively provide maximal discrimination between EE and SH groups.  
At the 22 month completion age of this study, total Aβ loads (diffuse + 
compact) in both parietal cortex and hippocampus of EE and SH mice were 
determined by immunohistochemistry with the 6E10 antibody.  Moderate Aβ 
loads (5-10%) were evident in both brain areas, with no differences between 
EE and SH mice (Fig. 3b), indicating that the cognitive benefits of EE occurred 
in AD transgenic mice without an accompanying decrease in brain Aβ 
deposition. 
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   These results indicate that a long-term period of EE in aged AD 
transgenic mice results in superior overall cognitive performance 
encompassing multiple cognitive domains (e.g., reference learning/memory, 
working memory, recognition, strategy switching).  Although a reduction in 
brain Aβ deposition has been associated with behavioral benefit of Aβ 
immunotherapy in similar AD transgenic mice13, the present results, together 
with our other study showing Aβ-independent cognitive benefit to AD 
transgenic mice given a blueberry-rich diet14, indicate that mechanisms 
autonomous from Aβ deposition are sufficient for behavioral benefit.  Along this 
line, EE-induced enhancements in neurogenesis3, synaptogenesis4, growth 
factor levels5, and gene expression6 have all been seen in normal mice.  In this 
first study to evaluate the potential of EE in AD transgenic mice, our results 
suggest that long-term intensive EE/CS (alone or in combination with 
cognition-stimulating drugs) could be useful in stabilizing or slowing the 
cognitive decline of AD and it’s predecessor, mild cognitive impairment (MCI), 
without needing to reduce Aβ load.  Largely because of practical 
considerations, longitudinal interventional studies have not been done in 
humans to confirm controversial retrospective studies reporting AD risk 
reduction with “lifelong” education/occupation-related intellectual activity7,8.  A 
recent 5-year longitudinal study involving non-demented 75+ year olds did find 
participation in cognitively-stimulating leisure activities to be associated with a 
lower risk of dementia15.  However, a cause and effect relationship could not 
be established because the leisure activities were self chosen.  Future studies 
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in which EE is initiated early in adulthood of AD transgenic mice should more 
definitively elucidate the potential protective effects of EE against development 
of cognitive impairment and neuropathology.  
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Figure Legends 
 
Fig. 1: Standard housing of individual mice (a) and enriched housing of 
multiple mice in a large bin containing an inner cage (with platforms, 
passageways, lofts), running wheels, toys, and novel habitats (b).  
 
Fig. 2: Environmental enrichment significantly improves reference 
learning, reference memory and recognition/identification abilities of AD 
transgenic mice.  (a) Over 10 days of Morris maze acquisition (learning) 
at 20 months of age, EE transgenic mice had lower escape latencies 
compared to SH transgenic mice. Latencies to escape to a stationary 
submerged platform in a 100-cm diameter pool over 4 daily trials were 
averaged and are  presented as five 2-day blocks. Group means were 
compared across blocks by Paired Design [ t(4) = 4.99; p=0.007] .  (b) 
Spatial memory retention of EE transgenic mice during a 60 sec. probe 
trial on Day 11 was better than SH transgenic mice since EE mice had 
an exclusive preference for the former platform-containing quadrant 
(Q2) while SH mice showed only nominal quadrant preference. * = 
significantly lower than Q2 percentage at p<0.05 or higher level of 
significance (ANOVA). There was no difference in swim speed between 
EE and SH transgenic groups.  (c) For 4 days of platform recognition 
testing at 21 months of age, transgenic mice were given 4 swim trials 
daily starting from the same position, with an elevated prominently-
ensigned escape platform moved to a different pool quadrant for each 
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trial.  EE mice were immediately able to switch from the reference 
learning/memory strategy of Morris maze to the search/identification 
strategy of platform recognition, as evidenced by their low escape 
latencies even on the first day of testing.  By contrast, SH mice had 
significantly higher escape latencies on the first 3 days of testing. * = 
significantly higher than enriched group at p<0.05 (Mann-Whitney U 
test). 
 
Fig. 3: Environmental enrichment results in better “overall” cognitive 
performance in aged APPsw mice without affecting forebrain Aβ 
deposition.  (a) EE mice had higher performance means vs. SH mice on 
two primary measures from each of four cognitive-based tasks 
evaluated between 20 - 22 months of age.  Significantly better overall 
performance of EE mice across those 8 measures was evident from 
both the Fisher Sign test and discriminant function analysis (see text).  
Abbreviations: WM acq. = Morris maze acquisition average escape 
latency; CP overall (x10) = circular platform average escape latency 
(1/10th scale); CP Final (x10) = circular platform escape latency on final 
day (1/10th scale); PR overall = platform recognition average escape 
latency; PR final = platform recognition escape latency on final day; RM 
overall (T5) = radial arm water maze average escape latency on the 
delayed retention trial; RM final (T5) = radial arm water maze escape 
latency on delayed retention trial in last block of testing; WM retention 
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deficit = % of time not spent in the former platform-containing quadrant 
during probe trial.  (b) At 22 months of age, total Aβ loads in both 
hippocampus and parietal cortex of APPsw mice were not affected by 4 
months of EE. 
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Figure 1
 
 
 
APPENDIX B (Continued) 
260 
        Figure 2 
 
a) 
                     
  
                 
                      
 
 
   
      
      
                        
   
         
  
            b) 
Quadrant
%
 T
im
e 
in
 Q
ua
dr
an
t
0
10
20
30
40
50
60
 
1 2 3 4
Quadrant
1 2 3 4
*
* *
*
Standard Housing Enriched Environment
 
        
           c)             
                                   Days
1 2 3 4
La
te
nc
y 
(s
ec
)
0
10
20
30
40
*
*
Enriched 
Environment
*
Standard 
Housing
 
 
Blocks
1 2 3 4 5
La
te
nc
y 
(s
ec
)
20
30
40
50
60
Standard 
Housing
Enriched 
Environment
 
 
 
APPENDIX B (Continued) 
261 
 
 
Figure 3 
 
Es
ca
pe
 L
at
en
cy
 (s
ec
)
0
10
20
30
40
50
60
Standard Housing 
Enriched Environment
W
M
 acq.
CP overall (x10)
CP Final (X10)
PR overall
PR final
RM
 overall (T5)
RM
 final (T5)
%
 T
im
e 
ou
ts
id
e
   
 p
la
tfo
rm
 q
ua
dr
an
t
0
20
40
60
W
M
 retention
deficit
 
 
 
 
 
 
To
ta
l A
b 
lo
ad
 (%
 a
re
a)
0
2
4
6
8
10 Standard Housing
Enriched Environment
Hippocampus Parietal Cortex
 
 
 
 
 
 
 
 
 
ABOUT THE AUTHOR 
 
 David Costa was born in Connecticut, but has lived most of his life in 
Florida.  He graduated, with honors, from the University of Florida in 1999, 
earning a Bachelor’s degree in Microbiology.  He earned his doctoral degree in 
medical sciences from the University of South Florida, College of Medicine, 
Department of Biochemistry and Molecular Biology in 2005.  David is a member 
of the Society for Neuroscience, The Alzheimer’s Association, and shares 
affiliations with the Johnnie B. Byrd, Sr. Alzheimer's Center & Research Institute 
and the Suncoast Gerontology Center.  David currently resides in Brandon, 
Florida with his wife, Heather.   
 
262 
